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Preface
This volume is comprised of the Final Report of a project commissioned by the
Wellcome Trust. In response to its request for a “comparative review of existing
controlled human infection studies in endemic settings to inform the development
of an international ethics framework”, this Report aims to (1) outline the primary
ethical and regulatory issues associated with human challenge studies in general,
(2) examine the implications of such issues (or any special/unique issues arising) in
endemic regions, and (3) provide detailed case studies of endemic region human
challenge studies. It is informed by reviews of relevant scientific and ethical lit-
erature, as well as in-depth interviews with science and ethics experts.
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Human infection challenge studies (HCS) are experiments that involve infecting
research participants with pathogens (or other micro-organisms) and primarily aim
to (i) test (novel) vaccines and/or therapeutics, (ii) generate knowledge regarding
the natural history of infectious diseases (and/or asymptomatic infection), and/or
(iii) develop “models of infection”—i.e., reliable methods (to be used in studies
with aims (i) and/or (ii)) of infecting human research participants with particular
pathogens. Modern HCS are sometimes referred to as “controlled human infection
studies,” because they involve controlling the selection and/or production of the
microorganism strain (s) and the timing, route, and/or dose of infection; infection in
a controlled environment; and/or (with the aim to avoid serious harm to research
participants) infection with microorganisms causing no disease or disease that is
self-limiting or can be (and is) controlled with effective cures or treatments; and/or
controlling who is being infected (and/or subjected to other experimental
interventions).
HCS have a good safety record over the last 50 years as a result of careful research
practices, including close monitoring of participants. They are ethically sensitive,
however, and raise complex questions regarding, inter alia, (i) the acceptable limit of
risks and other burdens which may be imposed on healthy volunteers (ii) the need for
protection of third parties from infection (by participants), (iii) appropriate criteria
for participant selection/exclusion (e.g., determinations of when, if ever, it would be
justifiable to recruit participants from especially vulnerable populations, including
children), (iv) appropriate financial payment of participants, (v) appropriate selec-
tion, development, and regulation of challenge strains, (vi) the role (s) of HCS in the
licensure of new interventions (e.g., vaccines), and (vii) the potential need for
specific research ethics principles/guidelines/frameworks and/or review procedures
(e.g., special review committees) for this kind of research.
Although many infectious diseases that have been, or could plausibly be,
investigated via HCS are primarily endemic in low- and middle-income countries
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(LMICs), the vast majority of HCS have been conducted in high-income countries
(HICs). This can perhaps be explained in part by inequitably low levels of research
capacity/infrastructure in LMICs and in part by a perceived need to avoid
recruitment of vulnerable participants (in LMICs). As a result, less than 1% of HCS
participants have been enrolled in LMICs since World War II. This is unfortunate,
because (e.g., due to population differences regarding naturally acquiredimmunity,
co-infections, genetics, microbiome, nutrition, etc.) research on HIC volunteers may
not always be generalisable to the populations in LMICs where many important but
neglected diseases are endemic.
There have thus been increased calls for more HCS to be conducted in LMICs in
order to produce results that will be more relevant to target populations in endemic
settings. This may be particularly important for (i) pathogens that are primarily
endemic in LMICs such as those causing many vector-borne diseases (e.g., malaria,
dengue, schistosomiasis, Zika, etc.) and diarrhoeal diseases (e.g., cholera, Shigella,
typhoid, etc.) and (ii) pathogens with a wider global distribution that nevertheless
cause a disproportionate disease burden in LMICs (e.g., pneumococcus, Neisseria,
respiratory syncytial virus, etc.). Although some of the ethical challenges related to
HCS may be exacerbated in the context of LMIC populations, it is precisely these
populations that are in greatest need of new interventions for neglected infectious
diseases.
Despite the potential advantages of conducting HCS in endemic countries, HCS
in LMICs may, in addition to more general worries about potentially risky research
involving vulnerable human subjects, raise particular ethical and/or regulatory
challenges regarding (i) informed consent (due to language barriers and/or limited
education of potential participants), (ii) concerns about “undue inducement” (e.g., if
financial payment is “too high”), (iii) potential transmission of infection from
participants to third parties (e.g., because of the presence of vectors for vector-borne
diseases, or the absence of adequate sanitation to prevent the spread of diarrhoeal
disease), (iv) the capacity of LMIC regulators and/or ethics committees and (v) the
public acceptance of HCS research by local communities.
On the other hand, there may be cases where infection during HCS is less
risky/harmful to participants in endemic settings than participants in wealthy
developed countries—e.g., if the former has innate (genetic) resistance and/or
naturally acquired (partial) immunity to the pathogen under study (making resultant
illness less severe), whereas, the latter does not. Participation in HCS may some-
times even have direct benefits for healthy participants in endemic, developing
countries (which is usually not the case for participants in wealthy developed
nations) if/when (i) controlled infection leads to protective immunity against
endemic diseases that otherwise would have put them at risk and/or (ii) HCS
involve infection with locally prevalent pathogen participants would have otherwise
likely been infected with later, but controlled infection (yielding immunity) leads to
less severe illness than would otherwise be expected (in light of monitoring of, and
care provided to, participants) and/or (iii) HCS involve the testing of a vaccine
candidate that results in protective immunity against wild-type infection.
x Executive Summary
This report maps the terrain of ethical and regulatory issues related to HCS with
a focus on studies conducted in endemic LMICs; and it includes an analysis of 13
LMIC HCS case studies of research (published 1992-2018) conducted in Thailand,
Colombia, Tanzania, Kenya, and Gabon. It is informed by qualitative interviews
involving key stakeholders with expertise relevant to LMIC HCS and a review of
relevant bioethical and scientific literature. Based on the views of stakeholders and
existing literature, this report concludes by highlighting areas of consensus
regarding LMIC HCS, as well as controversial and/or unresolved issues in need of
further analyse.
Key Points of Consensus
We found that there was a strong consensus in the literature, and among stake-
holders interviewed for this project, that (i) LMIC HCS can be ethically acceptable
if there is a sound scientific rationale and studies are conducted to adequate sci-
entific and ethical standards, and that (ii) the scientific rationale for LMIC HCS is
particularly strong when they are necessary to produce results that are (more)
relevant to the eventual target population for interventions under development. It
has even been suggested that (iii) there may be an ethical imperative to conduct
appropriately designed LMIC HCS in endemic populations in cases where this
would accelerate the development of new interventions that would significantly
reduce disease burden in these populations.
There was also consensus that (iv) there is a need to build scientific, ethical
review, and regulatory capacity for HCS in LMICs to ensure that HCS can be
conducted to high standards; (v) burdens (including risks) to participants and third
parties should both be minimised; (vi) high quality informed consent should be
assured, e.g., by routinely testing participant comprehension prior to enrolment
(which has been common practice in recent LMIC HCS); (vii) researchers should
engage with local communities regarding, among other things, the public accept-
ability of HCS; (viii) participants should receive adequate payment, at least
including reimbursement for costs and time; and (ix) children should not be
recruited for HCS without significant international consultation and local commu-
nity engagement/acceptance.
Unresolved Issues
Controversial and/or unresolved issues identified by this project include, first, the
question of how the scientific aim to produce generalisable results should be
weighed against the protection of participants. Many of the ways in which HCS
could be designed to reduce risks to participants might undermine the generalis-
ability of results (e.g., regarding vaccine efficacy). For example, conducting HCS
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with less virulent strains may be less risky for participants but such studies might
not provide reliable information about the wild-type strains of greatest public health
importance.
The second set of unresolved issues involves questions about burdens (including
risks) and benefits, including (i) the appropriate sharing of the benefits of
LMIC HCS with participants and/or local communities; (ii) the acceptable limits to
burdens imposed on HCS participants (including the overall upper limit to risk, the
conditions under which a low probability of lasting harm is an acceptable risk, and
the conditions under which curative treatment may be delayed after an HCS par-
ticipant is diagnosed with the challenge infection); (iii) the appropriate management
of potential risks of participants withdrawing from participation (or absconding)
after being infected; (iv) whether the degree of acceptable risk to third parties is
different in endemic settings given high local background risk (with some stake-
holders viewing third-party risk in such settings as arguably negligible and others
suggesting that third-party risks should be minimised whether or not the disease in
question is locally endemic). Ultimately, there may be difficult ethical trade-offs
between the potential benefits and burdens of different study designs (e.g. while
close inpatient monitoring during HCS may reduce the risks of severe infection as
compared with outpatient HCS or field trials, inpatient HCS designs may increase
other burdens related to the isolation of participants). Systematic risk-benefit
assessments that include both scientific and ethical evaluation of study designs may
help to optimise the design of HCS and/or vaccine development programs.
The third set of controversial and/or unresolved issues involves questions about
selection and payment of participants, for example, (i) the conditions under which
HCS should recruit students and/or highly educated individuals (on the one hand, it
has been argued that educated individuals are better able to give informed consent;
on the other hand, students may feel pressure to participate which could undermine
consent and, furthermore, excluding less well-educated individuals may be unfair
and/or reduce the generalisability of HCS results to key populations); (ii) the
conditions under which studies should recruit individuals with acquired immunity
and/or innate resistance to the challenge infection (which might make participation
less risky but also affect the generalisability of results); (iii) the conditions under
which, if any, HCS involving children would be accepted (by communities and
other HCS stakeholders); (iv) whether or not, or the extent to which, it would be
appropriate to pay participants beyond reimbursement for costs and time spent
participating in a given study.
Fourth, this project identified several unresolved issues regarding the governance
of HCS, including (i) whether specific ethical guidelines are needed for HCS and, if
so, what their content should be; (ii) whether or not, or the conditions under which,
HCS should be subject to special review procedures; and (iii) the appropriate
regulation of challenge strains (e.g., whether challenge strains should be subject to
existing “Investigational New Drug” regulations, and/or whether regulations should
be standardised at the international level).
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Conclusion
There are ethical and scientific reasons in favour of conducting LMIC HCS in order
to address the persistently high burden of infectious diseases in disadvantaged
populations. Careful attention to the ethically salient aspects of HCS design, rele-
vant governance mechanisms, and the acceptability of HCS among participants and
communities will help to ensure progress and sustainability of this important area of
research which will hopefully produce significant global health benefits. Given the
complexities of such studies, and the controversial and/or unresolved issues high-
lighted in this report, further work is needed by biological scientists, social scien-
tists, and bioethicists to support on-going improvements in the design, conduct, and
review of LMIC HCS.
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Infectious diseases cause a large burden of morbidity and mortality worldwide, with
a disproportionately high burden in low- and middle-income countries (LMICs). For
example, many vector-borne diseases (e.g., malaria, dengue, schistosomiasis, Zika,
etc.) and diarrhoeal diseases (e.g., cholera, Shigella, typhoid, etc.) are primarily
endemic in LMICs among populations where social, economic, and physiological
vulnerabilities are common and/or severe. Furthermore, many other pathogens with
a wider global distribution nevertheless cause a disproportionate disease burden in
LMICs (e.g., pneumococcus, streptococcus, Neisseria, respiratory syncytial virus,
etc.). In addition to improvements in public health measures and social determinants
of health, new medical interventions (e.g., vaccines and treatments) are urgently
needed for many such pathogens. This is because (i) in some cases, no effective
interventions exist and (ii) in others, existing interventions are becoming less effective
(e.g., due to antimicrobial resistance) and/or are associated with unacceptable risks
(e.g., drug toxicities).
Human infection challenge studies (HCS) involve the intentional infection of
research participants with pathogens (or other micro-organisms) and primarily aim
to (i) test (novel) vaccines and therapeutics, (ii) generate knowledge regarding the
natural history of infectious diseases (and/or asymptomatic infection), or (iii)
develop “models of infection”—i.e., reliable methods (to be used in studies with
aims (i) and/or (ii)) of infecting human research participants with particular
pathogens. Modern human infection challenge studies are sometimes referred to as
“controlled human infection studies,” because they involve controlling the selection
and/or production of the micro-organism strain(s) and the timing, route, and/or
dose of infection; infection in a controlled environment; and/or (with the aim to
avoid serious harm to research participants) infection with micro-organisms
causing no disease or disease that is self-limiting or can be (and is) controlled with
effective cures or treatments; and/or controlling who is being infected (and/or
subjected to other experimental interventions) (Selgelid and Jamrozik 2018).
HCS involving reliable models of infection provide an especially powerful
scientific method for the testing of vaccines and therapeutics; and they can be
© The Author(s) 2021
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2 1 Introduction
substantially smaller, shorter, and less expensive than other kinds of studies.
Among other benefits, they can significantly reduce the number of participants that
must be exposed to an experimental intervention in order to determine its efficacy.
This is because (at least in cases where correlates of protection are unknown)
determination of experimental vaccine efficacy requires that a sufficient number of
research subjects who receive it, and those (in a comparator arm of a trial) who do
not, are actually exposed to—i.e., “challenged” by—the pathogen in question
(which may only be a small proportion of participants in field trials).
HCS are commonly used in early stage research for the selection of candidate
interventions worthy of further investigation in larger studies. Well-designed HCS
can thus lead to significant public health benefits being achieved sooner than would
otherwise be possible, meaning that there is sometimes a strong ethical rationale
for conducting such studies. In some cases, there may also be strong scientific and
ethical justification to conduct HCS in LMIC populations in particular—especially
if this would help to generate findings (e.g., regarding immune mechanisms and/or
vaccine efficacy) that are more relevant to populations with the highest burden of
relevant diseases.
Though numerous infamous historical cases of unethical research involved the
intentional infection of human subjects with pathogens, the (sparse) existing
bioethical ethical discourse on modern HCS (Miller and Grady 2001; Hope and
McMillan 2004; UK Academy of Medical Sciences 2005; Lederer 2008; Miller
and Rosenstein 2008; Gutmann and Wagner 2012; Bambery et al. 2015; Shah et al.
2017) appears to reflect consensus that intentional infection of human research
participants per se is not ethically unacceptable—whereas grossly unethical
challenge studies of the past were wrong for other reasons (e.g., they involved
uncontrolled infection with especially dangerous and/or deadly pathogens; lack of
voluntary informed consent, and sometimes violent force; exceptionally vulnerable
populations, such as prisoners; etc.).
HCS are nonetheless ethically sensitive—and, inter alia, they raise complex
questions concerning (i) the limit of acceptable risks to which healthy volunteers
may be exposed, (ii) appropriate financial payment/compensation of participants,
(iii) the potential need for special review procedures (e.g., involving dedicated
committees and/or the involvement of infectious disease experts), (iv) the need for
protection of third-parties from infection (by participants), and (v) appropriate
criteria and processes for participant selection/exclusion.
Researchers involved in modern HCS have been especially careful to avoid
(severe and/or irreversible) harm to participants, in part via exclusion of vulnerable
individuals. This is a major reason why modern HCS have been conducted almost
entirely in wealthy developed nations, even for infections/diseases that are usually
only present elsewhere. This is unfortunate because—due to population differences
regarding naturally acquired immunity, co-infections, genetics, microbiome,
nutrition, and so on—research conducted in high-income settings may not always
translate well to LMICs where neglected diseases (for which research and
development of new interventions are especially important) are endemic. For this
1 Introduction 3
and other reasons, there have been increased calls for HCS in endemic settings
(Gordon et al. 2017; Baay et al. 2018; Elliott et al. 2018).
In a review of the literature for this project, we identified 13 LMIC HCS
published between 1992 and 2018 that were conducted in Thailand, Colombia,
Tanzania, Kenya, and Gabon—countries in which the pathogens used (malaria,
cholera, and Shigella) are endemic. These studies recruited around 400 individuals
in total, which is less than 1% of the >40,000 volunteers who have participated in
HCS in high income countries (HICs) in since World War II (Kalil et al. 2012;
Evers et al. 2015).
Despite the potential scientific benefits of conducting HCS in endemic countries,
HCS in such countries may raise (or be perceived to raise) particular challenges
regarding informed consent (due to language barriers and/or limited educational
background of potential participants) and/or concerns about “undue inducement”
(e.g., if financial compensation is “too high”, in light of socio-economic status of
potential participants) in addition to more general worries about potentially risky
research involving vulnerable human subjects. Furthermore, the risks of spreading
infections from study participants to third parties may be higher in some endemic
areas and/or underprivileged populations (e.g., because of the presence of vectors for
vector-borne diseases, or the absence of adequate sanitation to prevent the spread of
diarrhoeal disease).
On the other hand, there may be cases where infection during HCS is less
risky/harmful to participants in endemic settings than participants in wealthy
developed countries—e.g., if the former have naturally acquired (partial) immunity
to the pathogen under study (making resultant illness less severe) whereas the latter
do not. Participation in HCS may sometimes even have direct benefits for healthy
participants in endemic countries (which is usually not the case for participants
from non-endemic wealthy nations) if/when (i) controlled infection leads to
protective immunity against endemic diseases that otherwise would have put them
at risk and/or (ii) HCS involves infection with a locally prevalent pathogen
participants would have otherwise likely been infected with later, but controlled
infection (yielding immunity) leads to less severe illness than would otherwise be
expected (in light of monitoring of, and care provided to, participants) (Selgelid
and Jamrozik 2018) and/or (iii) HCS participants receive an experimental vaccine
that turns out to protect against subsequent infection (after the study) with locally
prevalent strains of the pathogen in question.
Weighing the potential benefits and burdens (including risks to participants and
third parties) associated with HCS requires careful attention to scientific and ethical
aspects of study design, and should also involve learning from local communities
regarding local priorities and the public acceptance of potential research designs
etc. In any case, HCS should be conducted according to appropriate requirements
of ethical and regulatory review, which may need to be adapted to this relatively
complex and (in some settings) novel area of scientific research.
4 1 Introduction
1.1 Focus of This Report
This report aims to fill a gap in the current literature by focusing particularly on ethical
and regulatory issues that are specific and/or highly salient to challenge studies
conducted in LMICs (where many pathogens of interest are primarily endemic).
Having reviewed relevant scientific and bioethical literature, constructed case studies
of LMIC HCS, and conducted qualitative interviews with relevant experts in LMIC
HCS, we ultimately sought to identify (i) areas of consensus regarding ethical issues




Our review of academic literature and regulatory documents was particularly
focused on identifying (i) primary scientific papers detailing LMIC HCS, (ii)
relevant historical examples of (other) HCS, (iii) regulatory documents or policy
consultations specific to HCS (whether HIC or LMIC), and (iv) bioethical analyses
of HCS and/or ethical issues relevant to HCS in LMICs.
Relevant articles published between 1700 and 31st December 2018 were
identified through searches in the authors’ personal files, Google Scholar, and
PubMed. Articles arising from these searches and citations within those articles
were reviewed. For LMIC HCS, we included primary publications that gave details
of HCS methods and results; conference abstracts were excluded due to lack of
detail. Searches were conducted in English and articles published in English were
the primary resources. Where articles in other languages had translations of their
abstract or article available in English, these were also reviewed. The search
strategy included the terms: bioethics, dengue, ethic*, cholera, challenge model,
challenge study, controlled human infection model (CHIM), controlled human
malaria infection (CHMI), histor*, human challenge, human infection study,
malaria, regulat*, schistosomiasis, shigella, typhoid, Zika.
1.2.2 Qualitative Interviews
Our research team conducted qualitative interviews with 45 participants. We initially
recruited informants based on involvement in the conduct of recent HCS in LMICs,
expertise related to HCS, expertise in research ethics, and/or involvement in the
regulation and/or funding of HCS research. Many interviewees currently working in
HICs had been involved in and/or had expertise related to LMIC HCS in particular.
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Primary area of expertise
Science 33 73.3
Ethics 7 15.6
Regulatory representative 4 8.9
Funder representative 1 2.2





North America 15 33.3






Further informants were recruited via “snowball” sampling, based on suggestions
from the above informants at timeof interview.Asdetailed in (Table 1.1),we recruited
a diverse group of participants with a wide range of expertise. Deidentified interview
transcripts were coded thematically with a combination of pre-set and open coding.
The research team, informed by the main aims of the study, agreed upon an initial
code list. Coding then progressed openly and iteratively as emergent codes arose
and coding categories were further refined as agreed by the research team. Data
were organised and cleaned for use in the final analysis. Coded data were analysed
to identify overarching themes and sub-themes (that were validated through initial
member checking in subsequent interviews and via themechanisms discussed below)
with validated themes being used to inform the structure of this Final Report. As part
of the consent processes, interview participants consented to be quoted anonymously
(by pseudonym) in this report and other relevant publications and/or towaive the right
to anonymity and be quoted by name.
1.2.3 Synthesis and Validity Checking
The findings of the literature review and thematic analyses of qualitative data were
synthesised in this Final Report. Draft copies of the Final Report were shared with
(i) a subset of participants who provided feedback to the research team (enabling
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an assessment of internal validity) and (ii) participants at two international meetings
of researchers and policymakers with relevant expertise (enabling an assessment of
external validity and transferability).1 Comments were incorporated, in most cases
with de-identified acknowledgement in light of participants’ wishes.
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Chapter 2
History of Human Challenge Studies
2.1 Experimental Infection in the 18th–19th Century
The intentional infection of human beings with pathogens with the aim of
achieving benefits (chiefly, the prevention of more severe disease) has occurred for
centuries; the (semi-)systematic testing and recording of such methods dates to the
18th Century in England (Halsband 1953; Weiss and Esparza 2015). Although the
credit for initiating a modern science of vaccination is usually accorded to Edward
Jenner (1749–1823), who pioneered the use of cowpox (cow giving rise to the
vache in vaccine, a term coined by Jenner) to prevent smallpox, variolation
(sometimes referred to as ‘inoculation’, i.e., the prevention of smallpox by injection
or insufflation of material believed to produce a mild infection and thus convey an
attenuated risk of the disease) began much earlier, in Asia and the Eastern
Mediterranean, and was introduced to England and North America in the early 18th
Century (Timonius and Woodward 1714; Halsband 1953, Gross and Sepkowitz
1998; Weiss and Esparza 2015). Furthermore, that prior infection with cowpox
protected humans against infection with smallpox was widely believed in cattle
farming communities in England (and elsewhere) long before Jenner’s
experiments; at least one English farmer, Benjamin Jesty, is known to have
intentionally infected members of his family with cowpox as a means of preventing
smallpox in 1774 (i.e., 25 years before Jenner’s experiments) (Gross and Sepkowitz
1998). Yet, although there were some earlier ‘trials’ of smallpox variolation and
cowpox vaccination, Jenner’s testing of the cowpox vaccine was more systematic,
and involved intentional exposure to smallpox after vaccination (with cowpox) to
test efficacy in 1796. However, unlike modern human challenge studies, Jenner’s
investigations in the late 18th Century did not involve (i) systematic study of the
methods required to induce disease safely and reliably in humans or (ii) the testing
of preventive/therapeutic interventions against a reliable model of infection.
© The Author(s) 2021
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One of Jenner’s teachers had been the prominent Scottish surgeon John Hunter,
a local pioneer of smallpox variolation (which carried higher risks than the later
practice of vaccination) (Turk and Allen 1990). Although Hunter is credited with
many positive achievements, he has also become infamous for his attempt to prove
his (later falsified) theory that gonorrhoea and syphilis were in fact the same
disease. In 1767, Hunter used an experimental (challenge) technique: the injection
of “venereal matter” from a patient with gonorrhoea into the penis of a single
research subject (Dempster 1978). Though it is sometimes claimed, even in recent
times (Gladstein 2005), that Hunter himself was the subject, there is no
contemporaneous evidence to support this theory, and it appears more likely that
Hunter experimented on another individual—especially since it was known that he
had attempted to transmit gonorrhoea to others via inoculation of the skin
(Dempster 1978). Importantly, the research subject developed evidence of syphilis,
which Hunter took (erroneously) as evidence in favour of his theory (that
gonorrhoea and syphilis were the same disease); it now appears more likely that the
patient with gonorrhoea from whom the sample was obtained was also infected
with syphilis. Thus, the experiment was scientifically flawed and (although
mercury-based treatment was provided for the experimental syphilis infection
(Wright 1981)) arguably carried significant risks that many would consider
unacceptably high—especially on the assumption that this was not a case of
self-experimentation (self-experimentation is discussed further below).
During the 19th Century there were significant developments in microbiological
understanding of infectious disease. Towards the end of the century in particular,
challenge experiments generally became more systematic (discussed below in
‘Early challenge studies with vector-borne diseases’). However, from 1800–1880,
several experiments that would now be judged highly unethical took place in
Europe (Macneill 2010). Irish, German, and Russian physician-investigators
injected infectious material from patients with gonorrhoea and syphilis into
children and babies, and at least one baby died as a result. Although these
investigations did appear to confirm the transmission of such infections, the studies
were poorly controlled (due to the rudimentary knowledge of microbiology and
lack of available treatments at the time, and perhaps also to the callousness of the
investigators). The use of, and harm to, minors (even though some were teenagers
who were said to have agreed to participate), furthermore, struck some physicians
of the time as immoral and likely unnecessary (Macneill 2010).
One reason it was not necessary to experiment on others (including minors) is that
challenge studies can involve self-experimentation, which—especially under such
uncontrolled and uncertain conditions—might be considered ethically preferable to
the recruitment of others. For example, two scientists deliberately infected themselves
with cholera bacteria in 1892. One developed clinical cholera, and this was taken as
significant evidence linking the microbe with the disease (Benyajati 1966). Another
early challenge study, testing a typhoid vaccine in two ‘Officers of the IndianMedical
Service’ took place in 1896. Though few details are supplied, if these individuals
were medically trained and aware of the details of the study then they may have been
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able to provide (what would now be considered) proper informed consent to the risks
to which they were exposed (Wright 1896).
2.2 Early Challenge Studies with Vector-Borne Diseases
In the late 19th and early 20th Century additional early challenge experiments began
to occur on a larger scale and (generally) with increasing scientific rigor. Challenge
studies investigating what would now be referred to as vector-borne diseases (e.g.,
yellow fever, malaria, and dengue) were particularly prominent at the time, and often
conducted in endemic countries (in contrast to later challenge studies which have
been predominantly conducted in non-endemic countries). Famous early examples of
such experiments include (i) the failed attempts by Carlos Finlay to transmit yellow
fever from symptomatic patients to healthy individuals in Cuba from 1881–18931
(Finlay 1886, 1937; Clements andHarbach 2017) and (ii) the successful transmission
of malaria via infected mosquitoes in Italy in 1898 by Battista Grassi (Grassi et al.
1898; Capanna 2006). The latter study provided the first experimental evidence that
malaria was transmitted to humans by mosquitoes.2 Since malaria was, at that time,
endemic to much of Italy (potentially casting doubt on Grassi’s findings, because
individuals exposed to mosquitoes during the trial could have contracted the disease
elsewhere), a similar experiment was repeated in London (with infected mosquitoes
transported from Italy) by Patrick Manson in 1900 (Manson 1900). Manson infected
two volunteers (thought to include his son), and successfully cured the induced
infection by administration of quinine (Cox 2010).
Elsewhere during the same period, other early research on yellow fever employed
challenge study techniques, though such efforts were sometimes unsuccessful and/or
harmful. In 1897, Giuseppe Sanarelli, an Italian physician in Uruguay, claimed to
have isolated a bacterial cause of yellow fever (now known to be caused by a virus)
and injected a culture of these bacteria into 5 hospital patients, perhaps without
their knowledge or consent, of whom 3 died (Lederer 2008). The famous Canadian
physician William Osler condemned these experiments in the following terms:
To deliberately inject a poison of known high degree of virulency into a human being, unless
you obtain that man’s sanction, is not ridiculous, it is criminal. (Sternberg 1898)
Beyond Osler’s sentiment regarding the importance of obtaining a person’s
sanction (i.e., consent) to be challenged, many contemporary readers will
additionally object to Sanarelli’s apparent callous disregard for the safety of his
1Although Finlay’s overall hypothesis was correct, these experiments failed to demonstrate
transmission because the interval between biting infected patients and biting healthy individuals
(now known as the ‘extrinsic incubation period’) was too short.
2Ronald Ross, the English contemporary of Grassi who was awarded the 1902 Nobel prize for
identifying mosquito transmission of malaria, had (in 1897) shown that parasites were transmitted
from human malaria patients to mosquitoes but used challenge studies in birds (with avian malaria),
rather than human challenge, to show the transmission from mosquitoes.
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‘research subjects’. While modern HCS standardly involve healthy volunteers,
Sanarelli’s subjects were neither healthy (being hospital patients) nor volunteers.
The virulence of the organism is a more complex issue: the ‘poison’ in questions
was, if not known to be highly virulent (since this was being ‘tested’), then at least
expected to be highly virulent (although in retrospect Sanarelli was clearly
ill-informed about the infectious agent he thought he was administering). It is
noteworthy, however, that other researchers at the time were also using potentially
highly virulent forms of the (presumed) agent of yellow fever, albeit with greater
care, less harm, and ultimately greater scientific success.
In the same year (1897), in Mexico, a Dr. Ruis injected the blood of yellow fever
patients into 3 individuals (whether they consented is unknown) without producing
symptoms of disease. Ruis’ unsuccessful experiments pre-dated the successful and
larger scale studies led by Walter Reed (Reed 1902). In 1900 experiments by Reed
and other members of the Yellow Fever Commission in Cuba demonstrated the
transmission of yellow fever to healthy volunteers (i) by injection of blood from
confirmed cases and (ii) by mosquitoes fed on confirmed cases. Reed’s research
ultimately led to the development of methods to prevent infection by avoiding
mosquitoes (Reed et al. 1900; Lederer 2008; Clements and Harbach 2017).
Reed is frequently credited for establishing a prototype of informed consent for
research because subjects in these (what would now be described as) yellow fever
challenge studies were asked to sign a contract that outlined the expected risks of
the research. The contract also entailed payment of $100 (USD)—the equivalent of
more than $3000 in 2019—for two months’ participation in the research, which
was doubled ($200, equivalent to ~$6000) for those who contracted yellow fever
(Lederer 2008; Clements and Harbach 2017). The contract also made note of the
high background risk of contracting yellow fever in Cuba at the time, and the
relative benefits of high quality medical care for those infected in the course of the
research (versus being infected in an uncontrolled fashion with less medical
oversight) (Lederer 2008). Although no research subjects in these initial
experiments died, the majority contracted yellow fever (in some cases with severe
symptoms). One member of the research team (Jesse Lazear) died from yellow
fever despite the best available care (Lederer 2008). It has been suggested that
Reed’s relatively scrupulous proto-consent procedures were motivated by his
awareness of earlier criticisms of Sanarelli (Lederer 2008). It has nevertheless been
argued that Reed’s consent form did not sufficiently emphasise the risk of death
due to experimental infection with yellow fever (Chaves-Carballo 2013).
Subsequent attempts to develop a yellow fever vaccine in Cuba using a challenge
study based on the work of Reed’s team (and using a similar consent form) led to
three deaths among research participants, public outcry, and the termination of such
experiments in Cuba (Chaves-Carballo 2013).
Elsewhere, from 1902 onwards, researchers in Lebanon, Syria, the Philippines,
and Australia conducted early challenge studies with dengue virus (which was, at
the time, endemic in parts of all four countries, though it has since been eliminated
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in Australia), which were followed by later studies (from the 1930s onwards) in the
USA and Japan (Cleland et al. 1918; Cleland and Bradley 1919; Simmons et al.
1930; Larsen et al. 2015). Early dengue challenge studies sometimes recruited
participants who were military personnel and/or medical researchers (including
cases of self-experimentation), although Australian researchers also recruited
patients from a local asylum (few details regarding recruitment procedures were
published), perhaps because of a reported “unexpected difficulty of obtaining
volunteers, even with a considerable monetary inducement” (amount not specified)
(Cleland and Bradley 1919).
Similarly, early challenge studies of leishmaniasis were conducted in endemic
regions of North Africa, the Eastern Mediterranean, and India.3 In 1910
investigators published results demonstrating that the inoculation of the skin of
research subjects with parasites presumed to cause cutaneous leishmaniasis caused
local eruption of the disease (though few details regarding the participants were
published) (Nicolle and Manceux 1910; Row 1912). In 1921, the transmission of
cutaneous leishmaniasis by sand flies was demonstrated in a human challenge
study involving self-experimentation (Théodoridès 1997). Two decades later, after
multiple failed attempts (Killick-Kendrick 2013), researchers in India demonstrated
the transmission of visceral leishmaniasis (kala-azar) to 5 out of 5 healthy
volunteers by infected sand fly bite (Swaminath et al. 1942). The researchers were
particularly alert to potential challenges of conducting such research in endemic
areas, including (i) the potential role of prior immunity among participants from
endemic regions (as a result of previous exposure) and (ii) the possibility that
participants might be bitten by other insects and/or infected with leishmania during
the study. As a result, they recruited volunteers from a nearby non-endemic area,
transported them to a research facility in an endemic area where the experimental
infection took place under (by the standards of the time) strict isolation from
contact with other insects, and returned them to a non-endemic area for longer term
observation. Volunteers were also ‘generously compensated’ with payment of 400
rupees per month (at a time when the usual wage for unskilled labour was less than
200 rupees per month (Palekar 1957)) and provided with curative treatment
(Killick-Kendrick 2013). Of note, these human experiments were considered
controversial at the time, and previous requests to use prisoners as research subjects
were denied (although this may have been in part because local authorities would
not permit a reduction in prison sentences as an inducement for inmates to
participate (Killick-Kendrick 2013); such inducements had been used in early
smallpox vaccine research in the 18th century during which six British prisoners
were freed as a reward for participation (Halsband 1953)). Senior British Army
officials also refused to approve the use of human participants (multiple animal
studies, including challenge studies, were also being conducted) although it has
been suggested that the practice was unofficially tolerated, in part because of the
significant expected scientific value of the research (Killick-Kendrick 2013).
3We are grateful to Dr. Kate Emary for pointing us in the direction of early leishmania challenge
studies.
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2.3 Malariotherapy
The 1927 Nobel Prize in Medicine was awarded to the Austrian psychiatrist Julius
Wagner-Jauregg for the discovery of malariotherapy (intentional infection with
malaria as treatment) for neurosyphilis,4 which became a routine treatment in many
psychiatric hospitals, administered either by mosquito challenge or by direct
injection of human blood infected with malaria (Chopra et al. 1941; Snounou and
Pérignon 2013). The use of this ‘therapeutic’ malaria infection was widespread in
Europe, North and South America, and India (Chopra et al. 1941)5 until the 1940s
when penicillin was discovered as an effective treatment for syphilis (Frith 2012;
Snounou and Pérignon 2013). The methods used to ‘prove’ that malariotherapy
was effective for neurosyphillis appear quite rudimentary in comparison with 21st
Century science (e.g., because the many case series published at the time lacked
control subjects), and any attempt to undertake a modern, retrospective review of
malariotherapy would inevitably be subject to possible biases, making it difficult to
draw firm conclusions (Austin et al. 1992). Some patients died after receiving
malariotherapy but, again, it is difficult to know how many of these cases were due
to malaria infection itself, as opposed to other factors, including complications of
neurosyphilis.6 In any case, (neuro)psychiatric patients undergoing malariotherapy
were effectively used as research subjects by malariologists in de facto human
challenge studies that improved scientific understanding of malaria with regards to
(i) confirmation that malaria was caused by several different species of
Plasmodium parasites, (ii) the natural history of disease, (iii) acquired immunity,
(iv) transmission dynamics, and (v) the dormant liver stage of vivax malaria7
(Shortt et al. 1948; Snounou and Pérignon 2013). At least one investigation
reportedly involved consent from the patient and his spouse for a study including
liver biopsies (Shortt et al. 1948). These malaria challenge studies undertaken as
part of malariotherapy (with or without what would now be considered valid
consent to research participation) are still cited by HCS researchers today,
including in some of the endemic-region malaria HCS reviewed in detail below
(Shekalaghe et al. 2014; Vallejo et al. 2016). Psychiatric malariotherapy patients
4The debilitating end-stage of syphilis that was relatively common at the time and had no effective
treatment.
5Interestingly (in the context of this review of endemic-region HCS research) while most
malariotherapy programs in Europe and North America reportedly used P. vivax, at least one Indian
centre used P. falciparum (which usually causes a more severe form of malaria) because it was
believed that the local population had significant immunity to P. vivax that would attenuate the
benefits of malariotherapy (see Chopra et al. 1941).
6However, when falciparum malaria (a more severe form) was used by mistake in malaria-naïve
patients for malariotherapy instead of vivax malaria (the milder form of malaria usually used), the
mortality rate was much higher (Austin et al. 1992). In contrast, see the use of falciparum in India
in the footnote above.
7First identified in 1948 when a malariotherapy patient reportedly consented to a liver biopsy (see
Shortt et al. 1948)—i.e., in a proto-challenge study.
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were, furthermore, the source of parasites used in other studies, including the
Stateville Penitentiary program discussed below (Alving et al. 1948; Miller 2013).
While it was not necessary to use malariotherapy patients to study malaria (since
at least one similar study with liver biopsy was done contemporaneously in a
particularly altruistic healthy volunteer (Shortt et al. 1949)), researchers may have
reasoned that malariotherapy patients were ideal candidates for such studies in light
of expectations (based on what was known at the time) that they would directly
benefit from infection. In retrospect, however, it is questionable whether (i) all
patients with neurosyphilis were able to understand and consent to such research
(even in cases where consent was sought), and (ii) the persistent use of
malariotherapy in the era of penicillin (as a treatment for neurosyphilis) could have
been ethically justified.
2.4 Infamous 20th Century Cases and the Rise of Modern
Research Ethics
The genesis of modern research ethics (including the development of relevant
codes, declarations, guidelines, principles, etc.) is frequently traced to responses to
egregious cases of unethical research in the 20th century (Hope and McMillan
2004; Meltzer and Childress 2008). Several of these infamous cases involved
intentional infection of research subjects. For example, some of the atrocities
committed in the wartime research programs of Germany and Japan during World
War II involved intentional infection with pathogens including anthrax, chlamydia,
cholera, dysentery, glanders, hantavirus, malaria, paratyphoid, plague, tetanus,
tuberculosis, typhoid, and typhus (Tsuchiya 2008; Weindling 2008; Bambery et al.
2015). These programs collectively involved thousands of victims, many of whom
died as a result. Prisoners were violently forced to ‘participate’ (with no option to
refuse nor effort to seek consent); participation often involved uncontrolled
infection with pathogens known to cause severe disease and sometimes involved
the torture and murder of those infected (e.g., by vivisection) (Tsuchiya 2008;
Weindling 2008). Despite claims that such research aimed to improve measures to
protect military personnel from infectious diseases, much of the ‘research’ and/or
the procedures involved therein did not have a sound scientific rationale and thus
would not have been able to inform the development of such measures, even if it
had been conducted in a less violent manner (Tsuchiya 2008; Weindling 2008).
In the USA, contemporaneous war-related research also included recruitment of
prisoners for infection challenge studies. Although these were conducted under more
humane conditions, the voluntariness of consent, and the legitimacy of recruiting
prisoners for research more generally, has since been called into question (Bonham
andMoreno 2008; Miller 2013). Of particular relevance to current malaria challenge
research, Americanmilitary research during (and after)WWII included the Stateville
Penitentiary experiments (discussed in more detail below), which involved infection
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of prisoners with malaria (including, in later studies, resistant strains of malaria)
(Arnold et al. 1961; Miller 2013).
Later (in 1946–48), studies of sexually transmitted infections performed by
American researchers in Guatemala involved intentional infection of vulnerable
groups (e.g., sex workers, prisoners, soldiers, mentally disabled and
institutionalised patients) with pathogens (e.g., bacteria causing syphilis,
gonorrhoea, and chancroid) without their knowledge or consent, and also involved
deliberately withholding treatment for these infections (Frieden and Collins 2010;
Gutmann and Wagner 2012). In the United States, the Willowbrook School study
of infectious hepatitis (1950s to 1970s) involved the intentional infection of
mentally disabled, institutionalised children with viral hepatitis (which was, at that
time, endemic at the school with very high rates of background infection in both
‘patients’ and staff), with the aim of better describing its natural history, and testing
preventive and/or therapeutic interventions (Ward et al. 1958; Rothman 1982;
Robinson and Unruh 2008).
Although these studies were eventually met with widespread condemnation,
there is a consensus in the (limited) academic research ethics literature (discussed
below in more detail) that it was not intentional infection per se that made these
studies unethical, but rather other issues, particularly those related to (i) lack of or
inadequate informed consent, and/or (ii) exploitation and/or brutal treatment of
vulnerable populations (Miller and Grady 2001; Hope and McMillan 2004; Miller
and Rosenstein 2008; Bambery et al. 2015).
Nevertheless, in high-income countries, studies did continue among populations
sometimes described as ‘vulnerable’, e.g., prisoners (Glew et al. 1974) and military
personnel (among whom, similarly, it may be more difficult to assure truly
voluntary informed consent) (Bonham and Moreno 2008). In a retrospective
analysis of the Stateville penitentiary malaria challenge studies conducted by the
US military, Franklin Miller contrasts this research program with the (other)
abusive wartime research discussed above, noting that (although imprisoned)
subjects were invited (not forced) to volunteer, carefully screened for health
conditions, and monitored closely during the studies—meaning that such research
practices would be largely in accordance with many (subsequently developed)
codes of research ethics (Miller 2013). Miller does note, however, that during the
research severe adverse reactions and one death occurred (the latter reportedly due
neither to infection challenge nor to the antimalarial drugs being trialled), raising
plausible but unverifiable concerns that researchers may have been more willing to
expose prisoners to higher risks because they were incarcerated (and/or because of
the perceived urgency of army research that could save the lives of deployed
soldiers) (Miller 2013).
By the 1970s, a consensus was building (although it has perhaps never become
unanimous) among research ethicists in developed countries that research among
such ‘captive’ groups could be ethically problematic, ultimately resulting in more
careful review of research involving military personnel (although this has not
necessarily resolved the underlying ethical tensions) (Bonham and Moreno 2008;
Miller 2013), and strict regulations regarding research in prisons that eventually
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curtailed the recruitment of prisoners (Mishkin 2000; Rosenbaum and Sepkowitz
2002).8 Some have noted that adult students as a group may sometimes share
characteristics with other ‘captive’ groups that might lead to concerns about their
ability to consent (although perhaps to a lesser degree)—especially where they are
financially or professionally dependent on their academic superiors and/or required
to enroll as research participants as part of their studies (Bonham and Moreno
2008). Such considerations may be important for more recent challenge studies,
which frequently recruit from student populations.
2.5 Late 20th Century
Later, some post-WWII challenge studies, such as those in the UK Common Cold
Unit, involved volunteers from the general population. Although they predated
modern ethics regulations, these studies reportedly involved a careful explanation
of risks, voluntary consent, and isolation to prevent third party transmission; they
did, however, involve risks that were not well characterised at the time, such as the
potential for transmission of other pathogens (e.g., in bodily secretions used to
administer the infection challenge) for which there were no testing methods
available (Tyrrell 1992).
Elsewhere, at least one early (post-WWII)malaria challenge study took place took
place in East Africa (an endemic-region), investigating the degree to which sickle
cell trait (a genetic condition affecting red blood cells) protects against malaria.
In the 1954 publication of this study (Allison 1954), the 30 research subjects are
described as adult male volunteers from the Luo people, and it is mentioned that
risks were controlled by giving infected subjects “a prolonged course of antimalarial
chemotherapy”. Few other details apart from the infection rate in sickle cell trait
versus non-sickle trait participants are noted—e.g., the publication records neither
the presence nor severity of symptoms among participants, nor any consent process.
In 1956 there was also a case of self-experimentation by a single investigator in
Nigeria who infected himself with Zika virus and attempted to transmit the virus
from himself to laboratory mice (Bearcroft 1956).
While it is possible (perhaps likely) that other endemic region/low-resource
country challenge studies were conducted between World War II and 1992 (the date
of the first case study reviewed later in this report), our review found that there was
a very sparse literature regarding endemic region challenge research during this
period, especially as compared to the significant and relatively numerous studies
published from the late 19th Century to World War II. This may in part be due to
the significant social changes that occurred in endemic regions (many of which
8In one countervailing consideration, Rosenbaum and Sepkowitz (2002) cite a case of a group of
prisoners at (US) Jackson State Prison filing an (unsuccessful) lawsuit arguing that prisoners should
have more freedom to participate in research, though this may have been partly because of a view
that participation in research would entail thorough medical examination and care, which can be
difficult for prisoners to access under usual circumstances.
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were previously controlled by European imperial powers) at the end of the colonial
period.
Ethical concerns (and reactions to the egregious cases discussed above) have
perhaps contributed to a reluctance to undertake more HCS in LMICs (in addition
to any technical difficulties regarding the availability of necessary laboratory
infrastructure etc.) because (i) impoverished individuals and communities may be
(perceived to be) particularly vulnerable (e.g., to various kinds of harm,
exploitation, inducement by monetary payment, etc.), and (ii) valid informed
consent may be (perceived to be) more difficult to assure in some populations
within LMICs (e.g., because of language barriers, limited educational background,
etc.).
In any case, HCS research has been largely concentrated in HICs, even where
such research addresses pathogens that are primarily endemic in LMICs. For
example, in the latter half of the 20th Century, North American and European
researchers developed malaria challenge models, ultimately leading to several
parallel research programs (Spring et al. 2014; Friedman-Klabanoff et al. 2019). At
the outset, such studies were subject to few regulatory requirements and/or ethical
oversight mechanisms. Parasites were obtained from infected human ‘donors’;
challenges involved multiple ‘wild-type’ malaria pathogens (rather than, in the case
of falciparum malaria, the few well-characterised laboratory strains in widespread
use today); and prisoners and/or army personnel featured prominently among early
recruitment of participants (see discussion of these groups above)
(Friedman-Klabanoff et al. 2019).
Since the 1980s, improvements in scientific techniques as well as rigorous
regulatory and ethical oversight have supported the development of multiple HCS
research programs, studying a wide range of pathogens predominantly in HICs
(Miller 2013; Darton et al. 2015). Studies collectively enrolling tens of thousands
of healthy volunteers (Darton et al. 2015; Evers et al. 2015) have been safely
conducted with no deaths and very few serious or lasting harms reported among
HCS participants (Roestenberg et al. 2012; Darton et al. 2015). Pathogens/diseases
studied in such trials have included adenovirus, BCG (bacille
Calmette–Guérin—an attenuated form of M. bovis used as a tuberculosis vaccine),
campylobacter, Candida albicans, cholera, coronaviruses, cryptosporidium,
Cyclospora cayetanensis, cytomegalovirus, dengue, E. coli, giardia, hepatitis A &
B, hookworm (Ancyclostoma caninum and Necator americanus), influenza,
gonorrhoea, H. ducreyi, H. pylori, listeria, malaria, norovirus, parainfluenza,
parvovirus, pneumococcus, Q fever, respiratory syncytial virus, rhinovirus,
rotavirus, scabies, streptococci (non-pneumococcal), Shigella spp., Strongyloides
spp., and typhoid. Overall, not only have the vast majority of HCS been conducted
in HICs, but most studies have hitherto focused on pathogens that cause disease in
HICs (though they may also affect LMICs), rather than those that are primarily
endemic to LMICs; for example, rhinovirus (a cause of the common cold) has been
the pathogen associated with by far the greatest number of HCS (at least 55 studies
enrolling, collectively, >18,000 participants, in both respects more than for any
other pathogen) (Kalil et al. 2012; Darton et al. 2015; Evers et al. 2015). HCS have
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resulted in unique insights into host-pathogen interactions, as well as the
accelerated development of beneficial interventions, including for pathogens
primarily endemic in LMICs. For example, HCS have played a role in the
development of recently approved and/or licensed vaccines against typhoid (Jin
et al. 2017), cholera (Tacket et al. 1999), and malaria (Ballou 2009).
2.6 Capacity Building in Low- and Middle-Income
Countries
More recently, there have been calls for more HCS in endemic settings (particularly
for pathogens that are primarily endemic in LMICs) in order to accelerate vaccine
development and test new interventions in the populations at highest risk of relevant
diseases (Gibani et al. 2015; Gordon et al. 2017; Baay et al. 2018). Our review
identified no HCS conducted in LMICs from 1956 until 1992 when what appears
to be the first LMIC HCS in nearly 40 years took place in Thailand (Suntharasamai
et al. 1992). Researchers from LMICs have, however, participated in international
HCS projects (where the challenge infection takes place in a HIC). For example, Thai
researchers furnished mosquitoes infected with malaria parasites for HCS conducted
in the USA (Malaria Vaccine Initiative 2016). However, it has been reported that Thai
institutions were initially reluctant to conduct vivax malaria HCS in Thailand (partly
because Thai authorities were awaiting further evidence of the safety and utility of
the challenge model in question) (Malaria Vaccine Initiative 2016).
From 1992 onwards, Thai researchers successfully conducted challenge studies
with cholera and Shigella in populations of Thai volunteers. Elsewhere, in the last
two decades, well-established research centres in Colombia, Tanzania, Kenya, and
Gabon have successfully conducted malaria HCS, often in collaboration with HIC
HCS researchers (discussed in detail in Chap. 5). Researchers in more
LMICs—including Equatorial Guinea, India, Indonesia, Malawi, Mali, Uganda,
and Vietnam—are understood to be considering and/or conducting HCS at present.
Later, we discuss the ethical and scientific case for conducting (more)
appropriately designed HCS in endemic LMICs in greater detail (Section
“Potential Individual Benefits of Participation in Endemic Settings”). However,
even if there is an especially strong case for conducting such studies, certain (other)
ethical issues related to their design and conduct warrant particularly careful
attention. This is because (i) HCS may sometimes involve, or at least be perceived
to involve, particularly high levels of risks (for participants and third parties) and
other burdens for participants (and such studies must therefore be carefully
designed and conducted to ensure that expected benefits outweigh risks and
burdens), and (ii) local and/or international community acceptance of HCS being
conducted in endemic LMICs may be contingent on such studies being designed
and conducted to especially high ethical (and scientific) standards, and (iii) certain
ethical considerations, though familiar in research ethics discourse, may have
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particular (underexplored) implications in the context of endemic LMIC HCS. The
evaluation of these latter implications may both improve the design and conduct of
LMIC HCS and/or provide novel case studies relevant to ongoing debates in
research ethics. The remainder of this report summarises ethical and regulatory
issues relevant to such studies, including insights from stakeholders interviewed for
the current project, followed by a comparative review of LMIC HCS published in
1992–2018.
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For members of the public, and perhaps many scientists and ethicists, who may be
surprised to learn that HCS involving intentional infection (still) take place, the first
ethical question may be whether intentionally infecting healthy volunteers as part
of research is ever acceptable (Lynch 2012; Evers et al. 2015). Intuitions that such
research practices should not be permitted may rest on presumptions that
intentional infection with pathogens would involve unacceptably high levels of risk
(see Sect. 3.3.1) and/or that physicians should be curing diseases rather causing
them to occur among research participants (i.e., that intentionally causing disease is
a moral wrong over and above the risks involved) (Hope and McMillan 2004). In an
early paper on ethical aspects of HCS, Hope and McMillan provide an extensive
philosophical analysis (summarised in the following paragraphs) of the question of
whether intentional infection of participants is worse, morally speaking, than
imposing other kinds of risks on participants (Hope and McMillan 2004).
Acts resulting in harm are often viewed as less morally acceptable where the
harm was intended, rather than merely foreseen. To explore the application of the
distinction between intended and foreseen harms to HCS, Hope and McMillan
compare infecting a research participant (with a potentially harmful disease) with
performing a lumbar puncture on a participant (with the aim of testing the person’s
cerebrospinal fluid, or CSF) which might generally be considered an acceptable
part of research involving human participants. Supposing that both acts might lead
to similar risks and/or harms (a lumbar puncture can cause a severe headache, for
example, as can many infectious diseases), one might think that only in the HCS
case is the harm intended—in the lumbar puncture case, the small probability of
severe side-effects might be considered foreseen, but not intended.
There are several possible ways of drawing distinctions between intended and
foreseen harms. First, one might argue that foreseen harms are those that occur when
the ultimate aim of an act is to bring about a beneficial outcome but there is no (other)
way of bringing about this beneficial outcome without bringing about the harm in
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question. This way of drawing the distinction might assume that in such cases the
(only) intent is to produce a good outcome, and any harm that occurs is a foreseeable
but unintended side-effect. For example, in the lumbar puncture case, there is usually
no less harmful way to test research participants’ CSF other than by performing a
lumbar puncture (i.e. puncturing the lining of the spinal cord with a needle, which
itself leads to the risk of side-effects). However, Hope and McMillan note that on
this way of drawing the distinction, the harms associated with HCS could also be
considered ‘merely’ foreseen:
[I]f there were less harmful means of bringing about the testing of the putative vaccine
they would be adopted: the risk of harm resulting from infecting the research participants is
foreseen but not intended. (Hope and McMillan 2004)
Hope and McMillan further argue that the view that the moral acceptability of an
action depends onwhether any resulting harms are intended versus (merely) foreseen,
where the intention/foresight distinction is drawn in this way, ultimately fails because
this would lead to counterintuitive judgements in other scenarios. For example, this
view would suggest that it would be acceptable to kill one innocent person if this
were the only way of saving more than one other person.
On a secondway of drawing the distinction between intended and foreseen harms,
one might argue that harms are merely foreseeable when an act that causes a harm
in the process of causing a beneficial outcome is more closely causally related to
producing the good outcome than it is to producing the harm (Hope and McMillan
cite Frances Kamm as articulating a similar idea with her “Principle of Permissible
Harm” (Kamm1989)).However, even if itwere the case that this distinction identified
an ethically salient difference,1 it is not clear that the causal connections between
intentional infection and harm are any closer than those between a lumbar puncture
and the harms of a known side-effect of such a procedure (Hope andMcMillan 2004).
Ultimately, Hope and McMillan conclude that such distinctions fail to support
ethically relevant differences between the harms of challenge infections and other
kinds of harms imposed on healthy volunteers in the pursuit of socially valuable
research. Thus, the intentional infection of participants involved in (carefully
conducted) HCS can, under certain conditions, be ethically acceptable. The authors
note that modern HCS researchers typically take great care to minimise risks to
participants (e.g. through the choice of challenge strain and close monitoring, early
diagnosis, and treatment of participants). If the risks of HCS are thus within
acceptable limits (i.e. such risks fall within widely accepted limits to research
risks), and arguments regarding the unacceptability of intentional infection (as
compared with other types of research risks) ultimately do not succeed, then there
is no prima facie reason to rule out the ethical acceptability of intentional infection
as a research practice.
1Hope and McMillan note that intuitions regarding the ethical salience of such ‘causal intimacy’
might actually arise because of the probability of certain harms and benefits arising from an act
(since close causal relations between an act and particular consequences are often correlated with
a higher probability of those consequences occurring), rather than any other meaningful difference
in causation.
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Moreover, in the limited ethics literature on HCS to date, there appears to be
a consensus that intentional infection per se (and the risk associated with it, once
appropriately minimised) can be permissible so long as certain ethical conditions
are met (Miller and Grady 2001; Hope and McMillan 2004; Pollard et al. 2012;
Bambery et al. 2015; Shah et al. 2017; Selgelid and Jamrozik 2018). As one ethicist
from North America noted during an interview for the current project, HCS are not
the only kind of research that involve risks to participants without the prospect of
benefit:
There are these arguments [that challenge studies are] contrary to physicians’ obligations,
[that] primum non nocere [the ethical principle that doctors should first do no harm] rules it
out and so on. I don’t buy those arguments. I think that would rule out most of all research.
Research puts people at risk, in part, for the benefit of others.
HCS are nonetheless ethically sensitive and raise important questions, some of
which are similar to issues in other areas of research although there may be specific
implications of such questions for HCS in particular. Such questions (discussed in
the following sections) include those regarding (i) the kinds and level of benefits
that would justify exposing healthy volunteers to risk, (ii) how the eventual benefits
of HCS should be shared with participants and relevant communities, (iii) the
acceptable limit of burdens (including risks) to which healthy volunteers may
acceptably be exposed, (iv) the need for protection of third-parties from infection
(by participants), (v) fair participant selection/exclusion, especially when
considering recruitment or exclusion of vulnerable individuals, (vi) appropriate
financial payment of participants, (vii) the potential need for special ethical
principles/guidelines/frameworks and/or review procedures (e.g. special
committees), (viii) appropriate selection, development, and regulation of challenge
strains, (ix) the role(s) of HCS in the licensure of new interventions (e.g., vaccines),
and (x) the need for community engagement to raise awareness of challenge studies
and ensure that such studies are publicly acceptable to the communities in which
they take place.
3.2 Benefits
3.2.1 Scientific Rationale and Social Value
There is a general consensus in research ethics that although research participants
may be exposed to risk without the prospect of individual benefit, such risks are only
justified to the extent that the study is designed according to a valid scientific rationale
that is plausibly expected to lead to significant social value (over and above other
study designs involving less risk to human volunteers) (Wikler 2017). The social
value of HCS research might include improved scientific knowledge and/or public
health benefits, with a key example of the latter being the (accelerated) development
of new interventions that reduce the harms caused by the infectious disease being
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studied (Savulescu 1998; Miller and Grady 2001; Hope andMcMillan 2004; Pollard
et al. 2012; Bambery et al. 2015).
Thus, where HCS involve particularly significant burdens (e.g., risks to
participants and third parties), they arguably require a particularly strong scientific
rationale. Inter alia, proposed HCS should be compared with other study designs to
(insofar as possible) ensure that similar benefits cannot be achieved with research
involving fewer burdens. Alternative study designs could include (i) animal
models2—thus the rationale for HCS might be stronger in cases where the
pathogen in question only infects humans and/or (ii) studies of natural history or
novel treatments in patients diagnosed as having been naturally infected with the
pathogen in question (although natural history studies might sometimes involve
withholding proven effective treatment, to which patients might not consent, or
which might be ethically problematic for other reasons), and/or (iii) field trials (e.g.,
where large numbers of individuals are given an investigational vaccine or placebo
(or an existing vaccine) and followed until a sufficient number of each group are
exposed to the infection in question to make accurate estimates of vaccine efficacy).
With respect to testing interventions, field trials are arguably the most important
comparator for HCS designs. Compared to field trials, HCSmay often be shorter, less
costly, and involve fewer participants—thus allowing a more efficient ‘selection’ of
potentially effective interventions which could (if this results in faster development,
licensure, and implementation of such interventions) lead to public health benefits
being achieved sooner (Sauerwein et al. 2011; Roestenberg et al. 2018b, c) (see also
Sect. 4.3.3). Where this is the case, there may thus be a strong ethical rationale to
pursue challenge studies as part of vaccine development.
Furthermore, other things being equal, there may be a stronger scientific and/or
ethical rationale to conduct challenge studies where (i) field studies are impractical
(e.g., where a pathogen is often asymptomatic and/or currently causes few cases
but is likely to cause sporadic epidemics in future (Shah et al. 2017)) and/or (ii)
immune correlates of protection are unknown (since, if it is already known that a
certain measurable immune response to a vaccine is correlated with a certain level
of clinical protection, then there would be arguably be less rationale for infecting
participants in order to measure vaccine efficacy), and/or (iii) there is a clear pathway
from HCS to licensure (discussed later in Sect. 4.3) (Chattopadhyay and Pratt 2017).
Thus far, the advantages of challenge studies in terms of reduced time and
reduced costs (etc.) have rarely been quantified. However, there are clearly
quantifiable advantages in terms of the number of participants—challenge studies
typically enroll less than 100 participants (see the Case Studies reviewed in
Chap. 5. of this report) or sometimes up to a few hundred, whereas field trials of
vaccines typically enroll thousands (or sometimes many tens of thousands) of
participants. To take one comparison, the recent HCS that supported WHO
pre-approval of a new typhoid vaccine challenged 103 participants with typhoid
(Jin et al. 2017), whereas previous field trials of other typhoid vaccines have
2Animal models, including animal challenge studies (perhaps especially in non-human primates),
may raise ethical issues of their own, although these are not the focus of this report.
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involved between tens of thousands and up to around 100,000 participants (Wahdan
et al. 1980; Levine et al. 1987). On the other hand, although vaccine field trials
involve risks for participants, including risks of exposure to the pathogen in
question (perhaps especially among groups who receive a placebo vaccine in cases
where the investigational vaccine is shown to provide individual protection), they
typically involve less burdens per participant than HCS (which, for example,
generally require much closer monitoring of participants, especially during
inpatient HCS), and do not necessarily involve a high probability of infection
(whereas HCS participants are intentionally exposed to infection, usually in such a
way as to ensure that most, if not all, become infected). Thus, risk-benefit
assessments comparing HCS with other designs will require both scientific and
ethical analysis. Ideally, researchers and funders would be able to specify the
expected benefits, expected burdens, and expected costs of all plausible potential
research programs (e.g., HCS vs. field trial) aimed at particular scientific
knowledge and/or public health benefits, so as to permit the rational and efficient
design of research programs and the efficient allocation of resources. This can be
difficult, especially when the results of different scientific investigations, and the
probability and/or benefit of eventual implementation of a new intervention, are
difficult to estimate ex ante (and often overestimated even by experts (Kiwanuka
et al. 2018)) in part because of uncertainties regarding the outcomes of scientific
research (see Box 3.1), and in part because of uncertainties about the translation of
(early phase) results (including via regulatory development pathways) into the
licensure and deployment of novel interventions leading ultimately to public health
benefits. Yet recent analyses of the role of HCS in vaccine development have
suggested developing systematic algorithms that could help to determine the
optimal development strategy and/or series of studies required (Roestenberg et al.
2018). Stakeholders interviewed for this project were optimistic regarding the
potential for well-designed HCS to accelerate the development of interventions
while involving fewer participants,3 although some were more cautious regarding
efficiency and/or cost-effectiveness comparisons between HCS and field trials (see
Box 3.1).
Box 3.1 Rationale for HCS
[I]f you have a good model … then I think it can be very useful in streamlining
vaccine development and … eliminating candidates that [are] not that great, and
ensuring [that] those candidates that have the best safety and efficacy profile move
forward … [You] could also translate that to therapeutics … if you have a model
that can be used for therapeutics, you can down select candidates in a much more
efficient and less costly manner. Prof. Anna Durbin, scientist, USA
3N.b. the interview sample for this report was potentially biased by the preferential inclusion of
scientists active in HCS research—see Sect. 1.2.
30 3 Ethical Issues
[HCS] will try to mimic as best as they can what happens when you’ve got a real
infection with the pathogens in order to detect … the ability of your vaccine to
protect, and you could do this with a limited amount of subjects … involved and not
requiring very large field trials in order to get information on the effectiveness of
your vaccine. [Regulatory representative]
[T]he essential question that needs to be asked is: If we pursue infection challenge
studies, how much marginal value are we getting from that pursuit against the
[alternative] of pursuing that same acquisition of knowledge by another means? …
It can be really, really hard to know which scientific method is going to be the most
expedient in arriving at a given state of knowledge … and often we’re not as good
at making those predictions as you would think … and I think part of the reason
why we’re not good at that is [that] there are a lot of different conditions that need
to hold in order for a particular research study to yield the kind of social benefits
that [the] research study is directed towards. [Jonathan Kimmelman, ethicist,
Canada]
[T]he point about cost effectiveness is really interesting … undoubtedly doing a
challenge trial of a vaccine is going to be quicker and cheaper than doing a large
phase 3 field trial that runs over several years—but it doesn’t mean that [challenge
studies are] as quick or as cheap as you might like …
[T]here are large costs associated with [them] financially and in terms of time, but
yeah they can certainly accelerate that process through but that relies on people
actually believing the data in the challenge model. [Malick Gibani, scientist, UK]
3.2.1.1 Generalisability
A key link between the scientific rationale and the social value of a study is the
generalisability of the findings (whether these consist of knowledge of disease
pathogenesis or estimates of the efficacy of a novel intervention) to the population
and context for which the eventual benefits of a research program are intended
(Wenner 2015, 2017). The ethical acceptability of LMIC HCS might thus be
contingent on such studies generating scientific knowledge that is particularly
relevant to LMICs (i.e., more relevant than knowledge that could be generated by
HCS in HIC study populations) and/or testing interventions that would (if found to
be effective) be particularly beneficial to communities in LMICs (Selgelid and
Jamrozik 2018, Wenner 2015, 2017).
Certain choices in studydesign (e.g., regarding the selection of participants, choice
of challenge strain, method of challenge, etc.) might lead to results that are more
or less generalisable to the populations most at risk of a particular disease. For
example, it would be ethically preferable to conduct HCS in LMICs if/when these
can provide results that are more generalisable to (LMIC) populations at risk than
results generated byHICHCS.Thismight often be the case because of features shared
by potential (LMIC) study participants and the (LMIC) population(s) most at risk of
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the infection in question (e.g., in terms of naturally acquired immunity, co-infections,
genetics,microbiome, nutrition, etc.). LMICHCS in such circumstanceswould, other
things being equal, arguably have a stronger scientific and ethical rationale than
a similar HCS design conducted in a (non-endemic) HIC population (see Section
“Potential Ethical Imperative for Challenge Studies in Endemic Settings”). Yet there
may be exceptions to this general pattern; such inferences are complex and require
careful assessment—especially, for example, where HCS in adult volunteers are
intended to be generalisable to children in endemic settings (see Sect. 3.5.4.1).
The choice of challenge strain is another element of study design that might
influence generalisability and thus give rise to ethical tensions. Using an attenuated
challenge strain (or a single well-characterised strain whereas natural infection
involves multiple strains), for example, might reduce the risks to participants. If
using such a strain means that the findings are not generalisable to wild-type
infection (i.e., do not accurately predict the efficacy of a vaccine) in the relevant
population and/or epidemiological context, however, then this could undermine the
ethical rationale for using HCS rather than an alternative study design
(Chattopadhyay and Pratt 2017; Selgelid and Jamrozik 2018). Thus, although the
risks to participants associated with the use of wild-type strains in HCS (such as
those used in the Colombian vivax program reviewed below or those used in the
pivotal trial supporting recent WHO approval of a typhoid vaccine (Jin et al. 2017))
require careful justification, the use of such strains may sometimes be more
ethically justifiable than the use of attenuated strains (or a strain that does not
adequately reflect the complexity of natural infection) (see Boxes 3.2 and 3.3).
Many stakeholders interviewed were well aware of these complexities, although it
was often acknowledged that more data are needed (e.g., comparing HCS findings
with subsequent field trials) to inform judgements regarding generalisability. In at
least one case, concerns regarding a lack of generalisability (from the challenge
strain to local malaria strains) reportedly led to the abandonment of a proposed
HCS in India (see Box 3.3).
Box 3.2 Generalisability of HCS
[A] challenge trial … produces information that’s very controlled and so translating
that to actually knowing about a vaccine’s efficacy… in a population that’s previously
been exposed to other infections or people who are infected by mosquitoes instead
of … intravenously, those things can be difficult … [J]ust knowing what the value is
of a challenge trial and how likely it is to lead to licensure is sometimes complicated.
[Ethicist, North America]
Challenge studies are a model for real infections. They are not real infections, in
the sense that you generally have to manipulate the dose to get higher attack rates,
[and] you [often] do a different type of monitoring than would happen in the field
and so you are dealing with a very different setting from wild infections. [Scientist,
UK/Europe]
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The problem is that [HCS are] a bit artificial in the sense that … you cannot really
give the right type organism because it will be too virulent and it will be ethically
challengeable, so the [end result] is that you end up [attenuating] your [challenge]
pathogen [to the point] where it is [not very] virulent [and then] you may wonder
what is the value [of the result of the study], what is the real efficacy of your vaccine?
The trade-off between these two extremes … is one of the key factors that will tell
us whether a human challenge can be helpful in the beginning of the development
[of a] vaccine. [Regulatory representative]
If that challenge is not really giving you a good readout on who that end target
population is, [then] you’re potentially putting people at risk [without a good
justification and] getting an answer that’s not going help you decide whether it
works or not in that target population. [Scientist, North America]
I think what the [dengue HCS] community is saying is that they’re developing
attenuated strains [for use in HCS] … but then, what is the relevance? How, how
can you justify [it] if it’s attenuated to the point it’s so different to [wild-type]
dengue infection? How do you know that it’s relevant to protection against dengue?
[Scientist, UK/Europe]
Box 3.3 Generalisability of malaria HCS
Each strain of each malaria species is different, so if we show [vaccine-induced]
protection against [a particular] HCS strain this might not lead to natural protection
[against wild-type strains]. [Scientist, Asia]
[With vivax malaria HCS] you’re using natural strains. That’s …a problem and it’s
an advantage. [It is] a problem because you don’t really know exactly which parasites
you’re giving to the volunteers, at least in the first instance, if you’re doing mosquito
challenge, because you have to [feed] the field mosquitoes on patients [who have] a
natural infection. [On the other hand, using such] wild type [parasites from natural
infection] is an advantage in terms of how you test your vaccine. The results of your
vaccine [trial] are much more real world [because] you’re exposing your vaccinated
volunteers to the same challenge as if they were walking through a jungle in an
endemic area. [Scientist, Asia]
[A] malaria challenge study … was taken to a committee constituted by the Indian
Council ofMedical Research. That committee told them that, you know, in principle,
all of this is fine but to make this study more epidemiologically relevant you must
use a challenge strain from India. I don’t think they understood what it takes to
make a challenge strain. And how difficult it would be for the vaccine developers to
come up with the challenge strain. That did not move forward because it was just too
complicated. [Gagandeep Kang, scientist, India]
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3.2.1.2 Potential Ethical Imperative for Challenge Studies
Given that HCS are often expected to lead to significant public health benefits more
efficiently than alternative research designs, some commentators have argued that
there is an ethical imperative to conduct HCS if (or when) no other (less
burdensome) feasible research design could obtain similar results and/or if (or
when) not performing HCS could lead to greater net harms including (i) longer
delays to the development and implementation of beneficial new interventions for
(neglected) infectious diseases and/or (ii) the exposure of more participants to
potentially greater risks in alternative study designs (e.g., field trials involving
larger numbers of participants exposed to risks associated with experimental
vaccines, where similar vaccine efficacy estimates could have been more efficiently
obtained with fewer participants in a challenge study) (Bambery et al. 2015;
Selgelid and Jamrozik 2018). Assuming useful HCS can be conducted safely (and
other general ethical requirements are satisfied), they might, in such circumstances,
be arguably not only ethically permissible, but ethically required or obligatory (i.e.,
there would be an ethical imperative to conduct such trials) (Bambery et al. 2015;
Selgelid and Jamrozik 2018). While few interviewees endorsed such a claim
without qualification, there was widespread agreement that the ethical (and
scientific) rationale for certain HCS designs in particular circumstances (including
in LMIC populations) could be particularly strong, and that pursuing alternative
study designs in certain circumstances might be less ethically acceptable (see
Box 3.4).
Box 3.4 Could HCS sometimes be ethically obligatory?
There may be a case where it is impossible to test a vaccine for some disease that we
can anticipate will arise and it is within the bounds of reasonable risk to do a human
challenge study. Then I think it might be pretty close to something I’d call ethically
obligatory, if not using that exact terminology. [Ethicist, North America]
I think where it … almost ethically would be obligatory is if you had a disease where
the conventional, old way of doing the testing was going to take five years and then
the placebo control group people were going to get sick and die, but you could do
a human challenge study [and] it’d be done in a month instead of recruiting people
over a long haul. [Scientist, North America]
we actually thought that Shigellawas an example of a case where…human challenge
studies are essentially the only responsibleway to proceedwith vaccine development.
To think that… one could immunise thousands of toddlers and then await disease
occurrence and incidence [in a field trial with] an experimental vaccine that hasn’t
been well characterised, you know, that’s also hard to justify when you can do a
challenge model in a handful of consenting adults [so that] some other issues can be
addressed before you take it out to the target population for its final efficacy studies.
I almost think it’s obligatory to do challenge studies. [Carl Mason, scientist, USA]
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Potential Ethical Imperative for Challenge Studies in Endemic Settings
The vast majority of HCS have been conducted in high-income countries. Over
40,000 people have participated in HCS in the ~70 years since World War II (Evers
et al. 2015), yet the 13 LMIC case studies we review below enrolled a total of
around 400 participants—i.e., less than 1% of the global total. Even HCS research
on pathogens that are primarily endemic in LMICs has been largely conducted in
non-endemic HICs. Potential reasons for this include: (i) the presence of
more/better funded research infrastructure and researchers in HICs (Baay et al.
2018), (ii) the availability of healthcare resources in HICs that can be devoted to
caring for HCS participants, thus providing greater assurance of risk minimisation
(Gordon et al. 2017), (iii) the view that recruitment among vulnerable populations
should be restricted to types of research that are likely to lead to novel medical
interventions that could be shared, ideally in the near future, with the local
population—this would thus rule out HCS except where these involve or (in the
case of HCS aimed at infection model development) facilitate testing drugs or
vaccines (Macklin 2003; Pratt et al. 2012; Wenner 2017), and (iv) regulations
and/or norms in LMICs that sometimes require prior testing (e.g., early phase
studies) of an intervention or research model in the country of the sponsor of the
research (usually in a HIC) before testing in an LMIC (Malaria Vaccine Initiative
2016).
The relative current research capacities of HICs and LMICs, including capacity
for HCS, are arguably the result of longstanding injustices in the global distribution
of wealth and thus funding for research. This has in turn contributed to a relative
neglect of research regarding pathogens that are mainly endemic in LMICs and the
perpetuation of large inequities in the global burden of disease. There have thus
been calls for more HCS in LMICs (Gibani et al. 2015; Gordon et al. 2017; Baay
et al. 2018). Furthermore, If there is an ethical imperative to conduct HCS (in
general) that is grounded (in part) in the need to relieve significant burdens of
infectious disease, then there is arguably an even stronger ethical imperative to
conduct (appropriately designed) HCS in LMICs in particular because, inter alia,
(i) LMIC infectious disease research (including HCS) could lead to significant
public health and/or research capacity-building benefits where they are most
needed, (ii) HCS may be more efficient and thus lead to such public health benefits
more quickly and/or cost-effectively than other study designs, (iii) HCS performed
in HIC populations (and estimates of efficacy of any interventions tested there) may
not always be generalisable to LMIC populations, and (iv) studies of acquired
immunity (which, it is hoped, will improve vaccine development for neglected
pathogens) must recruit previously infected individuals who (for many relevant
pathogens) live predominantly in LMICs (Selgelid and Jamrozik 2018). In some
cases, the ready availability of pathogen strains from locally infected patients may
also be an advantage (e.g., for vivax malaria, which currently cannot be maintained
in a laboratory culture), as compared with the logistical complexity and costs of
exporting these strains to HICs for HCS and other research (Malaria Vaccine
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Initiative 2016). Interviewees for the current project raised multiple reasons why it
might be advantageous to conduct HCS in LMICs (see Box 3.5).
Box 3.5 Rationale for HCS in LMICs
[I]t makes sense to bring a challenge model to evaluate … an intervention in the
population where it will ultimately be used because you’ll get the best handle of
whether it’s going to work or not … and, even if it doesn’t work, being able to
analyse the reasons why it failed might help you to do better the next time around.
[Gagandeep Kang, scientist, India]
[T]he main scientific justification for doing it in endemic regions [is] that you are
testing vaccines in the population where they will be deployed. [I]t’s just the correct
model, which always [involves doing the research in] the correct study population.
Because it is actually the population where you’ll be using the vaccine. [Scientist,
Asia]
I don’t think it’s in the best interest of low-resource countries [to require that HCS
are first conducted in HICs before moving to LMICs] because, if we start with those
stipulations, many of the things that are needed by low-resource settings will never
be studied. [Ethicist, North America]
If you do a challenge study in an endemic setting, it’s viewed as responsive to the
health needs of the people in that country in addressing a problem they understand
and think is important. There may be a baseline risk of transmission that people
already accept or just are aware of, and so introducing an additional risk doesn’t
change the risk profile for them greatly in their estimation. So I think these are the
types of reasons people give as saying it might be better, ethically, to do a study in
an endemic setting. [Ethicist, North America]
Not only are we opening up research possibilities for African institutions, we’re
actually [now] able now to address research questions that were off the table before
this happened … because you can only ask these questions in a malaria-exposed
population. [Scientist, North America]
Most of the malaria challenge models have been conducted in non-endemic settings
and that’s problematic from a scientific point of view, in that you don’t necessarily
know whether or not the volunteers are representative of the likely final beneficiaries
of a vaccine…either in terms of genetics or in terms of acquired immunity. [Scientist,
Asia]
Much malaria vaccine work was also done using human challenge studies in the US
and … you can set up a perfectly competent, capable study group in sub-Saharan
Africa that would be able to do it in endemic areas and answer many of the questions
that you really need to have answeredmuchmore quickly. [Scientist, North America]
I think [challenge studies in endemic settings are] great idea and… I think, in fact,
maybe justice demands it. … the notion of … distributive justice in research … says
that as early as it’s… reasonably safe to do so, we ought be doing these studies in the
population that stands to benefit. I mean … that’s what justifies the burden it seems
to me, in part. [Ethicist, North America]
Some interviewees even questioned whether continuing to conduct HCS in HICs
for pathogens primarily endemic in LMICs could (still) be scientifically and/or
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ethically justified (see Box 3.6).4 On the other hand, some participants noted that
both HIC and LMIC HCS could be justified, depending on the scientific question
being investigated. For example, as discussed above, some HCS aim to test
vaccines intended for use among young children who often have no immunity to
the pathogen in question (see Sect. 3.5.4). In such cases, even if the eventual target
population for the vaccine were children living in endemic areas of LMICs, adult
HCS participants in HICs may be a useful model, at least in respect of their level of
pre-existing immunity, since (like young children in LMICs) they have no
immunity from prior exposure, whereas many of the adults living in endemic areas
will already be (semi-)immune, and thus efficacy trials in the latter group would not
necessarily be highly generalisable to children (see Box 3.7).
Box 3.6 On-going justification of HCS in HICs
I don’t understand why you wouldn’t … do challenge studies in endemic countries?
I mean I would turn it around and say – why are we doing them in non-endemic
countries? [I think] research should be focused in the settings in which those health
problems are occurring and I think this is a colonial history that we have which has
been propagated by institutions [in high income countries]. The current situation is
that they’re the ones who have the facilities to do these. They have more funding
to do this kind of work, so they just do it where they are as opposed to where it’s
needed. [Scientist, UK/Europe]
[Starting HCS research in HICs was the most] pragmatic way but I’m starting to
question why we haven’t stopped. [C]onducting research in Oxford with all those
students, giving them so much money? I wonder if that’s a good thing to do. I would
question that. So rather than questioning: why here [in] an endemic setting? – Why
Bangkok? – I want to question: why Oxford? [Scientist, Asia]
I think it is, it’s almost unethical to conduct [HCS] in non-endemic settings because
those subjects do not benefit at all. They aren’t going to be exposed to the disease.
Their immune responses aren’t typical. The genetic makeup is different. For a whole
variety of factors. If you have a viable vaccine or you think it’s a viable vaccine, it
should be evaluated in endemic settings and, and brought to market as quickly as
possible to benefit those people. And conducting studies, non-endemic studies only
delays things. [Scientist, North America]
[F]or years, we’ve been doing CHIM studies in Maryland and Oxford where as it
turns out there isn’t a lot of malaria … I get the reasons to do that, that you need
facilities with all kinds of sophisticated technology and you need the expertise …
[but] morally there’s an argument for doing these studies in low resource settings
as soon as possible and indeed [the same argument] suggests that perhaps there’s
something even more problematic about doing them in settings where nobody’s …
going to be exposed the risk of disease. [Ethicist, North America]
4Although note again that the interview sample was potentially biased by the preferential inclusion
of researchers with an interest in LMIC HCS.
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Box 3.7 The need for both LMIC and HIC HCS
[T]here are certainly scientific argumentswhyonemight choose different populations
but I don’t think, as some people have argued, that, scientifically, it is, by definition,
better to be in an endemic setting. I don’t think that’s true. I think, scientifically,
there are good arguments for doing things in developing countries but … the case
isn’t always in my view adequately made, for why that is better, or not, [than in] a
developed country. [Scientist, UK/Europe]
[Testing interventions for which LMIC children are the target population] is the
one area [in which it might be justified to do] the challenge studies in non-endemic
countries because … the most practical way of providing data that is relevant to
young children, at least in the case of malaria, is [to conduct studies with] adults
[in non-endemic settings], because [like children] they’re non-immune. [Scientist,
UK/Europe]
[Y]ou could argue that … testing vaccines in malaria naïve adults in Oxford is more
predictive of the vaccine efficacy in… endemic regions… but we already know that
children growing up in endemic regions are exposed to other parasites [and] those
infections modulate their immune responses, there’s lots of other factors that impact
their immune response so even in that setting you can’t predict the efficacy on the
ground. [Scientist, UK/Europe]
3.2.2 Benefit Sharing
The topic of benefit sharing has been a prominent focus of international research
ethics discourse during recent decades (El Setouhy et al. 2004; Njue et al. 2014;
Wenner 2015). The sharing of benefits with study participants and/or local
populations is commonly cited as an ethical requirement for international research
involving human participants, but controversy surrounds questions regarding the
nature, content, and weight of such a requirement (El Setouhy et al. 2004; Wenner
2015, 2017). How such a requirement is understood has important implications for
the ethical justification of HCS conducted in LMICs.
For example, a requirement for tangible benefits, such as drugs or vaccines
approved as a result of a study, to be made available to the local population can lead
to a reluctance to conduct basic science and/or early phase research (including
some HCS designs) in LMICs because such research is not intended to lead to the
immediate development or approval of such interventions (Macklin 2003; Wenner
2015, 2017). Nevertheless, such research can lead to benefits in terms of scientific
knowledge that is necessary for the development of such interventions in future. In
particular, it can lead to knowledge that is of particular relevance to the population
in question (Wenner 2015, 2017). Indeed, many of the LMIC HCS reviewed later in
this report were focused on model development (where such models may be used
later for the testing of interventions) and/or understanding locally relevant aspects
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of host-pathogen interaction. It may thus be more relevant to consider the overall
long-term expected benefits of a program of research as a whole (rather than a
single study in isolation) (London and Kimmelman 2019) so long as there is
reasonable confidence that the program can/will continue—and this is
unfortunately not always the case, because a lack of funding or other issues may
delay or entirely halt a proposed research program (see Box 3.8).
Box 3.8 Benefit sharing
[T]hose subjects who are involved in these studies should be able to benefit from the
vaccine that is eventually licensed. So you should be focusing on doing the studies
in the target population. [Scientist, North America]
Often I find [that] much of … research ethics is preoccupied with a synchronic
view of clinical research looking merely at a single clinical trial as opposed to the
relationship of that investigation with subsequent investigations, and/or
investigations that preceded it. [Jonathan Kimmelman, ethicist, Canada]
I wish we had been part of a larger development plan… because of our bureaucracy,
our trials were slow and [because funding was no longer available] we were unable
to really conduct the studies that we needed or probably should have conducted or
would have been of important value … [O]nce we had established a good challenge
model, it would have been helpful and probablymore ethical… to be able to continue
working [and to test (more) vaccines]. [Carl Mason, scientist, USA]
On the other hand, if benefit sharing requirements apply to vulnerable populations
in HICs, and these populations are being recruited for HCS with pathogens that are
not locally endemic, then there might be no benefits that could meaningfully be
shared with such populations, which implies that it may be more ethical to conduct
such studies among vulnerable populations in LMICs than among those in HICs (see
Sect. 3.5.1).
3.2.3 Capacity Building
Research may lead to other kinds of ancillary benefits (not directly related to the
social value of answering a research question), including (i) research capacity
building, (ii) other assistance to the local community, (iii) ancillary benefits to
individual participants (e.g., healthcare, provision of testing, etc.), and (iv) payment
of participants (discussed in Sect. 3.6). Ethics committees usually exclude these
benefits from the risk-benefit assessment of individual studies but whether that is
appropriate is controversial and in any case it has been argued that such benefits at
least be considered as part of the justification for research programs in LMICs (El
Setouhy et al. 2004).
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Research capacity building might include contributions to relevant
infrastructure, equipment, training of scientific staff, and training of ethics review
and/or regulatory body members. Many of those interviewed as part of this project
saw building capacity for HCS (and other research) in the countries in which
relevant diseases are endemic as important. In addition to technical/scientific
capacity building, participants identified ethics capacity building as a particular
area of need because many ethics committee members (in LMICs) were not
familiar with HCS designs and required significant training and engagement (see
also Sect. 4.1) to facilitate review of recent LMIC HCS (see Box 3.9).
Box 3.9 Capacity building
[W]e’ve been receiving vaccines and drugs developed from other places, so some
other people have gone through this to enable us to have what we have now. Now
that we are building our capacity, it is also our time now to possibly start … helping
and building the next generation of vaccines and drugs. [Scientist, Africa]
[E]ngaging the investigators in developing countries, and having them involved at the
beginning, at the ground level of things, and having some of those research resources
distributed into places…where the research can be done locally [is] beneficial to the
local research community and… can sometimes be a source of pride for the country
itself. [Scientist, North America]
I do think capacity-building in endemic settings and making sure that other countries
have the ability to do research that theyvalue and that their communities value is really
important, and that,… just having collaborations that are global is not sufficient, that
we really do need to be thinking more about building capacity. And so it could be
that building capacity in human challenge studies will be important to help countries
do things … they really value and think are important. [Ethicist, North America]
The issue is how do we capacity build the ethics of your committees to address the
new changes that are coming in … proactively, not wait for things to happen, for
them to catch up with how they review… I think there’s a lot of experience in ethical
review, there’s a lot of capacity building that has been going on. [Scientist, Africa]
One of the things we did when we are setting up the platform was to [hold] joint
meetings between the scientists and the ethics committees, so that people are [able to]
share their experiences and possibly anxieties and I think this helped build capacity
andpeople, having seenmore of these protocols, now theyhave a better understanding
and nowwe have several teams that are now able to do this challenge study. [Scientist,
Africa]
3.2.4 Potential Individual Benefits of Participation
in Endemic Settings
Being infected with a pathogen during HCS often entails few, if any, benefits to
research participants. However, if a person is at high risk of infection with the
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relevant pathogen in day-to-day life, in some cases being infected in the course of
research will (i) entail less risk than being infected ‘in the wild’ (e.g., because of
more immediate diagnosis and comprehensive medical care) and (ii) confer a
benefit in terms of immunity (whether partial or complete/‘sterile’) similar to that
of vaccination (albeit achieved with a comparatively higher risk intervention)
(Selgelid and Jamrozik 2018), that will reduce the risk and/or severity of future
bouts of infection (Herrington et al. 1990). Such considerations of individual
benefit have not been widely discussed in the ethics literature, perhaps because
HCS have, for the most part, taken place in HICs with pathogens that are not
locally endemic and/or confer low risks of severe disease. In a recent exception, the
2017 Report on Ethical Considerations for Zika Virus Challenge Trials does
mention possible benefits of this kind for challenge study participants recruited in
endemic-regions during periods of significant transmission (Shah et al. 2017), and
the possibility of such benefits was also noted by Michael Selgelid in a presentation
at the 2013 Wellcome Trust Scientific Conference on Controlled Human Infection
Studies in the Development of Vaccines and Therapeutics (Selgelid 2013).
HCS might also entail benefits for individual participants in endemic settings if
they involve the testing of a vaccine candidate that provides protective immunity
against wild-type infection (although the demonstration of protection—or the lack
thereof—may be one of the goals of the study and thus be uncertain at the time of
enrolment). Such benefits would not arise from the challenge infection itself (and
would, for example, also arise in vaccine field trials in endemic settings), yet they
may nevertheless (in at least some cases) provide an additional ethical reason in
favour of conducting HCS in endemic, rather than non-endemic, settings.
Still, most HCS to date impose a net risk on participants (whether or not there
are any direct benefits), and it would be unusual if infection as part of a challenge
study entailed an expected net benefit. Exposure to attenuated pathogens is a
vaccination strategy that has been used for some diseases (e.g., live attenuated
vaccines for measles, yellow fever) and is being explored, for example, for malaria.
However, the benefits of attenuated malaria challenge in endemic settings are the
subject of on-going research and hence as yet uncertain (Arévalo-Herrera et al.
2016; Olotu et al. 2018). Thus, although HCS participation in an endemic setting
may be less risky and/or more beneficial than participation in a non-endemic
setting, participants would still (usually) be accepting a net risk in order to
contribute to a research program, the main goal of which is to lead to future public
health benefits (as opposed to immediate direct benefits to participants). As Prof.
Jonathan Kimmelman suggested in an interview for this project, if we had adequate
confidence that people would actually benefit from infection, then we should
arguably institute a public health program (rather than a research study) that
deliberately infects people with the pathogen in question. Other interviewees did
acknowledge a potential for individual benefit in endemic settings that would not
occur in non-endemic settings, although it was usually seen as a relatively minor
consideration, and one that was contingent on there being a high background risk
of infection in the local community (see Box 3.10).
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Box 3.10 Benefits of HCS participation in endemic settings
[The] rationale for participating in research is that … you may help yourself and
you may help your community and you may help the world and if you do it in … a
non-endemic country, then it’s just the last one of those; whereas here it’s probably
all three because, maybe, there is a small chance that an individual volunteering here
for a[n HCS] may benefit, in terms of enhanced immunity…when they go back into
their malaria endemic homes. [Scientist, Asia]
[Whether an individual participant can be said to benefit] depends on the attack rate
where you are and what the probability is [of being infected in daily life, as compared
with participating in HCS]. [I]f you [participate in a] challenge [study] you’ve got
a definite risk of infection and an unknown risk of severe complications. [Scientist,
UK/Europe]
3.3 Burdens for Participants
Research participation can involve a range of burdens of varying significance, and
some HCS designs could, overall, entail relatively high levels of burdens for
participants. In research ethics, distinctions are sometimes drawn between risks and
other types of burdens, although it has been argued that risks and other burdens
should be considered together since, despite apparent differences, they are both
(sets of) adverse consequences in the lives of study participants (Rid 2014). On the
other hand, study participants may distinguish between what they take to be risks
and burdens in various ways (Kraft et al. 2019). Here, we will bracket these debates
and use ‘burdens’ to capture all adverse aspects of research for
participants—including exposure to risk (and thus sometimes harm), privacy
infringements, restrictions of freedom of movement (e.g., being isolated in an
inpatient unit), and/or other reductions in well-being etc.
3.3.1 Limits to Risk
Among other burdens, research often involves risks to participants, although
infectious disease research (in particular) also sometimes involves potential risks to
third parties (discussed in the next section). HCS may involve varying degrees of
risk to participants depending on the study design. Level of risk may depend upon
decisions regarding pathogen/challenge strain, study population, whether
participants will be inpatients (with close monitoring) or outpatients (with less
monitoring), etc. Risks consist of two components: the probability of a harm
occurring, and the magnitude of that potential harm (Rid 2014). Furthermore, the
42 3 Ethical Issues
magnitude of a harm is a function of its severity and average duration (with more
severe and longer duration harms being of higher magnitude and thus more
concerning—See Sect. 3.3.4).
HCS have been identified as a group of studies that can, at least sometimes, pose
significantly more than minimal risks to participants (Miller 2003), raising questions
regarding the upper limit of permissible risk imposition in research among healthy
volunteers, and in HCS in particular. Reviews of recent challenge studies have found
no deaths or lasting harms among participants (Roestenberg et al. 2012; Darton et al.
2015), however accurate estimates of the risks associated with a particular challenge
study (or programme of studies) may not always be explicitly quantified.
As a comparator in healthy volunteer research, one reviewof phase I non-oncology
drug trials performed by one pharmaceutical company found a risk of serious adverse
events (those that result in hospital admission, persistent or major disability, life
threatening event, birth defect, or death) of up to 0.3% (with no deaths) and a rate
of severe adverse events (those that interfere in a major way with a participant’s
basic daily functioning) of up to 1%; a second review of publicly available phase
I trial data found similarly that severe and serious adverse effects comprised less
than 1% of all adverse events (Emanuel et al. 2015; Johnson et al. 2016). However,
these reviews did capture all phase I (or similar) studies. Rare cases of severe harm
among healthy volunteers have included multi-organ failure requiring intensive care
admission (in a phase I immunotherapy drug trial) (Goodyear 2006), brain damage
and death (in a phase I neurological drug trial) (Moore 2016), and respiratory distress
leading to death (in a chemical challenge study where healthy volunteers inhaled an
active agent to simulate the pathophysiology of asthma) (Moore 2016).
HCS taken together could be associated with a range of risks, from very low
(e.g., studies with low virulence pathogen and/or inpatient studies of treatable
pathogens with very early diagnosis and treatment) to significantly higher risks
(e.g., infection of immune-naïve individuals in outpatient studies with highly
virulent pathogen). Lower risk HCS (e.g., many study designs in current use) might
well be safer than many phase 1 drug trials, whereas higher risk challenge designs
(and first-in-human HCS) might expose volunteers to significantly greater risk
and/or uncertainty. Two questions arise: firstly, should very low risk HCS be
classified as minimal risk research?; secondly, if more than minimal risk HCS are
in-principle ethically acceptable, what should be the upper limit of risk to which
HCS volunteers should be exposed?
3.3.1.1 Minimal Risk
While it is sometimes held that research with healthy volunteers (including HCS)
should entail no more than ‘minimal risk’, or a minor increase above minimal risk,
the definition of minimal risk is contentious, and (as above) at least some challenge
designs would plausibly exceed such a threshold (as drawn by common definitions)
(Hope and McMillan 2004; Resnik 2005). On the one hand, if ‘minimal risk’ is
defined as no more than the usual risks encountered in daily life, then this fails
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to take into account the fact that some people regularly encounter higher levels of
risk in daily life than others, either due to their appetite for high risk activities (e.g.,
motorcycle riding) or because of the prevailing conditionswhere they live (e.g., being
exposed to endemic infectious diseases, or not having access to adequate sanitation—
see Sect. 3.3.3) (Hope and McMillan 2004; Resnik 2005; Wendler 2005; Wendler
and Emanuel 2005; London 2006; Shaw 2014). Likewise, setting the standard at the
level of the risk that a risk-averse person would encounter in daily life is arguably too
strict (Hope and McMillan 2004), and would certainly rule out many HCS—since
a risk-averse person would not usually deliberately infect herself with a pathogen.
Anecdotally, many individuals volunteering for HCS have a significant appetite for
risk. As one scientist describes them: “These were the same young people whowould
go down the hairiest parts of rivers on rafts” (Cohen 2016).
Alternatively, minimal risk might be specified numerically, for example minimal
risk research might be limited to studies involving a less than 1 in a million chance
of lasting harm (which would exclude at least some HCS designs—see Sect. 3.3.4)
or no more than a 1 in 1000 chance of severe adverse effects to participants.
3.3.1.2 Upper Limit to Risk
Propositions for an upper limit to acceptable risk in research with healthy volunteers
include (i) no limit (since consenting adults should be able to decide on the level
of risk they will accept) (Shaw 2014), (ii) the risks of high-risk, socially beneficial
occupations like fire-fighting (since, similar to research, such jobs involve some
individuals taking on net risk to benefit society) (London 2007), or (iii) the risks of
kidney donation (since norms in non-research contexts permit this to be done from a
sense of altruism, which may also motivate some research participants) (Miller and
Joffe 2009).
There is, in any case, no universally agreed upon upper limit for the degree of
research risk permissible in HCS. Some argue that it is more justifiable to pursue
higher risk research where there is a high likelihood that a given study will produce
significant benefits—but most commentators agree that easily imaginable HCS with
very high risks5 would not be justifiable (Hope and McMillan 2004; Miller and
Rosenstein 2008; Miller and Joffe 2009). In part, this is for pragmatic reasons, since
the public reaction to a case of severe harm in high risk HCS research could lead
to a moratorium on other lower risk but potentially beneficial studies (Hope and
McMillan 2004). Thus, the need to avoid such an outcome provides (additional)
reasons for (i) community engagement around HCS, (ii) careful review of higher
risk studies and/or HCS in general, and (iii) enhanced safety monitoring practices
during the conduct of HCS (Hope and McMillan 2004; UK Academy of Medical
Sciences 2005; Bambery et al. 2015).
5Consider HCS involving HIV for example.
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Many interviewees agreed that an absolute upper limit to risk forwould be difficult
to define, and some suggested that limits in particular contexts should be partly
defined through community consultation, with this in turn being partly with a view
tomaintaining public trust in research—meaning that even if a higher risk studywere
judged acceptable under a given ethics framework (e.g., because of high expected
benefits), there might be good reasons to find out whether relevant communities
would actually accept such a study design (e.g., through community engagement
activities) (see Box 3.11).
Box 3.11 Limits to risk and public acceptability of research
[T]he way I understand [limits to risk in the context of ethics review] … is that …
we’re not just trying to make sure that this specific study is done well and it’s ethical
– we’re also, to some extent, trying to protect the institution of research. [Ethicist,
North America]
I also think that those limits ought to be dictated by public perception, to a certain
degree … [I]t’s not merely a question … [of] how much can we ask an individual to
put their lives at stake; it also really bears on how much is the public willing to view
this as a kind of legitimate and sanctioned activity, if we put people at this level of
risk. [Jonathan Kimmelman, ethicist, Canada]
[W]hat we’ve learned in my [African] setting, and this is also looking back at some
of the studies done here (which we thought were very safe) and how they became
problematic … [W]e’ve learnt that we don’t take anything for granted … in the
community. We just have to be very careful about it, because it’s got the potential to
be misunderstood … in all different ways. It doesn’t matter whether it is the most
safe procedure you thought you were introducing; as long as it is unfamiliar in the
community, it is likely to flare up all kinds of rumors. [Scientist, Africa]
[O]n the essential question of ‘Can the study proceed from a regulatory perspective?’,
what are we looking for in terms of ensuring it’s safe? And the criteria that we hold
to is ‘Are there unreasonable risks?’ And admittedly that is somewhat of a judgment
call about what’s reasonable and unreasonable, but the regulatory bar is, is ‘Are there
unreasonable risks?’ [Regulatory representative]
3.3.2 Minimising Risks
It is widely held that risks to participants should be minimised. A key consideration
is whether exposing participants to a given risk is necessary to answering an
important research question. If not, then such (unnecessary) risks should arguably
be eliminated, thus minimising the quantum of risk for a given expected social
benefit (US Department of Health and Human Services 1979; Savulescu 1998;
Miller and Grady 2001; Hope and McMillan 2004; World Medical Association
2008; Rid et al. 2010; Bambery et al. 2015).
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Minimisation of risks to participants during HCS might involve, inter alia (i)
selection of study populations at lower risk of severe disease, (ii) use of pathogens
and/or strains that produce less severe disease, (iii) early diagnosis and/or
treatment, (iv) keeping participants as ‘inpatients’ to enable particularly close
monitoring for at least part of the study, (v) close monitoring of (any) outpatient
participants, and (vi) careful follow-up for long term outcomes of infection and
treatment. Risk minimisation might be considered particularly important in the
context of HCS; as one North American scientist argued:
[Y]ou’re completely responsible [from] the moment you … give that injection until that
person is clear, either doesn’t get it and you’ve documented that or you’ve diagnosed it and
treated it. So that’s different [from] other … non-therapeutic interventions … you have total
responsibility and, if you can’t be certain that you can take that total responsibility, you have
no business doing this. [North American Scientist]
3.3.2.1 Early Diagnosis and Treatment
For HCS with pathogens (such as malaria) where effective treatments are already
available, the diagnostic strategy used in a given HCS may significantly influence
the risk of symptoms and/or disease as well as the need for inpatient isolation. The
potential to reduce such risks will often be particularly important where curative
(as opposed to merely supportive) treatments are available. As one North American
scientist stated:
[D]iagnostics [drive] the whole study design in malaria – because if you can’t diagnose
[participants] until they’re pretty sick, then you have to keep them in a hotel. And, if you
diagnose them really early, then all that hotel stuff…gets eliminated. And so…we’re almost
not interested in doing any studies that require hotel phases for malaria anymore because …
you don’t need to have a whole wing of a hotel when you could just have a more sensitive
test. [North American Scientist]
Such observations reveal the ways that study design involves practical and ethical
trade-offs. While inpatient studies (and the especially close monitoring these permit)
reduce risks for participants, for example, they also increase the burdens related to
isolation and close monitoring. Early diagnosis can mitigate both risks and other
burdens. Thus, except in situations where there is a strong rationale in terms of
the research question that requires delaying treatment, there is arguably a strong
ethical case for early diagnosis and curative treatment during HCS for pathogens
for which such treatments exist, although thresholds for treatment initiation remain
controversial (see Box 3.12).
Even the use of very sensitive microbiological tests and early effective
treatment, however, does not always preclude the development of significant
symptoms during HCS. One reason that symptoms might occur despite the use of
very sensitive diagnostic testing is that some individuals develop symptoms at
lower levels of pathogen concentration in the body than others. Unless the
threshold for treatment selected as a part of the design of the study is set at or below
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the level at which the most “sensitive” individual develops symptoms (which might
be unknown or difficult to estimate with certainty prior to the conduct of such
studies) some individuals may develop symptoms whereas others may not.
Investigators may be able to set very low thresholds for treatment in cases where
this would not compromise the scientific rationale of the study. In other cases there
may be (ethical and scientific) trade-offs between the burdens to participants
(experiencing symptoms) and additional important scientific information gained by
allowing infections to continue past the point where symptoms develop. Such
additional burdens would presumably only be ethically justifiable where similar
scientific information could not be gleaned by less burdensome methods (see
Box 3.12). For malaria in particular it may be possible to employ treatment(s)
against the form of the pathogen that causes symptoms (thus reducing the burdens
associated with symptoms among participants) while allowing progression of, and
observing, development of other forms of the pathogen (see Sect. 3.4.1).
A second reason that symptoms might occur despite the availability of highly
sensitive tests is that there may be trade-offs between a higher frequency of testing
(so as to diagnose an infection as early as possible) and the burdens that such close
monitoring entails for participants. Since diagnostic tests cannot usually be
administered continuously (e.g., 24 hours a day), and since participants have an
interest in retaining some privacy and freedom of movement (whether in the
context of inpatient or outpatient HCS), the availability of highly sensitive tests and
a low threshold for the initiation of treatment might not prevent symptoms from
developing in all cases, since there will be a certain amount of time between
administrations of the diagnostic test and/or a certain amount of distance between
participants and the testing centre (in outpatient studies)—see also Box 3.18 (in
Sect. 3.3.7.2) for an example of the development of symptoms in an outpatient.
Box 3.12 Early diagnosis and treatment during HCS
[Some HCS designs are] pushing the boundaries. I know [some scientists] would
make [a] case forwhy theywouldwant to see the severe symptoms in the participants.
That is where I would draw some lines and say at the end of the day, in as much as
it’s about science and new knowledge and benefit for everyone else, but how much
are we making people bear the burden and the risk. Is there a level to which we find
we are crossing a very thin line between what is ethical and what is not? What is
allowable and what is not? And for me severe symptoms are crossing that line very
quickly. [Scientist, Africa]
I think it’s really inappropriate [to delay] treatment … [S]ome people said … if we
delay it for another forty-eight hours then … we’ll get more interesting data and
we can plot pretty curves of the PCR quantitatively and this kind of stuff. And, for
drugs, the longer you leave it the better. I’m very uneasy about that because it seems
to me that scientifically, the longer you leave it … even for one hour [or if] you leave
it for longer after you confirm infection, there has to be an increased risk of some
complication and we know you can get severe malaria. [Scientist, UK/Europe]
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So there’s like two camps and everything in-between. The one camp is: we need all
the data.We should just let them go all the way to become blood-smear positive [with
relatively high burden malaria infection], then we can do PCR on everything and get
beautiful curves, and it’ll tell us everything. The other camp is: any of these suckers
in the blood means it failed so we should treat at the first sign of smoke, right. And
doing either extreme isn’t great. [Scientist, North America]
3.3.3 Risks to Participants in Endemic Settings
Conducting HCS in LMICs might influence the potential risks to participants in
several ways. On the one hand, where local health and related infrastructure is
fragile, HCS participants may encounter higher risks due to delays to treatment
during outpatient studies if/when they develop symptoms of the challenge
infection. It may sometimes be possible to mitigate risks such as these via capacity
building of treatment centres and/or inpatient study designs.
On the other hand, HCS in LMICs could involve lower risks of severe disease if
they recruit individuals who have (partial) acquired immunity due to prior infection
and/or innate forms of resistance to particular pathogens—e.g., genetic conditions
affecting red blood cells such as sickle cell that reduce the severity of malaria, an
effect demonstrated in one LMIC HCS reviewed below (Lell et al. 2017). It may
also be ethically important to purposefully recruit individuals with such traits for
HCS that involve testing interventions that (if licensed) would be intended for use in
such (sub-)populations, since the safety and efficacy of a given intervention may be
different in certain groups.
Furthermore, where participants in a challenge study are at risk of being infected
with a pathogen in daily life (e.g., because they live in an endemic area6), one
might think that, in some cases, this background risk reduces the marginal risk an
individual would take on by participating in a challenge study7 (c.f. Sect. 3.2.4). It
may thus be more ethically acceptable, from the point of view of balancing the
risks and benefits of a study, to enrol those who already face higher background
risk (other things being equal). There was widespread agreement among
interviewees that such considerations could be ethically relevant in terms of
minimising risk in HCS study design, and might often favour of conducting HCS in
endemic populations (see Box 3.13). Research ethics literature regarding
background risk more generally (Rothman 1982; Robinson and Unruh 2008),
however, provides reasons for being wary about the sentiment that risk imposition
6Importantly, it should not be assumed that anyone living in a country in which a pathogen is being
actively transmitted (in part of the country) is at risk of infection on a day-to-day basis (note, for
example, that the malaria HCS in Kenya and Colombia reviewed below actually took place in cities
in which malaria is not endemic).
7With the exception of pathogens such as dengue, for which the sequence of infectionswith different
strains influences the probability of severe disease (see Selgelid and Jamrozik 2018).
48 3 Ethical Issues
on participants might be more acceptable where background levels of risk are
higher when/if (i) higher levels of background risk (e.g., in LMICs) themselves
reflect injustices and/or (ii) research participation would significantly increase risk
to participants who already face high background risks (while it should be kept in
mind that the absolute magnitude of net/marginal risk increase is a key
consideration, independent of background risk magnitude).8
Box 3.13 Background risks of infection and risk to participants
[I]t’s less ethically difficult in recruiting volunteers [in endemic areas], considering
that you’re giving someone an infectious disease, to use volunteers drawn from a
population that’s at risk anyway, rather than a population that would never be at risk,
in terms of justifying the balance of risk. [Scientist, Asia]
[I]f you are already exposed, if you’re at a greater risk, [the risk] you’re being asked
to accept as a result of your … participation in the study is lower and the benefit is
going to be the same. So the benefit versus risk profile [is better]. [Ethicist, North
America]
[T]here are some compelling reasons [to conduct endemic-region HCS], and that’s
one of them, that… the background prevalencemeans there is less of a differential…
between the [alternative] of not participating and … deliberate exposure. [Jonathan
Kimmelman, ethicist, Canada]
[Y]ou get into all of these questions about whose daily life is the right comparator.
Is it a local standard? Is it a universal standard? And so that makes me think it’s
preferable to do the challenge trials in endemic settings because there’s an argument
that it’s actually lower risk in those contexts. [Ethicist, North America]
3.3.4 Long-Term Risks and Lasting Harms
Most commentators have argued that, as a general rule, HCS should involve
infectious diseases that are treatable and/or self-limiting (i.e., resolving without
treatment) (Miller and Grady 2001; Miller and Rosenstein 2008; Bambery et al.
2015; Roestenberg et al. 2018a). Some have added the criterion (or interpreted
8Part of the point of (ii) is that those who favour a Rawlsian account of ethics/justice, which
requires making the worst off groups of society as well off as possible, might conclude that it is
more acceptable to impose higher marginal research risks on well off participants in HICs (with
lower background risks) than to impose lower marginal risks on less well off participants in LMICs
(with higher background risks)—because we should avoid worsening the situation of those who
are already worst off. A second point of (ii) is that if the net/marginal increase of risk resulting
fromHCS participation is high enough for those who already face high background risks, then HCS
may not be justified even if the net/marginal increase in risk for such participants is lower than
would have been the case for participants elsewhere: a comparatively lower level of net/marginal
risk increase does not entail an acceptable level of net/marginal risk increase (if the lower level of
net/marginal risk increase is itself quite high).
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‘self-limiting’ in such a way) that there be “no lasting consequences” (Miller and
Rosenstein 2008) or no “irreversible pathology” (Roestenberg et al. 2018a).
Requirements that there be no lasting consequences or harms are potentially
important since (i) some infections can (after partial treatment) reactivate from a
latent or dormant form (e.g., vivax malaria), (ii) certain pathogens are sometimes
more severe on subsequent infection (e.g., dengue), and (iii) some post-infectious
syndromes can lead to lasting morbidity even after the acute infection has resolved
or been “cured” (e.g., post-infectious irritable bowel syndrome, post-infectious
‘reactive’ arthritis, Guillain-Barré syndrome, etc.).
Regarding (i), the dormant form of vivax can usually be definitively treated,
although certain individuals are at higher risk of adverse effects of treatment and/or
treatment failure, and are thus sometimes excluded from vivax HCS (Bennett et al.
2013). Regarding (ii), the risk of severe dengue (either during or after HCS) can be
mitigated via careful participant and/or strain selection, although dengue HCS
nevertheless require particularly careful study design (Thomas 2013; Mammen
et al. 2014; Larsen et al. 2015; Selgelid and Jamrozik 2018). Regarding (iii), while
some post-infectious syndromes have known risk factors (see Table 3.1), meaning
that individuals known to be at higher risk can be excluded from HCS, such
strategies often cannot prevent these outcomes entirely. The fact that lasting harms
have not been documented among HCS participants for these pathogens may reflect
careful selection practices and/or relatively low numbers of total participants (in
whom, by chance, a rare event has not been observed) and/or publication bias (i.e.,
events that may have occurred might not have been published).
One HIC researcher interviewed was aware of at least one case of presumed
post-infectious arthritis occurring after HCS with an enteric pathogen (the case
remains confidential and unpublished, consistent with publication bias mentioned
above). More generally, interviewees agreed that such lasting harms were
particularly concerning and, at a minimum, require (i) careful risk mitigation
strategies, (ii) systems to compensate any participants who experience harm, and,
in some cases, (iii) long-term follow-up of participants.. However, there was no
clear consensus about what level of residual risk of such outcomes, if any, should
be considered acceptable. Some experts noted that several pathogens already used
in HCS are (rarely) associated with lasting harms (see Box 3.14 and Table 3.1). Of
note, many of the LMIC HCS reviewed later in this report were carefully designed
to reduce such risks, usually by exclusion of those with known risk factors for such
outcomes.
Box 3.14 Lasting and/or irreversible harms
I’mvery uncomfortablewith the idea that youmight leave somebodywith irreversible
harm when they haven’t been given any possible benefit. [Scientist, UK/Europe]
[A] healthy volunteer … has no expectation of incurring Guillain-Barré syndrome
or… amajor infection and so… the risk is really… quite pronounced in the healthy
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volunteer because of the fact that the counterfactual [the risk of not participating] …
is virtually no risk at all. [Jonathan Kimmelman, ethicist, Canada]
Would I give somebody something that [would cause] long-term risks? … I know
that there’s been controversy about Zika [which] can cause Guillain Barré syndrome
…And who knows how many? One in a million. One in a hundred-thousand. That’s
a risk … that has to be taken into consideration. [Scientist, North America]
[I]f there’s irreversible harm, I think most people would say that that’s unreasonable
risk … [T]here may be risk of severe injury in some human challenge studies; but, if
the risk is very low – one in a million, one in a hundred-thousand – perhaps then that
might be considered a reasonable risk. But that’s where it does get into judgement.
[Regulatory representative]




























































HLA-B27: human leukocyte antigen B27, a genetic risk factor for post-infectious arthritis. CYP
2D6: Cytochrome P450 2D6, a genetic risk factor for primaquine treatment failure (identified in
previous HCS research) leading to vivax relapse. N/A: no dengue HCS have been conducted in
LMICs to date
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[S]ome of these infections or some of these infection models [involve] risks that you
don’t know about and you can develop chronic consequences after these infections.
And so I think … we need to fully inform [potential participants] that it’s not just
… this acute infection, that it could lead to something chronically. [Scientist, North
America]
[M]ost of the models will have their very rare risks, [just] like [natural] infections.
Likewe knowmany [natural] infections [are associatedwith] a rare risk of something
… exotic occurring, which we rarely see, but… if [natural] infections have that, then
challenge models for sure will have that. And obviously you should try to limit that
as much as possible, but you’re not going to get to 100% safety. [Meta Roestenberg,
the Netherlands]
The borderline cases [ethically speaking] are [firstly, challenge studies] where the
diseases are serious and people get really sick … and the second kind is where there
are these long term effects that aren’t entirely predictable. To me those are kind of
like two features of the borderline cases. [Ethicist, North America]
3.3.5 Uncertainty
Even for pathogens where the natural history of infection is thought to be well
characterised, the fact that HCS allows for a closer examination of pathogenesis
from the moment of infection means that not all risks will be known, particularly at
the beginning of a research program with a novel HCS design (and/or new challenge
strain) when few (or no) people have yet been challenged. Indeed, HCS research has
revealed new and/or unexpected aspects of certain diseases, and these findings have
led to refinement of HCS exclusion criteria as well as further research (see Table 3.2).
Furthermore, HCS trials of new vaccines may also lead to unexpected adverse
effects, given the potential for unexpected interactions between the pathogen, the
vaccine, and the host immune system (for example, vaccines for RSV and dengue
have in some cases been shown to increase the risk of severe disease upon exposure
to infection after vaccination (Acosta et al. 2016; Wilder-Smith et al. 2018)). In
any case, such uncertainties are not unique to HCS. First-in-human trials of new
drugs have sometimes lead to severe harms among healthy volunteers, such as the
infamous first-in-human phase 1 TGN1412 immunotherapy trial that lead to several
healthy participants being admitted to intensive care (Kenter and Cohen 2006). One
interviewee for the current project specifically cited the TGN1412 trial and made an
analogy with first-in-human challenge studies on this point:
[W]hen you put something into a human being for the first time you really don’t knowwhat’s
going to happen, right? You could kill them. … So you just have a pilot individual or two
… You put in a low dose. You have very close observation. You’ve done toxicology studies.
I mean it’s so gingerly done. And then you build your way up. [Scientist, North America]
Such uncertainties have implications for consent of HCS participants and ethical
review of HCS, particularly new designs (or designs that have as yet enrolled only
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Table 3.2 New and/or unexpected findings in challenge studies



































small numbers of participants). As a given challenge strain infection and/or HCS
design has been conducted in increasing numbers of participants, researchers (as
well as reviewers and regulators) can have greater confidence that estimated risks
are increasingly accurate and uncertainty reduced. However, since one of the virtues
of HCS is that they involve fewer participants than field trials, larger studies (and/or
post marketing surveillance of vaccines) may still reveal rare adverse effects (e.g.,
interactions between the vaccine, the pathogen, and the human host) that were not
observed in the small number of HCS participants in earlier phase studies.
In the 2017 NIH Report on Zika HCS, uncertainties regarding the risks to
participants and third parties (e.g., due to sexual transmission) were appealed to as
considerations (among others) against conducting of Zika HCS (Shah et al. 2017).
However, as better estimates of relevant risks are now available and greater
understanding of the underlying mechanisms may allow for mitigation strategies,
these considerations might now be considered less weighty (by some). More
generally, first-in-human HCS in particular will always involve a significant degree
of uncertainty. Although this does not preclude novel HCS, it does justify an
especially thorough review of prior evidence regarding the pathogen in question
(see Box 3.15).
Box 3.15 Uncertainty
I think with most [HCS designs] you know if you do your screening properly, you
hope that nothing will go wrong, but here are people who have conditions that are
unrecognized and unrecognizable by the screening tools that we use. For example,
this isn’t a challenge study, but, for the flu vaccine and narcolepsy, who would’ve
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known to screen for HLA-type before giving a flu vaccine, right? So I don’t think
you could predict everything. [Gagandeep Kang, scientist, India]
I think there are types of challenge studies or models that … are completely safe if
not more safe than other types of trials we do all the time. I think what’s hard is when
we don’t have a good sense of the disease and what all of its longer-term effects
might be. With those trials it’s very difficult to even evaluate what the level of risk
would be. And that’s where it’s not clear to me whether their level of risk is fully
in-line with what we already permit. [Ethicist, North America]
[T]housands of people have been in [malaria] studies over the years, and they must
have been a lot more nerve-racking [back when] less than a 100 people [had] been
in these studies. [Scientist, North America]
3.3.6 Other Burdens for Participants
Almost all clinical research entails multiple burdens (other than risks) for
participants. These can range from minor burdens, such as filling out a short
questionnaire or being subject to standard medical examinations, to potentially
more significant burdens such as the privacy infringement of revealing one’s
medical or personal information, to major burdens such as a long duration of
hospital stay and/or isolation. Certain study interventions will be more burdensome
for some individuals/populations than for others. Due to cultural beliefs regarding
the value/importance of blood, for example, blood draws (especially of larger
volumes) may be especially worrisome, and thus burdensome, to research
participants in sub-Saharan Africa, as compared with other groups who may be less
concerned regarding blood draws (Saethre and Stadler 2013; Njue et al. 2018).
Since HCS frequently involve multiple study visits, blood draws, and
monitoring by study staff—and since inpatient HCS in particular involve
significant time away from normal activities—many HCS designs are potentially
associated with a level of burdens that would be high compared with most studies
conducted in healthy volunteers. There are other analogous cases in non-HCS
research, although infrequent, such as metabolic chamber studies (in which
participants sometimes spend days in a tightly controlled, isolated environment, for
precise measurement of metabolic parameters), which, when they are conducted in
HICs, frequently attract high levels of payment (see Box 3.16). Likewise, major
burdens for participants in HIC HCS typically attract significant payment of
participants; and this has sometimes been the case in LMIC HCS, often because
payment for one night in an inpatient facility is indexed to local wages and
participants spend 1–4 weeks of confinement during the study (see Sect. 3.6).
Recent social scienceworkwith participants has suggested thatHCSparticipation,
particularly in inpatient studies, can lead to a wide range of burdens and/or secondary
effects on the families of participants. In one LMIC study, for example, the children
of participants were unable to attend school while a parent was participating in HCS
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(Njue et al. 2018). One HIC study found that outpatient HCS participants often
encountered significant disruptions to their daily lives as a result of participation
(Kraft et al. 2019). Many stakeholders we interviewed for this project felt that the
burdens of participation (i.e., burdens other than risk imposition) raised ethically
important issues for HCS design in need of further analysis.
Box 3.16 Burdens of participation
[HCS protocols often] keep people in residence for a long period of time. I think
that’s pretty unique. I don’t think we do that for many other studies … just that
phenomenon of saying to people – you know, you might need to be in residence for a
month or even longer, six weeks, you’ll need to stay here and you will not be able to
leave, under any circumstances … I don’t think we fully understand what the ethical
implications of that are. [Scientist, Africa]
[T]here’s physical risk, which I think for [some HCS] is quite small, but there is also
the emotional risk … but the bigger thing is the burdens. [In some HCS designs]
you have to be in residence for fourteen days, minimum, [and] being in residence
means that you have to make sure that other parts of your life … and kids, and jobs
[are taken care of] … so that’s quite a big commitment, and a sacrifice, I would say.
[Scientist, Asia]
How can we make [participation a good] experience good for them? What kind [of]
residence would that be required to be? … If we are curtailing their freedoms of
movement, how does that then balance against the risk? … We are telling them not
to go to endemic areas, even when they do get out of there – they’re still within
the study. In other words, we’re interfering with their freedom, and how do we take
account for that? [Scientist, Africa]
[Y]ou pay a lot of money for someone to stay as an inpatient. [For example, in a]
metabolic chamber study…people were getting paid $6,000 for that, because you’re
in a chamber for a month. [Ethicist, North America]
3.3.6.1 Mental Health
Since challenge studies often involve significant burdens for participants, these
burdens could plausibly include and/or lead to deterioration in mental health
(whether or not the participant had a prior history of psychiatric illness). Such risks
may be particularly significant during prolonged inpatient studies involving social
isolation, and some research groups have adopted careful psychological screening
of potential participants to inform judgements about their ability to tolerate periods
of isolation (sometimes of several weeks’ duration) (Pitisuttithum 2018). Even with
careful recruitment practices, one previous LMIC HCS recorded a serious adverse
effect related to a participant who was briefly admitted to hospital due to an anxiety
crisis (by comparison, in the same study, no physical serious adverse events
occurred from the challenge infection) (Herrera et al. 2011). The mental health of
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participants is thus potentially an area warranting further social science work
and/or ethical analysis; the exclusion of any potential participant with a psychiatric
history may be overly restrictive and/or unfair, thus a nuanced approach is needed.
As one stakeholder noted:
[In] Oxford we have a very high proportion of volunteers who have a known psychiatric
diagnosis: anxiety, depressive. The majority of those are managed … it doesn’t affect their
activities of daily living. As toworking,maybe they take antidepressants. So it’s not as simple
as just saying ‘Anyone with any psychiatric history is not suitable.’ [Scientist, UK/Europe]
3.3.7 Participant Behaviour
All research with human participants involves the possibility of unexpected human
behaviours. In the context of HCS, certain participant behaviours might lead to
greater risks than those anticipated in the study protocol—for example, participants
(i) choosing to withdraw from the study and/or refusing to be treated after
challenge infection, and/or (ii) leaving the study site and/or becoming
uncontactable after being infected. Since researchers are exposing healthy
volunteers (and sometimes third parties) to potential severe harms (e.g., if an
infection with malaria were to go untreated), investigators arguably have especially
weighty ethical responsibilities to ensure that the risks entailed by such human
behaviours are minimised. It is perhaps also the case that participants who consent
to be infected have an ethical responsibility to abide by monitoring, treatment,
and/or social distancing requirements during and/or after the study (especially
where not complying might entail risks being imposed on others). We discuss the
right to withdraw and the risk of participants absconding (i.e., leaving the study
without informing research staff) below.
3.3.7.1 Participants’ Right to Withdraw
The right of participants to withdraw from a study—at any time, for any reason,
and without having to give a reason—is widely endorsed in theoretical research
ethics and in practice, although the practical implications of this right have been a
matter of debate in particular contexts (Edwards 2005; Helgesson and Johnsson
2005; McConnell 2010; Schaefer and Wertheimer 2010). If a challenge study
participant were to exercise this right after being infected with certain pathogens
and before the infection has resolved (with or without curative treatment) then this
might increase risks to participants themselves and/or risks to third parties. Many
HCS researchers interviewed for this project recognised the difficulties that might
arise in such contexts and the potential for adverse outcomes that could undermine
public trust in research, including (in some cases) a higher potential for third-party
risk in LMICs. Investigators have tried to account for this in study protocols;
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however it was seen as an unresolved issue in need of further analysis and guidance
for researchers (see Box 3.17).
Box 3.17 Participants’ right to withdraw
[T]hese are adults and … their participation in the study is voluntary. They could
always withdraw their informed consent. They could walk even though that is a
risk to the community at large. We can’t hold them against their will. And that was
a concern. And so we spent a lot of time emphasising to them … early on in the
trial, how important it was that they complete the treatment and they complete the
follow-up. And that we understand that it’s a long time. [Carl Mason, scientist, USA]
[I]n our consent forms,we [advise participants that] in the event that youwish to leave
the study, of course you’re allowed to do this, but we would expect you to complete
a course of treatment … But I think if there was a scenario where somebody left and
they wouldn’t take the treatment, we didn’t have a protocol to follow in that scenario.
I think we would have to let them go. We did say if somebody went missing … we
would notify the local authorities to search for thembecause therewould be a concern
about their mental and physical health. And we would contact their next of kin to
try and locate them … Of course, in the UK, the concern [in malaria HCS] is not
about transmission, it’s about wellbeing of the patient. But, you know, in Nairobi
[given the nearby presence of vector mosquitoes] there’s a potential to have onward
transmission as a result of not having treatment. [Scientist, UK/Europe]
Another issue I see as more complicated in the context of challenge trials is the right
to withdraw… [W]ithin the context of the US regulations it’s considered a right that
people have, that they can exercise at any time. There are other trials where you still
can’t quite just leave when you want to leave because it may not be safe for you,
but challenge trials are trials where that issue becomes difficult. And I think it would
be helpful to know more, to have a better public health framework maybe similar to
what we think about for quarantine, to understand what [are] the limits of measures
to restrict someone’s liberty, if they’re in a challenge trial, like when is that even
acceptable and to what extent. [Ethicist, North America]
[W]hat we have in these consent forms [in Gabon], and what we also explained to
them, is that they can leave anytime – but when they have been infected… they need
to come back to be treated. [Benjamin Mordmüller, scientist, Germany]
[T]here are reviews of the data on informed consent [but] the right to withdraw is less
well-understood in low-income countries. And if that’s right the rates of withdrawal
are something that is really tricky in the context of challenge studies because there
may be times when it’s not safe for someone to leave the research. [Ethicist, North
America]
3.3.7.2 Risk of Absconding from Studies
Participants have occasionally absconded from HCS after being challenged,
including one high profile case of a participant in a UK malaria HCS who was
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eventually located in the Netherlands.9 Absconding from a study might in some
scenarios be a special case of the right to withdraw (i.e., participants exercising the
right without notifying study staff), or, in others, it might reflect impaired
decision-making by a participant due to physical or mental illness. Many of the
scientists we interviewed identified the possibility of such events as a significant
concern that had (in some cases) led to revisions of study design and procedures
(see Box 3.18). One solution might be closer monitoring of participants. However,
the more closely participants are monitored during the study (whether on an
inpatient or outpatient basis), the more this monitoring may be burdensome for
them. Thus there are important ethical trade-offs to be made in study design
between post-challenge monitoring that is sufficiently close to minimise risk but
not so intrusive as to be overly burdensome.
Box 3.18 Risk of participants absconding and risk mitigation strategies
[W]e had someone in one of our typhoid studies who absconded because he was an
actor and had an audition, which he hadn’t been expecting, for a lead role in a play
… [W]hilst he was developing typhoid he went to do his audition, and we lost touch
with him and we were very worried about him and in fact he got the role … and he
actually had positive blood cultures for typhoid at the time. [Scientist, UK/Europe]
[W]e had one volunteer leave from one of our studies … [H]e’d been challenged as
part of that study and he decided he’d go and see his uncle [in another country]. And
fortunately we caught him and we made sure he took [treatment for his infection],
and so on. [Scientist, North America]
There was talk of once in a while somebody sneaking out and going to the shops but
not much of like, somebody being away in terms of going home and putting others
at risk … Somebody will sneak out of the gate of the university and go to the shops
nearby and come back. [Scientist, Africa]
[A]s a result of our lost volunteer … we wrote into our consent document and our
volunteer information sheet and our protocol, actions that we would undertake if a
volunteer went missing. [Scientist, UK/Europe]
3.4 Risks to Third Parties
Many types of research with infectious diseases can pose risks of infection to those
not directly participating in the research (i.e., third parties) (Kimmelman 2005; Battin
et al. 2008; Eyal et al. 2018; Shah et al. 2018). In the case of HCS, the principle risks
to third parties are related to transmission of the challenge strain(s) from infected
participants to others—and potentially onwards to many more people. Third-party
9https://www.theguardian.com/society/2010/oct/19/malaria-trial-nurse-found [Accessed 29 March
2019].
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risks are sometimes referred to as ‘bystander risks’;we eschew this termhere, because
an infectious disease can, via a chain of transmission (sometimes of great distance
and/or duration), harm distant others, not only bystanders (i.e., those who happen to
be present when the research is taking place although not themselves participants).10
Risks to third parties include the possibility of transmission (and/or harm) to unborn
children, providing a reason to exclude pregnant women from HCS (Shah et al.
2017). Other third parties at risk can include participants’ family members, but also
members of the general public (Miller and Grady 2001; Hope and McMillan 2004;
Bambery et al. 2015; Shah et al. 2017).
Other effects on third parties may be relevant for certain HCS designs. Where
live-attenuated vaccine strains are tested in HCS (particularly vaccines for enteric
pathogens such as Shigella), for example, there is sometimes a small probability of
transmission of the vaccine strain to third parties (Kimmelman 2005) (although,
given adequate attenuation, the potential harms are low, at least for
immunocompetent individuals, and there may even be a net benefit of such
transmission (Paul 2004)). Where challenge with vector-borne pathogens is
administered by mosquito bite, furthermore, the potential introduction of a new
vector species (imported from elsewhere for the purposes of HCS) could alter local
ecology11 (were the vectors to escape from the study facility) and, in endemic
settings, the epidemiology of vector-borne diseases transmitted by this vector
(Orjuela-Sanchez et al. 2018).
Some have argued that researchers have extensive ethical duties to third parties
where there is a risk that infection will be transmitted to them from research
participants. In the context of infectious disease research more generally (though
not focused specifically on HCS), Battin et al. have argued that, where it is possible
to identify specific people at risk, researchers should obtain individual informed
consent from these third parties before commencing a study and/or, where the risks
are significant but particular third parties are not readily identifiable, some form of
community consent should be sought (Battin et al. 2008).
One way to obviate the need for such additional consent procedures is to reduce
third-party risks to near zero by (i) rigorous infection control and biosafety
procedures at HCS research centres, and, in some cases (ii) strict isolation of
participants (e.g., by keeping them in an ‘inpatient’ setting for the period in which
they are potentially contagious), although this in turn entails significant burdens for
participants. Alternatively, where such third-party risks are not reduced to near zero
they could in some cases be monitored and/or quantified by (enhanced) public
health surveillance in the local area including genotyping of strains detected to
assess the degree to which the challenge strain is transmitted to the local
population. For example, one recent paratyphoid HCS design by UK investigators
explicitly included provisions for the institution of such public health surveillance
10Others have opted for ‘risks to nonparticipants’ (see Eyal et al. 2018).
11This risk is not unique to challenge studies, as other types of (vector-borne disease) research
sometimes involve maintaining colonies of vector species and, in some cases, the importation of
such species.
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measures in the event of presumed or suspected transmission of infection from
participants, including the provision of the challenge strain to local public health
microbiological laboratory for comparison with any clinical isolates (e.g. those
detected during a public health outbreak occurring around the time of the proposed
study) so that it would be possible to make accurate assessments of whether
third-party transmission from study participants had occurred (McCullagh et al.
2015). This, however, might significantly increase study costs and require capacity
building of local public health laboratories in LMICs.
In any case, while some may debate whether such strict duties (to obtain consent
from any third parties at risk) always apply, the potential risks (even if small) may
vary in different contexts depending on the mode of disease transmission. For vector-
borne diseases such as malaria, if there are no local vectors then there are minimal
risks of third party transmission (apart from blood donation by participants while
infected) (Herrera et al. 2009; Hodgson et al. 2014; Hodgson et al. 2015). The risks
of transmission of diarrhoeal pathogens via sewerage systems have been considered
in reviews of HCS protocols (Cohen 2016; Pitisuttithum 2018). Such risks may be
low in HICs with adequate sanitation, but could be higher in communities with
poor access to sanitation (e.g., in LMICs), suggesting a strong rationale for inpatient
studies and/or robust biosafety procedures in such settings (Pitisuttithum 2018).
Conducting HCS in endemic LMICs may affect the potential third-party risks
of such studies in multiple ways. On the one hand third parties with pre-existing
immunity (and/or other forms of resistance to the infection in question) may be
at lower risk of severe disease were they to be infected as a result of third-party
transmission from study participants. On the other hand, other third parties might be
at higher risk, including children (especially those who are malnourished, unwell for
other reasons, etc.), those with health issues including other chronic infections (e.g.
HIV), and/or those with poor access to healthcare. More generally, since populations
in LMICs often have higher levels of ill health partly because of inequities in the
social determinants of health, somemight consider it less ethically acceptable (and/or
potentially more unjust) to impose third-party risks of infectious disease in such
contexts, even if the background risk of the infection in question is already relatively
high12 (e.g., where HCS are conducted in an endemic area—see related discussion
of background risk in Sect. 3.3.3).
Thus, the potential for higher third-party risks in certain contexts can lead to
controversial questions.How important, for example, is a small third-party risk and/or
single episode of transmission (e.g., from a study participant to a third party) in
the context of high local endemic transmission (and/or high average local levels of
immunity)? Some individuals and communities may consider this additional risk
negligible, while others may see each additional episode of transmission as highly
significant –stakeholders interviewed for this project held widely divergent opinions
12A further relevant consideration, depending on the disease in question, is whether the challenge
strain is already prevalent in a given endemic area (since participants and third parties may have
immunity from prior infection with locally prevalent strains that would not necessarily protect
against severe disease when infected with a different challenge strain).
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on thismatter (seeBox 3.19). Given this potential controversy, and given the potential
for third-party risks to undermine public trust in research (see Box 3.20), the potential
for such risks would constitute an additional reason for community engagement (to
assess community views on the importance of such risks and/or to seek community
consent for the research to proceed) and for carefully designed research procedures
that reduce transmission risks.
Box 3.19 Third party risk and background risk
I think [the risk to third parties of a malaria HCS in a highly endemic area] is a very,
very small risk only if you can even, or should even, call it a risk –[because] eighty
per cent and more [of the local population] harbour malaria parasites at any given
time point. [Scientist, UK/Europe]
I think it really depends on the background transmission rate … [I]f you’re working
in a hyper endemic setting, I just don’t think there’s any quantifiable increased risk to
the population … [P]eople are being infected every week, all the time, so … I don’t
think that’s a risk, a real increase[d] risk for the population. [Scientist, UK/Europe]
[If] there is not much greater risk [to third parties, compared to background risk] and
you are not using a strain that is resistant to any of the drugs that are available, then
people [once they understand this] will be much more comfortable I think … most
of the risk that we see are much more academic than real [or] practical. [Scientist,
Africa]
[In Thailand, even if a participant were able to leave the isolation ward, local
population] antibody levels were much higher than the antibody levels that were
seen in volunteers in the previous studies in the US. So for [Shigella], and probably
for some other diseases as well, such as malaria in challenge studies in endemic
areas, you’re going to have people [in the general population] that have partial
immunity. And the risk [to third parties] might actually be a little less. [Scientist,
North America]
[C]ontainment is possible. It’s expensive. Not so expensive in developing countries
as it is in developed countries, but it’s possible and if you can minimise risk [to third
parties] you should do so, and remember that it’s a drop in the ocean, but it’s a drop
in the ocean that can result in death. [Scientist, UK/Europe]
I think of the response if an individual is inadvertently infected. A third party
individual is going to [feel] different[ly about it] if they later learn that it’s because
they came into contact with someone who was in a scientific experiment, than if it’s
[just] because of a mosquito … [R]isk is, or has, these … moral layers … that we
all … bracket when we talk about risk … in a quantitative way. [Jonathan
Kimmelman, ethicist, Canada]
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Box 3.20 Third party risk and public acceptance of research
[T]hird party risks are a very, very important component, both on … first principle
research ethics that … if there are third party risks there are risks that are being born
involuntarily by other individuals but also from the standpoint of public perception…
[W]hen the public perceives a risk that is enduring, [and] as having been involuntarily
endured, then there tends to be much more acrimony and controversy than when the
public feels that … there’s a voluntariness and an awareness … and so I think those
kind of third-party risks are the kinds of risks that you worry about in terms of
destabilising or undermining… public support for research. [Jonathan Kimmelman,
ethicist, Canada]
We just need someone with typhoid on the Oxford study to go and not tell them
they’re working in a food van and have an outbreak in Oxford and that will be it [for
the whole field of challenge studies]. [Scientist, UK/Europe]
3.4.1 Third-Party Risks and Studies of Transmissibility
SomeHCSare designed to investigate the transmissibility of the pathogen in question.
For example, such studies might involve measuring the number of microbes in the
blood and/or stool of an infected participant (the idea being that the number of
microbes present is in many cases correlated with the risk of transmission to others).
Investigation of transmission was one of the goals of several historic yellow fever
and malaria HCS (see Sect. 2.2) and was also identified as an area potentially in
need of further work by malaria HCS researchers based in Kenya (Hodgson et al.
2015). HCS that specifically aim to investigate the transmissibility of the challenge
infection warrant particularly careful design with regards to third-party risk (e.g.,
because studies not investigating transmissibility can be designed with early curative
treatment, whereas transmissibility studieswill often be required to leave participants
infected with the challenge strain for longer periods of time, during which they may
be able to transmit the infection to others).
Australian investigators recently conducted a falciparum malaria HCS assessing
the transmissibility of falciparum malaria in malaria-naïve Australian volunteers
whowere treated post-challenge so as to reduce symptoms among participants (since
malaria symptoms are caused by a particular formof the parasite, amenable to specific
treatment) without affecting the transmissible forms of malaria (gametocytes). These
transmissible forms were then measured by feeding mosquitoes on the blood of
participants so as to provide a model of transmissibility against which transmission-
blocking interventions could be tested (Collins et al. 2018). Toour knowledge the only
similar HCS testing transmissibility in an LMIC is a vivaxmalaria study in Colombia
that was based on secondary analysis of samples from one of the HCS case studies
reviewed below (Arévalo-Herrera et al. 2014). Both the Australian and Colombian
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studieswere performed (usingmosquitoes in tightly controlled laboratory settings) in
non-endemic areas lacking malaria vector mosquitoes in the wild, meaning that there
would be effectively no risks to third parties. Were such transmissibility studies to
be conducted in malaria-endemic settings and/or areas with local vector mosquitoes,
study design and reviewwould arguably require careful assessment and/ormitigation
of third-party risks.
3.5 Participant Selection
Since the formalisation of ethical principles for research, there have been debates
regarding how fairness should be understood in the context of selecting participants
for research and the extent to which special considerations apply to recruitment from
vulnerable populations (National Commission for the Proptection ofHumanSubjects
of Biomedicaland Behavioral Research 1978; Meltzer and Childress 2008).
Individuals and populations can be vulnerable in different ways, and the term
‘vulnerability’ is generally used in research ethics to identify those who are more
likely to be exploited and/or harmed as a result of participation in research
(Macklin 2003; Luna 2009; Rogers et al. 2012; Lange et al. 2013). Individuals
might be physiologically vulnerable (e.g., at higher risk of severe harm as a result
of participation in research), socio-economically vulnerable (e.g., perhaps more
likely to be influenced by payment for research participation—see Sect. 3.6),
and/or vulnerable in terms of being unable to provide autonomous consent (e.g.,
children—see Sect. 3.5.4) or because of dependence on others (e.g., children,
institutionalised individuals) (Goodin 1986; Luna 1997; Macklin 2003).
A particular concern regarding exploitation of vulnerable populations is that
relatively privileged populations may be the primary beneficiaries of research
conducted in more underprivileged populations (Macklin 2003). However,
conducting HCS in LMICs may be less exploitative in this regard if (i) the findings
from such studies are thus more relevant to the (LMIC) populations in which the
pathogen being studied is endemic and (ii) scientific knowledge and/or new
interventions produced by HCS are ultimately made available to those populations
(Wenner 2015, 2017).
An increasingly recognised problem is that excluding vulnerable populations from
research as away of protecting them from further burdens can ultimately lead to these
same populations being excluded from the benefits of research (Sheffield et al. 2018).
It may sometimes thus be ethically important to include vulnerable populations (with
appropriate measures to minimise burdens), especially where the results of research
in other populations are not likely to be generalisable to the vulnerable populations in
question. This is one consideration that is sometimes in favour of conducting (more)
HCS in LMICs.
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3.5.1 Vulnerable Populations in Human Challenge Studies
Since many pathogens for which HCS might be considered occur at higher rates in
poor LMIC communities that are particularly vulnerable (in multiple ways), fair
participant selection for HCS may be especially complex (World Health
Organization 2017). Concerns regarding the potential for exploitation of, or harm
to, individuals from vulnerable populations might thus explain why more HCS
haven’t been conducted in LMICs to date. However, there are several
countervailing considerations. First, in cases where the results of HCS in
non-endemic HIC populations are not likely to be generalisable to LMIC
populations where a given pathogen is primarily endemic, there may be both
scientific and ethical reasons to recruit HCS participants from an endemic
population (Hodgson et al. 2015) (see Sect. 3.2.1.1). Second HCS in endemic
LMICs might sometimes entail relatively lower risks and/or potential for direct
benefits to participants (e.g., related to immunity) as compared with those in
non-endemic settings—meaning that HCS in some ‘vulnerable’ populations might
(perhaps counterintuitively) involve less risk to participants (Selgelid 2013; Lell
et al. 2017; Selgelid and Jamrozik 2018) (see Sect. 3.3.3). Thirdly, undertaking
HCS (and/or other kinds of research) only in HICs might undermine efforts to build
research capacity in endemic settings and exacerbate the research neglect of certain
pathogens (Selgelid and Jamrozik 2018). Finally, recruitment in HICs might still
end up disproportionately selecting vulnerable individuals, especially since HCS
often involve large time commitments and/or isolation from other social activities,
meaning that, for example, unemployed people and/or students might be
overrepresented in HIC study populations (see Box 3.21) (Elliott and Abadie 2008).
Many of those interviewed for this project supported conducting HCS in LMICs
because the results may then be more relevant/generalisable to the eventual target
population for novel interventions. Some noted that although the rates of poverty and
some other vulnerabilities are often higher (on average) in LMICs, LMICpopulations
should not be labelled as vulnerable en masse and thus excluded from research.
Each community, in HICs as well as LMICs, includes a range of individuals with
different levels of various vulnerabilities. Whether HCS are conducted in HICs or
LMICs it is thus important to evaluate the specific vulnerabilities of the (potential)
study population and design studies in ways that reduce the chance of harm and/or
exploitation accordingly.
Box 3.21 Participant selection and vulnerable populations
I do think location matters. I understand the concern about exploiting populations
that are already vulnerable because they’re living in an endemic setting, and, like,
“Oh well, now you’re adding to their risks.” But I, I think there are reasons to do it
in endemic settings first. [Ethicist, North America]
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[O]ccasionally I see people… neglect the fact that in low income andmiddle income
countries you have islands of affluence, and in high income countries you have
islands, if not continents, of disadvantage. [Jonathan Kimmelman, ethicist, Canada]
I’m completely committed to the value of fairness. But I think we, as a result of that,
should not act as if persons in low- and middle-income countries were incapable of
altruistically participating in research that benefits others. [Ethicist, North America]
[HCS participants are] usually younger people because we need healthy people, and
they tend to be people who have enough time to manage this. So … sometimes it’s
so demanding in terms of time that people who have high-stress jobs or very busy
families can’t really participate. And so it’s generally people who just really care
about contributing something and feel good about contributing something to science
and biology. [Scientist, North America]
I wouldn’t say all of them but a significant proportion are people that are unemployed,
you know. And so… you’re giving them a nice opportunity for income. And whether
they understand…And then that needs to be balanced with them fully understanding
the risks. [Scientist, North America]
3.5.2 Consent
Informed consent for research participation involves a potential participant with
adequate cognitive capacity who is adequately informed regarding the details of a
study, understands this information, and makes a voluntary, uncoerced decision to
participate. Among those interviewed, there was widespread agreement that HCS per
se did not need a special consent process. However, many supported the notion that
(in research in general, and in HCS in particular) the higher the burdens (including
risks) of a given study, the greater the responsibility of those conducting the study
to ensure that participants are able to give fully informed consent. HCS that involve
new or particularly complex models, higher risks, and/or those recruiting individuals
with little prior experience and/or understanding of research may thus warrant an
especially careful consent process (see Box 3.22). Our review of LMIC HCS case
studies found that consent processes inHCS frequently involvedmultiple information
sessions and/or tests of understanding, suggesting that investigators recognise the
importance of more stringent consent processes in such studies.
Box 3.22 More stringent consent requirements
[W]hen you have elevated risk … that expectation for understanding and for
voluntariness is much more enhanced than when you have low levels of risk, and so
under those circumstances there ought to be a much more demanding and exacting
consent process. That really seems straightforward but that also seems embedded in
the standard notion of … how we do informed consent so [it] doesn’t seem that
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claim is a radical departure from what we already believe and practice. [Jonathan
Kimmelman, ethicist, Canada]
[T]he greater the risks of study participation, the greater your duty to really be sure
that your subjects are fully understanding what’s at stake. [Ethicist, North America]
[T]he things that do actually improve understanding are giving people more time
to think about a consent document and then testing their understanding, and then
re-educating them on the things they don’t get right. So those things I think probably
should be more universally implemented than we do right now. And they would also
be useful for challenge studies. [Ethicist, North America]
CHIM studies might be a good example of a circumstance where you’d actually want
to build in some comprehension checks and that’s definitely not just an issue for low
resource settings [Ethicist, North America]
So [in Gabon] we explained [the risks of the study] but we also have a quiz
afterwards, so they actively have to answer these questions by themselves … [W]e
have a quiz with multiple choice answers, and they have to pass this quiz [so] that
we can somehow have evidence that they really understood. [Benjamin
Mordmüller, scientist, Germany]
3.5.3 Education Level
It is sometimes thought that it would be more ethical to recruit those with higher
levels of education as research participants because this may improve informed
consent (if educated participants more easily understand information about the
study). Some HCS (including in LMICs) have thus aimed to recruit
tertiary-educated individuals and/or university students (especially medical
students) in particular (Hodgson et al. 2014; Shekalaghe et al. 2014). Despite these
apparent advantages, there are also several ethical disadvantages of such a
recruitment strategy: (i) excluding less well-educated individuals might be
unjustified if they are able to understand a study well enough to provide adequate
informed consent, (ii) university students (or those who have received university
education) may not be representative of the eventual target population for an
intervention (e.g., because they are more likely to be affluent and/or to live in cities
and less likely to live in highly endemic parts of LMICs and/or because in some
countries women are much less likely than men to receive university educated), (iii)
excluding less well educated individuals from HCS research may thus be unfair,
especially where poor and/or less well educated individuals are at higher risk of the
disease in question and/or where women are underrepresented in tertiary education
(leading to the exclusion of such individuals from research), (iv) students may feel
pressure to participate (e.g., from academics within the faculty with an interest in
the study) making consent less voluntary (Bonham and Moreno 2008), (v) educated
individuals (e.g., healthcare workers) may sometimes actually be less compliant
with study protocols than other potential participants. Two anecdotal cases support
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the latter point: (1) the participant who absconded from one falciparum malaria
HCS (discussed below) was a healthcare worker, and (2) in a Colombian malaria
HCS discussed below, one participant who worked as a paramedic was strongly
suspected to have self-treated with antimalarials after challenge, thus undermining
the scientific value of his or her participation in the experiment (Herrera et al.
2009).
3.5.3.1 Education Level in Low- and Middle-Income Countries
In practice, LMIC investigators have sometimes been successful in recruiting enough
tertiary-educated individuals for HCS (Shekalaghe et al. 2014; Jongo et al. 2018),
whereas others have found it difficult to recruit as many students as planned (and thus
recruited others with lower average education levels (Hodgson et al. 2015)). Social
scientists embedded with more recent challenge studies have suggested that many
less educated individuals appeared to be able to provide adequate informed consent,
especiallywithwell-designed community engagement andmultiple opportunities for
careful explanation of the study (Njue et al. 2018). Including less educated individuals
can help researchers to recruit more people from rural, highly endemic areas, and
thus learn more about acquired immunity and the efficacy of interventions in those
at particularly high risk of the infection in daily life (Hodgson et al. 2014; Hodgson
et al. 2015). More work will be required in other settings to assess the quality of
informed consent and whether the presumption in favour of recruiting especially
well-educated individuals is justified.
There may be one additional way in which recruiting those who live in or near
highly endemic areas, even if they are less educated, is ethically preferable (so long
as adequate informed consent is assured): such individuals may be more likely, on
average, to have an interest in the goals of the research because prior experience of
the infection in question (e.g., in themselves or those close to them) may lead to
greater understanding of the need to reduce the harms of such familiar infections and
thus motivate participation in research, above and beyond a more general sense of
altruism that maymotivate individuals in non-endemic areas (see Box 3.23) (London
2005; Njue et al. 2018).
Box 3.23 Consent in LMICs where HCS pathogens are endemic
Some people worry that, if you do a challenge study in an endemic setting, you
have to do more education because people would be less likely to understand what
the study actually involves. And there … the data on informed consent actually are
somewhat reassuring … [T]he data on informed consent suggests that there isn’t a
systematic difference in terms of geography, in terms of what people understand.
[Ethicist, North America]
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[In] a country like Brazil, where Zika has been a problem … there are people who
are willing to… be soldiers against the disease that they see afflicting… their peers,
as opposed to … a low income person in Baltimore, who is unlikely to get Zika
exposure, unlikely to know someone who has Zika, and is [participating in research]
to pay the rent. [Jonathan Kimmelman, ethicist, Canada]
[W]e had [one paticipant] who’d never been to school, but he passed the test of
understanding … and we had a few [with] really the low primary level kind of
education … So, there were all kinds of education levels. [Our work with these
participants] helped us to … realise it does not necessarily have to be the level of
education that mattered, it’s about understanding what the key elements … of this
study are. [Scientist, Africa]
I wouldn’t call [consent practices in LMIC HCS] special … [E]verywhere we go
the informed consent is adapted to the local setting. And some places are better-
educated than others. Some have two or three different languages that you … need
to translate into … The informed consent doesn’t change hugely between different
sites, and we have had steers in the past by the IRBs to say … ‘You can make this a
bit more simplified,’ or, ‘You could clarify that.’ So we rely heavily on the advice of
the [LMIC] IRBs to help us with that as well and get some excellent feedback from
them in that regard. [Scientist, North America]
If you’re developing a vaccine, and you’re planning to actually deploy that in super
rural areas where the majority of the population is illiterate, obviously you would
want to move that controlled human infection model to that population also because
that population for lots of scientific reasons might respond differently so you need to
… research whether it’s going to work in that population as well. [Meta Roestenberg,
the Netherlands]
3.5.4 Children
One of the most controversial questions regarding HCS is when, if ever, it might
be ethically acceptable to recruit children as participants in studies that could cause
significant symptoms/disease among (child) participants. On the one hand, many
pathogens of interest (e.g., falciparummalaria, Shigella) predominantly harm young
children in endemic settings whowould thus stand to benefit most from new vaccines
(and thus the research in question). Therewould thus be a scientific rationale for HCS
in children. On the other hand, (i) HCS in carefully selected adult volunteers might
be sufficiently generalisable to children at risk (and thus obviate the need to recruit
children), (ii) children lack the capacity to provide informed consent to participation,
which is especially important given that the consent of participants arguably matters
more for burdensome and/or higher risk studies (as discussed above), (iii) challenge
infection might sometimes be higher risk in children, and (iv) public perceptions
of the enrolment of children in HCS could undermine trust in HCS and/or research
more generally.
For these and other reasons, the onlyHCSperformedwith children have used (live-
attenuated) vaccine strains of micro-organisms as the challenge agent (Groome et al.
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2017)13; recent/modern HCS have thus avoided the use of disease-causing challenge
organisms in children (WHOExpert Committee on Biological Standardization 2016;
Baay et al. 2018). Among those interviewed for this project, there was widespread
consensus that, even if HCS in (involving disease-causing organisms) in children
could be conducted safely, there should be a presumption against enrolling children
in HCS (involving disease-causing organisms) with HCS in adults and/or field trials
in children as plausible alternatives to be tried first. Many suggested that a very
carefully described rationale and wide consultation would be required before any
such study were considered. A particularly strong theme was the issue of public
and/or community acceptance and the risk of undermining trust in research (see
Box 3.24).
Box 3.24 HCS in children
[T]o do these challenge studies for some of these diseases that occur so early in life,
you know … a child with diarrhoea … in order for you to really get a good readout
on the value of vaccine for child diarrhoea, you can’t do it in an adult. You have to
do it in a child. But … I don’t think we’re talking about doing human challenges
in children, because I think that there’s a lot of issues there in terms of consent.
[Scientist, North America]
[A]s a researcher, I would say you could do [a malaria HCS in children with early
treatment] safely, but getting it past an ethics committee would be a massive
challenge. Certainly, you know, giving kids malaria … the optics of it are not good.
So, it would have to be preceded by a massive public and stakeholder engagement
campaign. [Scientist, Asia]
I think we might be able to justify [a Shigella HCS vaccine trial in children] but it
would…definitely be on a case-by-case basis and therewould have to be tremendous
consensus both in the host country probably as well as globally. That’s something
you would have to take to [a] body like WHO and really try to build a consensus.
[Carl Mason, scientist, USA]
[T]here are certain kinds of risks and certain kinds of incidents that tend to, more than
other kinds of incidents, galvanize public opposition campaigns and among those
I mentioned is involuntary exposure but among those is risk to children. [Jonathan
Kimmelman, ethicist, Canada]
[Y]ou know the difficultly of doing vaccine research in children and you just have
to have a few things, coincidently, go wrong and you can destroy a whole program
of research or public health implementation. [Scientist, UK/Europe]
I think … in general most people would say that it’s just … unacceptable to do
challenge studies in children. I think that’s most people’s starting point, and I think
before we move away from that position, we’d have to be on really very solid ground
… I hope nothing like that proceeds without all sorts of very extensive consultations
and discussions. [Scientist, UK/Europe]
13In such cases, exposure to the live-attenuated vaccine strain as a challenge agent would entail an
extremely low risk of harm and perhaps even a net benefit to participants.
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[T]here’s already, to me, a serious public relations issue about challenging people
with a pathogen… and if you were then to translate that to doing that in a group who
can’t provide consent and something goes wrong I think is obviously a disaster for
that family but perhaps for the whole challenge community an even bigger disaster
and it starts to feel like [the unethical HCS] around the time of the Second World
War. [Scientist, UK/Europe]
3.5.4.1 Generalisability of Adult Challenge Studies to Children
If children are excluded from HCS aimed at understanding and preventing
infections that predominantly cause harm to children, then, for pathogens that
mainly affect this population, researchers should arguably select participants such
that the findings (e.g., regarding vaccine efficacy in the target population) can be
generalised to children in endemic settings as reliably as possible (even if there
remain important differences between children and adults with respect to the
infection in question and/or vaccine efficacy estimates). This raises a further
difficulty: children in endemic settings share certain characteristics with adults in
similar endemic settings (e.g., genetics, microbiome, etc.); but, with respect to
immunity, they may actually be more similar to adults in non-endemic settings
(since both young children in endemic settings and most adults in non-endemic
settings will be non-immune to the pathogen in question).
Because many adults in endemic settings will have (partial) immunity to the
pathogen in question, it may be difficult to recruit non-immune adults locally. Thus it
may not always be clear whether it would be (ethically and scientifically) preferable
to conduct a given HCS design with adult volunteers from a LMIC in which the
pathogen is endemic or in those from a non-endemic (LMIC or HIC) population.
An ideal approach, with respect to the scientific aim of generalisability, would be
to recruit non-immune (ideally never exposed) adults from a population in a non-
endemic area of a LMIC (rather than, for example, from a geographically distant
and genetically different HIC population) that would also be closer to a population
of children in an endemic area in other respects (e.g., genetics, microbiome). From
a pragmatic point of view, it may sometimes be difficult to identify and/or recruit a
sufficient number of such individuals (especially if non-immune adults are a rarity
in areas near endemic settings), in which case HIC HCS might be more justifiable
(see Box 3.25).
Box 3.25 Alternatives to HCS in children
[D]oing something in children with a challenge model, when you could do that in
adults, or in naive individuals in [a] developed country, to me, doesn’t feel justifiable.
[Scientist, UK/Europe]
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[S]cientifically, the advantage of working in a developing country is where the
relevance of the challenge model is increased by working in the relevant
population; and, so, in the context of a disease which primarily affects children,
studying adults in an endemic setting, in a developing country, may not be a very
good model for understanding the disease in children and it could be that studying
healthy volunteers in Australia or in the UK, who are naive to that disease, may be
more relevant to children. [Scientist, UK/Europe]
I think [enrolling children in HCS] is really quite likely to have a major adverse
effect on the public perception of research … even if you could find parents that
would consent … I would be very concerned about that. I think, this is the one area
[for] which [there] might be some justification for doing the challenge studies in
non-endemic countries… [T]he most practical way of providing data that is relevant
to young children, at least in the case of malaria, is with non-endemic adults, because
in both cases they’re non-immune. [Scientist, UK/Europe]
3.5.4.2 Recent Example of a Low Risk Challenge Study in Children
One recent study of a rotavirus vaccine in SouthAfrica used anHCS design, although
the authors do not refer to it as a challenge study (Groome et al. 2017). The study
recruited healthy children aged 2–3 years with the aim of testing the safety and
immunogenicity of an inactivated injectable rotavirus vaccine; the injectable vaccine
contained rotavirus proteins (in contrast to live-attenuated rotavirus vaccines that
contain a complete virus potentially capable of replication). After vaccination (or
placebo), the childrenwere challengedwith a live-attenuated rotavirus vaccine strain,
and investigators tested (among other outcomes) whether the inactivated injectable
vaccine reduced the shedding (in stool) of the live-attenuated rotavirus vaccine strain.
There was some evidence that the inactivated vaccine reduced such shedding (thus,
if such an effect were generalisable from the live-attenuated rotavirus strain to wild-
type strains, this would suggest that the injectable vaccine might reduce replication
of and/or disease resulting from and/or the transmissibility of wild-type rotavirus in
those vaccinated and subsequently exposed) (Groome et al. 2017).
It is interesting that the authors did not refer to the above study as a challenge
study, although other researchers have identified it as an example of HCS in
children (Baay et al. 2018). One might think that it was not considered an HCS
design because the challenge agent was not a disease-causing strain of rotavirus
(i.e., it was attenuated to a degree that, like other live-attenuated vaccines, it would
be expected to lead to immunity to the infection in question without itself causing
symptoms/disease). However, HCS need not always be designed to result in
symptoms/disease in volunteers (See, for example, Sect. 3.3.2.1), and HCS using
(asymptomatic) infection/viraemia as the goal/endpoint of challenge (i.e., an
‘infection model’ involving few or no symptoms among participants as opposed to
a ‘disease model’ involving significant symptoms) have been proposed and/or
conducted with arboviruses such as dengue and Zika (Larsen et al. 2015; Durbin
and Whitehead 2017).
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In any case, the rotavirus study discussed above does not set a precedent for
disease-causing HCS in children since the challenge agent used (a live-attenuated
vaccine strain) would (i) entail minimal, if any, risk to participants, and (ii)
potentially provide direct benefits to participants if the live-attenuated vaccine
strain provided/increased immunity against wild-type infection.
HCS with such highly-attenuated strains (whether designed as vaccines or not)
might not be especially generalisable to wild-type infection, which would in some
cases undermine the scientific rationale for the use of such designs (see Sect. 3.2.1.1)
(Selgelid and Jamrozik 2018). However, if it were shown that an attenuated strain
that is incapable of causing disease among participants nevertheless provided useful
generalisable knowledge regarding infection with wild-type strains, such a strain
could potentially be ideal for use in HCS (in children or in adults) with respect to
the assessment of the relative burdens and benefits of such a design.
3.6 Payment of Participants
Enrolling in a challenge study often entails (i) potential financial costs for participants
(e.g., travel costs, childcare, and time away from usual activities, including paid
work), (ii) potential burdens during participation (including, for example, exposure
to risk and/or harm and potentially long periods of isolation—see Sect. 3.3). Since
research participants endure these costs and burdens contributing to projects that
primarily aim to benefit others (e.g., future people at risk of the disease being studied),
it has been argued that payment is often ethically appropriate—although payment
of research participants remains controversial, especially in the contexts involving
(economically) vulnerable populations and/or high levels of payment (Macklin 1981;
McNeill 1997; Savulescu 2001; Cryder et al. 2010; Gelinas et al. 2018). Importantly,
payment may be intended as (i) reimbursement for costs incurred, (ii) compensation
for harms (if they occur), (iii) compensation for other burdens, (iv) an incentive for
participation, or some combination of all of these goals (Gelinas et al. 2018).
Attitudes toward the payment of research participants vary across individuals
and across different cultures/countries, as do payment practices. Small
reimbursements (e.g., for travel costs) are relatively uncontroversial and quite
common across jurisdictions. The need for compensation for research-related
harms (if they occur) is also relatively uncontroversial, and was widely supported
among interviewees for this project, although legislation and current practices
regarding such payments vary considerably in different countries (Chingarande and
Moodley 2018). For example, LMIC researchers may sometimes have difficulty
obtaining the necessary insurance to cover such compensation for harm, which can
be one factor that undermines local research capacity (see Colombian vivax HCS
reviewed in Sect. 5.3).
Payment intended to compensate for other burdens and/or incentivise research
participation, however, are more controversial (Gelinas et al. 2018). Such
payments, and even high levels of payment, are widely viewed as appropriate in
72 3 Ethical Issues
some countries (e.g., UK and USA (Savulescu 2001; Cryder et al. 2010)) but they
are less accepted in other countries and are sometimes even proscribed by local
regulations and/or norms (e.g., in some Latin American countries). Recent HCS
have sometimes involved high levels of payment; for example, an HIC influenza
HCS offered participants USD $4,000 (Cohen 2016). Among HCS in LMICs
reviewed below, participants were paid (i) in Kenya, up to approximately USD
$500 (depending on duration of infection and other factors) (Hodgson et al. 2015;
Nordling 2018), (ii) in Thailand, amounts indexed to local wages (Thai minimum
wage is equal to approximately USD $10 per day,14 meaning that payment for
participation in a one month inpatient study might amount to approximately USD
$300 or more), and (iii) in Colombia, no payment apart from reimbursement for
costs (travel etc.). Stakeholders interviewed for this report generally agreed that
payment for participation in (LMIC) HCS was ethically acceptable, and that it was
particularly appropriate to pay individuals who participate in particularly
burdensome HCS designs (e.g., inpatient studies). However, determination of the
appropriate method(s) for titration of payment according to the burdens of
participation was an area that was considered contentious and/or unresolved (see
Box 3.26).
Arguments in favour of payment of participants have focused on (i) reciprocity
(because participants take on burdens and risks in order to benefit others) (Njue
et al. 2018), (ii) analogies between research participation and other forms of labour
(Gelinas et al. 2018), (iii), payment for taking on risk as for other types of high-risk
socially beneficial activities (e.g., fire-fighting) (Savulescu 2001), (iv) evidence that
payment may be a signal that reminds potential participants that studies in healthy
volunteers are usually not beneficial for them and may impose a net risk of harm
(Cryder et al. 2010), (v) a potentially important incentive to increase participant
enrolment numbers (in socially valuable, appropriately low-risk research) (Macklin
1981). As mentioned above, it has also been argued that there should be a system to
compensate those who suffer (rare but potentially significant) harms as a result of
HCS participation, even if risks have been minimised and fully disclosed to
participants (Bambery et al. 2015).
Box 3.26 payment in LMICs
[T]he current situation is … for whatever reason, [that] somebody says it’s not
appropriate to pay people in developing countries … and sometimes that didn’t
come from developing countries themselves, it comes from somewhere else and it’s
14Current Thai minimum wage was 325 THB at time of writing, see https://tradingeconomics.com/
thailand/minimum-wages [Accessed 30 March 2019].
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also perfectly clear that the amounts that are paid in some US settings are grossly
inappropriate. [Scientist, UK/Europe]
[I]n endemic countries I think … when you’re asking people to give up ten days of
their life, to stay in an inpatient unit … I think they should be compensated. That’s
… a lot of their time and freedom. Certainly it’s time away from how they could be
making other money – and it’s difficult, frankly, to find people altruistic enough [to]
say ‘Sure, I’ll stay in your inpatient unit for ten days, for the betterment of science.’
Prof. Anna Durbin, scientist, USA
[F]or a long time, in a [low-income] setting [the standard view has been that] people
should not be compensated, so that they can make a voluntary decision not driven by
gains that might accrue from participating in the study … [A]s much as people get
worried about [payment in LMICs], it is the same as what you are seeing with people
who are doing the phase one studies in Europe … [T]he students end up doing that
[i.e., serving as participants], because they want some extra money [and] because
they want to be a part of something. [Scientist, Africa]
[We]’re thinking [that] because we need a population that … has a better chance of
understanding the study, it would be people around [the research institution] – so
either hospital staff, students, lecturers, so people who are in the campus probably
… so they won’t go for minimum wage, it’s crazy right? Ah, so that’s compensation
for burdens and then there should be incentives. I mean this is a challenge study,
no incentives, forget it. No-one’s going to come and I think we should incentivise
people properly. [Scientist, Asia]
[H]ow do we appropriately compensate for all these inconveniences? And I think
tied to that is, and this is what we struggle with, is are we compensating for the
risk? Are we compensating for the fact that the inmate actually gets sick and feels
all the discomfort that comes with the sickness? How do you even know what to
compensate for that? You can compensate for time stayed, you can compensate for
expenses, you can fund expenses, but how do you compensate for someone being
sick? [Scientist, Africa]
I don’t want to underpay people because it’s not fair to underpay people. If I take
two weeks out [to participate in research], committing this amount of time and
sacrificing my social life, [and] probably [drinking] no alcohol for two weeks, [that
would constitute a significant burden]. Come on, you have to pay people! [Scientist,
Asia]
Often the procedures for challenge studies are really quite onerous compared to
other studies so if you just add all that up together, just logically, the amount that
they should be paid is more than for other studies. How much that should be, should
probably be linked to local purchasing parity. That makes sense to me. [Scientist,
UK/Europe]
3.6.1 Undue Inducement
Many researchers and ethicists might be concerned that payment of participants
(particularly high levels of payment, and/or among economically disadvantaged
populations) may result in ‘undue inducement’ to enrol in research. This
presupposes that some payments or inducements may be appropriate or ‘due’ (for
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example, reimbursements of travel costs or payments in lieu of lost wages) whereas
others are inappropriate (Macklin 1981). Undue financial inducement might (or
might be perceived to) (i) undermine the understanding and/or voluntariness
components of informed consent by impairing decision-making (leading, for
example, to participants accepting more risk than they would usually accept and/or
forsaking responsibilities to children and family members) (Grady 2001; Njue et al.
2014, 2018), and/or (ii) lead participants to conceal important details of their
medical or psychiatric history resulting in increased risks to them and/or perhaps
compromising the scientific validity of the study (Gelinas et al. 2018; Taylor and
Morales 2018), and/or (iii) lead participants to ‘over-volunteer’, e,g., participate in
multiple studies simultaneously, which could have similar deleterious effects (see
Box 3.27). In contrast, some have argued that—because each of these ethical
concerns can be appropriately remedied without removing financial
payment—payment per se is not ethically problematic, and even very high levels of
payment may be acceptable (Savulescu 2001; Emanuel 2005).
Many of our interviewees were concerned about the potential for undue
inducement to participate in HCS (in both HICs and LMICs) and acknowledged
that higher levels of poverty, as well as cultural norms, could alter local perceptions
of payment for research participation. However, some also argued that this should
not necessarily preclude the payment of participants in LMICs, especially for
highly burdensome (and/or highly socially valuable) research including some HCS
designs. Several noted the potential for undue inducement among economically
vulnerable participants in HICs, emphasising that this potential issue was not
unique to LMICs, but one that required further work in different settings to
determine and review fair levels of payment (see Box 3.27).
Box 3.27 Undue inducement and vulnerable populations
[O]ur ethics committees are very worried about compensation and inducement …
But if you look at challenge studies in the West, you look at challenge studies in
Africa, whoever is [participating in] the study always says, ‘My main motivation is
the money.’ But, has anybody set a price on what is enough, and what is insufficient?
… [I]f I paid someone $100 a day in Baltimore would they participate? If I paid them
$1000 a day in Baltimore would they participate? Where do you set the price? … In
India or in Africa or anywhere else, I think you should compensate people who are
volunteering, and I think you should compensate them well. Inpatient studies should
definitely be compensated more than outpatient studies but … I don’t think we’ve
done enough work on what’s right, and what is actually inducement. [Gagandeep
Kang, scientist, India]
[Concerns about undue inducement of vulnerable participants] very rarely came up
… in [a research site conducting HCS in UK/Europe]. We mainly had excessively
educated, sort of, philosophy students and that kind of thing who found it very
interesting, and I think [to] a lot of them … the amount of money we paid really
didn’t make much difference to them…whereas in [a research site conducting HCS
in North America], I’ve been there and witnessed how they do things there … [and]
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it’s some of the most vulnerable people in that society [who end up participating].
[Scientist, UK/Europe]
I don’t have anything against what they are doing in the States. [The] situation might
be completely different; [the] country is completely different. So I don’t, I don’t
think the payment is harming anybody; and … from the volunteers that I have seen
in the States, I think that they accept the money because they like the money, but not
because they need it … It’s not that you are influencing them by—possibly, I mean,
who knows? It’s very difficult to know. [Sócrates Herrera, scientist, Colombia]
[T]he one worry I have is that if you pay people a lot of money that you could have
a higher increase in people not revealing certain information to the study team and
lying about inclusion criteria, exclusion criteria, or what they did in the course of the
trial, or what side effects they’re experiencing. And all of those things could have
a detrimental impact on safety. So I think we probably need more data on whether
higher payments induce people to conceal information that would relate to their own
protection. [Ethicist, North America]
3.6.2 Other Ethical Issues Related to Payment
In addition to undue inducement, there may sometimes be other ethically concerning
effects of (high levels of) payment. Firstly, payment may lead to the disproportionate
recruitment of impoverished individuals and groups, which would in some cases
arguably be unjust, for example if the disease under study did not primarily occur in
similar populations (see ‘Participant selection’) (Macklin 1981; Elliott and Abadie
2008). Secondly, high payment may undermine sustainable research practices and
fair availability of research opportunities, an effect to which institutions in resource-
limited settings may be particularly susceptible; for example, if certain types of
research involve much greater payments, it may be more difficult for other studies
(with lower levels of payment) to enrol participants; in the longer term, some worry
that this could jeopardise participation in research more generally (Njue et al. 2014).
Finally, some worry that payment may change the way that researchers treat research
participants and/or that participants will view themselves as being akin to employees
as opposed to volunteers (Njue et al. 2014) (see Box 3.28).
There are already fears of creating an ‘underclass’ of research participants in
HICs (drawn from underprivileged groups in society) (Elliott and Abadie 2008)
and/or of ‘over-volunteering’ (i.e. participating in research too frequently in order
to receive payment, see Sect. 4.3.4). These patterns of participant selection could in
some cases undermine the safety of participants (e.g., because compounds used in
one study interact with those used in another study) and/or scientific analyses (e.g.,
because data generated with the research ‘underclass’ are not generalisable to the
eventual target population) (Shamoo and Resnik 2006; Allen et al. 2017). Such
concerns could be magnified in LMIC settings and/or impoverished communities in
HICs, especially where there are large populations of unemployed individuals and a
fragile social support system. Further social science research on potential
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inducement of participants and/or over-volunteering as well as transparent
longitudinal data (e.g., regarding the level of payment in different studies and the
sustainability of research with variable levels of payment over time) would help to
clarify the practical importance of such concerns (see Box 3.28).
Payment in both HIC and LMICs is a significant motivator for participation, often
rated by participants as more important than the altruistic motives of contributing to
important science (though such motivations commonly co-exist) (Njue et al. 2018;
Kraft et al. 2019). In endemic settings, where many members of the local population
may be more likely to be poor (and/or vulnerable in other respects), even carefully
considered levels of payment have caused controversy. For example, in June 2018
a Kenyan media article expressed concern regarding payment of participants in a
malaria HCS, despite prior community engagement and thorough consideration of
appropriate levels of compensation of appropriate levels of compensation (Gathura
2018; Kenya Medical Research Institute (KEMRI) 2018). In the interviews for this
project, payment of HCS participants was identified as a complex issue in need of
further analysis (see Box 3.28).
Box 3.28 Sustainability, over-volunteering, and relationships between researchers
and participants
There are institutions that are involved, and look at what should be acceptable …
[W]ithin our setting, what can we possibly keep up with, and what can we sustain?
… [O]nce you start compensating people at a … certain level, they will expect that
to continue. And when it comes to another study they will not [have the same levels
of compensation], so I think it’s one way [of] looking at what would be acceptable
within our frameworks, I think, if you are driven by local institutions [and their views
on sustainable payment levels]. [Scientist, Africa]
[T]here are several … phase one trials that are happening in India where we have
these professional trial participants. They make a livelihood out of trial participation
… [T]here is a washout period of 45 days or something and… after every…45 days,
they just go and participate in one trial after another; and these people, if there is no
trial, if they are not eligible to participate in a trial, they go hungry. [Vijayaprasad
Gopichandran, ethicist, India]
[Overvolunteering] will undermine the science, but I think the primary thing is …
thinking from a more society than science perspective … [w]hat it winds up doing
is giving all of research a bad name. So the fact that your own research got ruined
is bad enough, but you are ruining then research for a number of different areas.
[Gagandeep Kang, scientist, India]
[O]ftentimes people think entirely in terms of how paying people might change a
person’s decision to go into the research, losing sight of the fact that the person
that’s doing the paying is also altering his or her relationship with that individual by
paying them … If you feel like … you can … retain a person in a trial by paying
them more, you probably are … feeling much less pressure to treat that person with
respect and to try and do various things [to] keep their motivations aligned with your
own. [Jonathan Kimmelman, ethicist, Canada]
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Chapter 4
Community Engagement, Ethics Review,
and Regulation
4.1 Community Engagement
Community engagement is ethically important for many types of research. Given
that HCS represent a particularly complex, sometimes unfamiliar, and potentially
controversial type of research, engagement may be especially warranted in the
context of HCS (World Health Organization 2017). Since different issues may arise
in different communities, and since HCS may be particularly unfamiliar in LMICs,
community engagement is arguably an essential part of setting up and maintaining
HCS capacity in LMICs (El Setouhy et al. 2004; Njue et al. 2014; Hodgson et al.
2015). The LMIC HCS case studies reviewed below generally occurred within
long-established research institutions, some of which had teams specifically
appointed to engage with local communities. The group in Kenya has a particularly
significant track record of community engagement regarding research in general
and, more recently, HCS in particular (Gikonyo et al. 2008; Njue et al. 2014, 2018).
Several interviewees noted that, ideally, engagement does not merely entail
researchers informing communities about planned or on-going research, but should
be a two-way process from which researchers could also learn about community
perspectives, suggestions, or concerns etc. (see Box 4.1). Engagement activities
might also involve consultation with other institutional staff, including ethics
committee members. Indeed, several stakeholders identified engagement with, and
capacity building of, local ethics committees as a key area that had been necessary
for the conduct of some HCS (in both HICs and LMICs), especially where those
committees had little previous experience of HCS designs (see Box 4.2).
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Box 4.1 Community engagement for HCS
[Our trials have a significant] community engagement component…[O]ne of the first
things is to set up a website and … map up stakeholders … [W]e have [participants,
and] the research ethics guidelines [for them] are quite comprehensive. What about
the stakeholders? … [W]e have … ethics committees … and then we have friends
and family [of participants], including social media, for instance … it can go crazy,
you know, [and] you need to manage it from the beginning and then you have the
media and the wider public … [A]ll these stakeholders … they have their interest[s]
… and they would want certain types of information. [Scientist, Asia]
[Regarding community engagement] I’d have more rather than less information. I
think that often we have this bad reputation because we create a vacuum of
information, a void. And that void gets filled by misunderstanding. So … I think we
ought to be proactive and avoid that void by filling it with information for the
community. And openly … I think that for a number of reasons, not just, you know,
pragmatically getting involvement but also for people to understand what is it that
comes out of these studies, what the risks are. I mean we say so little about the
benefits from research in lower/middle-income countries, in general. [Ethicist,
North America]
We are lucky we have … a group that is called the KEMRI [Kenya Medical
Research Institute] Community Representatives. These are people elected. We have
two hundred and twenty people that we are interacting with every three months.
Just to talk about the work of the KEMRI but also to hear comments from the
community … [T]hose become key people whom community members can go to,
ask questions, get clarifications, you know, complain too, if they want to complain,
and so they give us this information. [Scientist, Africa]
I thinkwith something like challenge studies where… there is a potential if messages
are half heard, or shared, you know, out of context … there is a potential [for]
rumours, or worries, or, you know, issues to flare up. And so, if you don’t have the
sort of mechanisms and relationships that allow people to say, “Hold on, I’m actually
worried about this or that,” or “No, I don’t like the fact that this or that is happening.”
And you’re able to discuss it, and do so in a way that isn’t defensive or dishonest, I
think that’s the only way, really, that you can get this kind of complex information
discussed, and that there can be mutual learning. So I think it’s important for all
kinds of studies because I think it’s remarkable what kind of activities can lead to
concerns that you don’t necessarily predict. [Scientist, Africa]
Box 4.2 Engagement with ethics committees and by ethicists
[Wh]at we did in Kenya was to possibly spend a couple of years before we did a
challenge study to sensitise the scientific community why we wanted to do challenge
studies and [what] we think they [are] really warrant[ed] for, at this point in time, and
there was a back and forth. Initially, people were very sceptical; but … we explained
to them more [and] then were able to meet with the ethics committees and explain
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to them about this technology, why we wanted to go through this route, what … it
bring[s] to the table for everybody. [Scientist, Africa]
One of our key stakeholder groups here in Thailand, is ethics committees. Not just
our own ethics committees, and obviously we have to engage with them properly
because they need to look at our protocol and all that. But also making an effort
to engage with other ethics committees … because we have a reputational risk,
right? The reputational risk for our ethics committee: ‘You what? You approve[d]
this study?’ Other committees might say ‘You’re crazy!’ – so we should engage with
them. [Scientist, Asia]
[F]or ethicists in particular, engaging with the community becomes kind of like ‘Of
course it must be done, yes it must be done’, but I don’t see them doing it very
often. So, it requires a lot of effort; social scientists tend to do a better job than
biomedical ethicists. But I think it is something we’re going to increasingly need to
think about, not just for challenge studies but for all of clinical research. [Gagandeep
Kang, scientist, India]
4.2 Ethical Review
HCS are sometimes perceived to be an unusual and/or particularly sensitive type of
research, and thus some commentators have recommended policies of special
ethics review procedures, for example by a specialised and/or national committee
(UK Academy of Medical Sciences 2005; Bambery et al. 2015; Shah et al. 2018).
In contrast, some have argued for maintenance of the status quo—i.e., that HCS
should be reviewed according to normal procedures for research with healthy
volunteers—since other kinds of research involving similar levels of risk are
adequately handled via ordinary ethics review committee oversight processes (and
even though HCS might be particularly complex and/or specialised, committees are
generally empowered to appoint experts to assist with review of highly specialised
research) (Hope and McMillan 2004) (see Box 4.3).
Box 4.3 Standard ethics review of HCS
[A]t the end of the day, the requirement[s] for a trial just like any other trial are the
same … I think the main thing is building the capacity of the ethics committees to
know what are the issues around challenge studies, what are the salient issues and
what are the emerging issues. [Scientist, Africa]
I think the important thing is that they’re reviewed by a committee with sufficient
capacity to perform the review, full stop. It doesn’t need to be a national committee.
But theremaybe some settingswhere they don’t really have that capacity. Theywould
need to be able to really understand this, and it actually relates to … a general issue
about this review, which is how the scientific aspects are reviewed. [Importantly,]
somebody needs to be able to look at the scientific basis for the risks and the benefits
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… [The committee] needs to have adequate capacity [to review] both the scientific
and the ethical … considerations … I would say that’s the same for all clinical
research. [Scientist, UK/Europe]
I would recommend against [specialised ethics review]. I think we would be creating
red tape. I think the … fundamental concept of an IRB applies to any research study
… I don’t think there’s anything special about a human challenge trial … any phase
I study almost by definition is not going to benefit the participants. [Scientist, North
America]
[Y]ou can imagine [that], in science, we’ll always have new things coming up …
The issue is how do we capacity build the ethics of your committees to address the
new changes that are coming in … proactively, not wait[ing] for things to happen,
for them to catch up with how they review … I think there’s a lot of experience in
ethical review, there’s a lot of capacity building that has been going on. [Scientist,
Africa]
4.2.1 Ethical Frameworks for Human Challenge Studies
One option for enhancing the review of HCS would be the development of specific
ethical principles/guidelines/frameworks for HCS (and/or, for example, for HCS
with particular pathogen) (Miller and Grady 2001; Selgelid 2013; WHO Expert
Committee on Biological Standardization 2016; Davies 2019). Some stakeholders
were in favour of such ethical frameworks, whereas others argued that specific
considerations related to particular pathogens were more important, and thus that
the scientific expertise of ethics committee members (e.g., regarding the pathogen
in question) would be more important to ensure the ethical conduct of HCS (see
Box 4.4). Among those who favoured the development of specific ethical
guidelines/frameworks for HCS, certain ethical issues were identified as potential
candidates for inclusion (and/or as issues not covered satisfactorily by existing
research ethics frameworks), including (i) limits to risk to participants, (ii)
third-party risk management, and (iii) risk-benefit assessments of HCS as
compared with alternative study designs (see Box 4.4).
Box 4.4 Ethical frameworks/guidelines for HCS
I think we do need more frameworks and guidelines for human challenge studies
because I think they do raise [particularly salient] questions… and, therefore, require
more careful thinking thanwe’ve done in the context of other types of trials. [Ethicist,
North America]
I wouldn’t make it a special framework specific to challenge studies. There are things
that arise in challenge studies that might also arise in other contexts that I think call
for a different framework. [For example,] bystander risks come up in challenge trials
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but also come up in other types of research like HIV cure studies. And [bystander
risks] are not something that IRBs or the US regulations cover. So you do need a
different framework to think about bystander risks. [Ethicist, North America]
[HCS are] a challenge for our [standard research ethics] benefit framework. Is it really
the case that, if the question is socially important enough (and [diseases] like malaria
and dengue and Zika, are pretty damn socially important), an adult can consent to,
in effect, an unlimited amount of [or at least] a very high degree of risk? I think that
can’t be right. So, I think there has to be a line there somewhere …What that line is
to me, is really the hard question of CHIM. [Ethicist, North America]
I think the principles are largely the same as with other types of studies but there
are these additional questions that we’ve actually been debating like [for example]
if there’s a perfectly good animal model or you’ve got a very high attack rate in
the field and you only need to recruit twenty people in the field, why would you
deliberately expose healthy people to the pathogen? So I think there are issues around
understanding challenge studies [and] the scientific process which leads into the
ethical questions is quite important. [Scientist, UK/Europe]
[Ethics committees reviewing HCS] generally [have] some expertise in the disease
that you’re working with and [disease-specific expertise] is, I think, more important
than having a general framework for all the different challenge models. So I would
rather put my protocol in front of amalaria specialist than a generalist in… challenge
models … There are different risks for Shigella, for Salmonella, [and] for malaria
– and to generalise those into one framework I think you run the risk of trivialising
some of those risks or [by trying to] make a level playing field for everyone you’ll
[make], say, Shigella [on parwith]malariawhen they’re really not on a par. [Scientist,
North America]
I think it would probably be useful to have special guidance for low resource
settings. I think there are just enough issues around how much infrastructure is
enough infrastructure, payment issues, community consultation issues, [etc.]. So I
think the idea of guidance that’s directed at low resource settings would be useful.
[Ethicist, North America]
As discussed earlier (see Chap. 3), the bioethical literature includes examples of
ethical frameworks, principles, and/or criteria for HCS (and/or specific issues
related to HCS) (Miller and Grady 2001; Bambery et al. 2015; Shah et al. 2018).
One framework for HCS review (drawing on such literature and prior experience of
ethics review more generally) has been proposed by Hugh Davies as part of the
online resource ‘Reviewing Research’ (Davies 2019). In addition to more general
research ethics considerations, Davies highlights the importance of (i) “public
consultation, involvement in design and public access to study details” (i.e.,
community engagement and transparency), given the sensitivity of HCS designs,
and (ii) assessment of “harms to possible contacts and the environment” given the
risk of transmission of challenge strains (Davies 2019). Given the growing number
of HCS in multiple countries, the growing ethics literature on HCS, and the
controversial and/or unresolved issues highlighted in this report, there may be a
role for ethical frameworks for HCS. Among other related developments, the WHO
Global Health Ethics Unit is in the process of developing guidance on ethical issues
related to HCS.
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4.2.2 Potential Models for Special Ethical Review
Regarding potential special review procedures for HCS, different models have been
proposed, including: (i) the appointment of a special committee (e.g., a national
committee) or sub-committee for review of all HCS (e.g., with additional infectious
disease expertise) (UK Academy of Medical Sciences 2005; Bambery et al. 2015),
(ii) special review for new challenge models in particular (e.g., with two independent
experts, perhaps followed by more usual review for future use of that model, once
it is shown to be safe and scientifically valuable) (Bambery et al. 2015; Shah et al.
2017), or (iii) usual reviewwith particularly strict requirements for a prior systematic
review, publicly available rationale, and well-defined compensation for harm (all of
which might be required for other kinds of studies, but could perhaps be more strictly
required in the case of HCS) (Bambery et al. 2015).
Ultimately, policymakers in any given jurisdiction will need to adopt a policy
regarding HCS review that is apt for the local context. Ethically, the important
outcomes (regardless of the policy chosen) might include that burdens, including
risks (to both participants and third parties), are appropriately minimised; that
public trust in research is maintained; and that scientifically valuable, acceptably
low-risk studies are not unduly impeded by excessively costly or slow review
procedures (Eyal et al. 2018).
As noted in other sections of this report, public controversies have the potential
to undermine support/acceptance of (other) research and/or public health
endeavours—domestically and/or internationally. Thus, in some cases,
international consultation and/or appeal to international agencies (e.g., WHO) may
be appropriate. Whether or not a particular jurisdiction decides on specialised or
standard review, international agreement on an ethical and regulatory framework
for HCS may help to improve review and ensure that relevant issues are
consistently addressed (WHO Expert Committee on Biological Standardization
2016). Stakeholders interviewed in this project held a range of different views, with
some in favour of standard review procedures (see Box 4.3 above) whereas others
favoured some form of specialised review (see Box 4.5). Finally, some raised
potential problems with specialised review (see Box 4.6).
Box 4.5 Advantages of specialised ethics review for HCS
IRBs work really well for fairly routine … garden variety research, but I think when
you’re at the vanguard, you want some sort of specialised mechanism and … I think
there are substantive reasons for that, that get to the quality of the expertise that
you get – and specialised review, the ability to pick through and second guess the
scientific rationale, is really key. [Jonathan Kimmelman, ethicist, Canada]
I think the most important thing is to be transparent. So whatever process you set up
– and perhaps having a central high-level review mechanisms for all such studies is
the way to go –… to make it clear that there is nothing being hidden from anybody is
4.2 Ethical Review 89
the important thing. To some extent, having a centrally mandated committee would
also be helpful because it would provide some distancing and protection from the
investigators and their institutions. [Gagandeep Kang, scientist, India]
[T]here may be some cases where having an extra layer of review that the researcher
either voluntary agrees to or that the sponsor puts in a place can help make sure that
everything is done as rigorously and carefully as possible and then … reassure the
existing levels of review that we already have. [Ethicist, North America]
Box 4.6 Potential problems with special review for HCS
[S]pecial challenge ethics committees … can give you clearance to do stuff which
nobody else can and [that] doesn’t sit right with me … [I]t should be … the general
ethics committee and … they should have training and they should understand the
issues and … of course, also I think investigators [should] make sure that the issues
are clearly articulated. [Scientist, Asia]
I suppose you could [have a specialised IRB for HCS] but they’re so rare in a given
place … and to set up something separate just for one study a year for challenge
[studies] is a bit over the top I feel. It’s an over-response to a problem that doesn’t
exist. [Scientist, North America]
I’m not sure that having a panel of experts will speed anything up! … [W]e had
difficulty enough just explaining the host country [i.e., LMIC] processes to [those
involved in] the US regulatory review process … I would think that kind of
requirement should probably come from the host country. If the host country wants
to have [an] additional advisory [body] or ask the WHO, or ask some other group
… it’s really up to them to decide what level of review they think is necessary. [Carl
Mason, scientist, USA]
4.3 Regulation
HCS are governed by standard regulations related to the scientific conduct of
research (including the need for ethical review procedures, etc.) and those related to
the development and use of investigational interventions (e.g., where vaccines or
drugs are tested during HCS). More specifically, HCS may be subject to particular
regulations related to the development and use of a challenge organism (and, in
some cases, additional regulations if the organism is genetically modified)
(Academy of Medical Sciences 2018). Since the general regulations governing
research and the use of investigational vaccines are not specific to HCS, this section
focuses particularly on (i) the regulation of challenge organisms, and (ii) the role of
HCS in regulatory development pathways towards the licensure of new vaccines
(and/or treatments).
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4.3.1 International Regulations
In 2016, the WHO Expert Committee on Biological Standardisation published a
short guidance document entitled ‘Human Challenge Trials for Vaccine
Development: Regulatory Considerations’ (WHO Expert Committee on Biological
Standardization 2016). The Working Group involved in the preparation of this
document included representatives from HIC regulators and research institutes as
well as similar bodies in Sub-Saharan Africa. The guidance document does not
contain binding requirements but is intended to provide general advice to regulators
and manufacturers of biological products in WHO Member States. Overall, it is
suggested that HCS should be conducted in a similar way to a (non-HCS) vaccine
study—i.e., following standard requirements for clinical research (e.g.,
International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use (ICH) Good Clinical Practice (CGP) procedures
and local regulatory Clinical Trial Authorisation (CTA) procedures for the conduct
of a study)—although the document notes potential variations in local regulations,
for example those governing genetically modified organisms.
Among other points, the guidance document notes that HCS have been
conducted in LMICs, and that, where this occurs, “the same standards apply as in
more developed countries” (WHO Expert Committee on Biological
Standardization 2016), including compliance with local regulations (with a
recommendation for the establishment of an appropriate framework for challenge
studies if none exists), and ethics review with a particular emphasis on risks to
participants and third parties. Further, the document recommended that ethical
considerations regarding HCS should be thoroughly evaluated. As of 2019, WHO
has initiated a process to review relevant considerations with the goal of developing
ethical guidance related to HCS.
4.3.2 Regulating Challenge Strains
Themajority ofHCShave been conducted inHICs, particularly in theUK/Europe and
USA. Challenge studies in LMICs have also frequently involved collaborators from
HICs and, with the exception of the Colombian vivax HCS program (see Chap. 5),
it has usually been the case that the challenge organism has undergone part or all
of its development in an HIC before being used in an LMIC HCS (although this
may change with future capacity building). Nevertheless, many challenge strains
originated in LMICs (particularly for pathogens primarily endemic to LMICs): for
example, although the NF54 malaria parasite used in the African challenge studies
was first obtained from a patient in the Netherlands, and subsequently developed
primarily in the USA, there is evidence that it originated in Africa (Eldering et al.
2016).
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In cases where a strain (wherever it originated) undergoes preparation in a HIC
before use in an LMIC HCS, the challenge organism will usually be subject to
regulatory oversight in both countries—as occurred for the African studies reviewed
below (which involved a strain prepared in the USA). Thus, we review US, UK,
and European regulatory requirements below before discussing the regulation of
challenge strains in LMICs.
4.3.2.1 US, UK and European Regulatory Requirements
The US Food and Drug Administration (FDA) requires that challenge organisms
comply with current Good Manufacturing Practices (cGMP) regulations, a set of
controls that aim to ensure the safe production, monitoring, and use of investigational
agents (including drugs, vaccines, and challenge organisms) for use in humans.1
The situation for genetically modified challenge strains (which, to date, have not
been used in LMIC HCS) is more complex, requiring review by the local USA
Institutional Biosafety Committee (IBC), and—in some cases—the Recombinant
DNA Advisory Committee (RAC). Of particular importance for LMIC HCS, the
FDA also has jurisdiction over challenge strains exported from the USA to other
countries (with the exception of a short list of countries with national regulatory
authorities (NRAs) recognised by the FDA2) (Academy of Medical Sciences 2018;
Baay et al. 2018).
The US FDA is relatively unique in its regulation of challenge strains—with the
norm in many other jurisdictions being more ad hoc and/or responsibility for the
quality of a challenge strain devolving to the (usually academic) institution where
the organism is prepared. As the 2016 WHO document on regulations governing
challenge studies noted, “in many countries, because the challenge stock … itself is
not considered to be a medicinal product, [challenge studies without the use of an
investigational drug or vaccine] would not come under the NRA’s review and
authorization. Thus, much less clarity exists on regulatory expectations and quality
matters in such cases” (WHO Expert Committee on Biological Standardization
2016).
For example, the UK Medicines and Healthcare products Regulatory Agency
(MHRA) does not currently require that challenge organisms are prepared
according to the kind of stringent regulations applied to vaccines and drugs, nor
does it require a CTA for a particular HCS unless it also employs an investigational
drug or vaccine (e.g., to be tested against an infection challenge). This largely
reflects the international “default” where there are no specific regulations for
challenge strains (perhaps because of the relative novelty of HCS and small number
of sites conducting such studies). Thus, in the UK and in many other countries,
1See https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm.
[Accessed 29 March 2019].
2EU/EEC, Australia, Canada, Japan, Israel, New Zealand, Switzerland, South Africa—see FDA 21
CFR 312.110.
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Table 4.1 Regulatory bodies and/or specific regulations relevant to challenge organisms
International
Regulatory agency Relevant regulation Comments
















Nil specific challenge strain
regulation
ACRE and DEFRA (if
genetically modified)
United States of America
US FDA
cGMP (for both challenge
strain and other
investigational products)










ECBS Expert Committee on Biological Standardisation, FDA Food and Drug Administration,
cGMP current Good Manufacturing Practices, IND Investigational New Drugs, IBC Institutional
Biosafety Committee, RAC Recombinant DNA Advisory Committee, ACRE UK Advisory
Committee on Releases to the Environment, DEFRA Department for Environment, Food, and
Rural Affairs
HCS are conducted largely within academic institutions and these institutions are
de facto responsible for the development and use of challenge strains (see Box 4.7).
For genetically modified organisms (GMOs), additional requirements apply,
similar to those in the USA. For example, the UK Advisory Committee on Releases
to the Environment (ACRE) and the Department for Environment, Food, and Rural
Affairs (DEFRA) have (sometimes-overlapping) responsibilities for GMOs
(whether or not scientists intend to release such a challenge strain beyond the
laboratory) (Academy of Medical Sciences 2018) (see Table 4.1).
Box 4.7 Regulating challenge strains
[In the UK, challenge strains such as] malaria parasites are not a regulatory
product. So we have ethical approval but no regulatory approval, and so the
stringent assessments of the quality of products and storage and all those other
things, we just don’t have anyone who controls that and so you don’t have that
added reassurance that you might do with the GMP. That’s one thing that could
come in that could really help control the field and give some reassurance about the
whole process. [Scientist, UK/Europe]
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When we’re talking about the challenge strains, the manufacturing quality, purity,
and reproducibility from batch to batch… all of these things are really important
considerations but they’re not, at least in the UK, currently subjected to the same
level of regulatory scrutiny [as, for example, vaccines]. So it’s a little bit of a grey
area, and it benefits us because it makes it easier to do the challenge studies but
also there’s potential risk there, I think, and maybe it is touching some ethical issues
as well because actually you know, we make all of our challenge strains to a GMP
standard; it’s very time consuming, very costly, but it has benefits: a fair amount
of stability, reproducibility from batch to batch, and also we can have a degree of
confidence that we’re happy with what is given to our volunteers. [The volunteers]
assume that what you’re challenging them with is going to be safe. [Malick Gibani,
scientist, UK]
I think from a regulatory point of view they do need special handling because there
are issues like understanding a non-GMP manufacturing process that is still safe
enough—because [not all challenge strains are] manufacturable to GMP. Probably
those [GMP] standards are excessive for something which is never going to be a final
product. You can have very tight systems around producing a challenge agent but
[that] are not as [extensive] as GMP, and defining what those are, I think, is difficult
to do in the abstract; you have to talk about individual agents... but I think, from a
regulation point of view, there has to be enormous expertise in looking at those agents
to make sure that they are as safe as possible and that protocols include information
to show the limitations of that. [Scientist, UK/Europe]
[W]e could reconsider how we’re requiring the production and the characterisation
of the challenge product because that sometimes … is limiting because … if there’s
only so many products that have been made in this GMPmanufacturing style, you’re
limited [with respect] to the study questions that you can ask and the relevance of
that. And… it’s limiting in a way because of that huge amount of scrutiny/oversight
of that product. At the same time, you want to make sure that you’re delivering a
product that’s safe. [Scientist, North America]
As an investigator I would say [that regulating challenge strains is] not necessary or I
would say it’s very cumbersome. But, on the other hand, it is also very important that
there is an independent review of the GMP aspects of the challenge strains because
… there is risk. Maybe it’s not so high, but there is quite a bit of risk. But I think it’s
a good [mechanism] at the European level, what they call [an] “auxiliary medicinal
product” [because] the set-up of preclinical investigations may be quite different
for something that you only use … for such a purpose in clinical [challenge] trials,
compared to something [like a vaccine] that you readily release [for use in] the health
system. [Benjamin Mordmüller, scientist, Germany]
The European Union, via the European Medicines Agency (EMA), does have
GMP requirements similar to those of the FDA—but these procedures typically
apply to facilities that produce agents for human use, rather than to individual
products. However, each product must have a Qualified Person who is uniquely
responsible for each and every release of a clinical trial lot of material for research.
These requirements potentially extend to challenge organisms—which are covered
by EMA regulations as Auxiliary Medicinal Products (AMPs); however, these
regulations do not include detailed requirements for infection challenge strains in
particular and, in any case, all EMA regulations must be implemented by each EU
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Member State and (as of early 2019) they have not yet been widely ratified (Baay
et al. 2018).
Some pathogens that cannot currently be maintained in a laboratory (e.g., vivax
malaria) may not be able to be prepared according to strict GMP requirements.
Several investigators interviewed for this project indicated that they nevertheless
routinely follow GMP requirements to the extent that this is possible within current
scientific limits. Overall, many stakeholders felt that clear and (ideally
internationally) consistent guidance from regulatory bodies would be useful to
researchers, although there were unresolved issues regarding the optimum
regulatory model for challenge strains and for HCS more generally (see Box 4.7
above). With recent increases in HCS in both HICs and LMICs, there will be
opportunities for regulatory agencies to develop appropriate national, regional, and
international norms specific to challenge strains and other aspects of HCS,
including their role in licensure of new interventions (discussed in Sect. 4.3.3).
4.3.2.2 Low- and Middle-Income Country Regulatory Requirements
Given the relatively small number of challenge studies performed in LMICs to
date, many LMICs may not yet have specific regulations related to HCS and/or
challenge strains—although, similar to countries like the UK, there are usually
local regulations governing investigational drugs and vaccines (which may be used
in some HCS). Nevertheless, challenge strains have sometimes been reviewed and
approved for use in research by relevant LMIC pharmaceutical regulators (see
Table 4.2), generally after approval by a HIC regulator (e.g., US FDA) for
international collaborative studies (Hodgson et al. 2014, 2015; Shekalaghe et al.
2014). Likewise, researchers in some countries are required to obtain clearance
from other agencies (generally Ministry of Health or similar) for certain types of
Table 4.2 LMIC regulators
Country Regulator Approval of challenge
strains
Other relevant agencies




Gabon Direction Médicament et
de la Pharmacie
Yes Ministry of Health
Kenya Pharmacy and Poisons
Board
Yes
Tanzania Tanzanian FDA Yes
Thailand Thai FDA N/A Ministry of Public Health
Note No specific regulations govern challenge strains in these jurisdictions; African regulators
listed above have approved challenge strains in conjunction with US FDA
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research (e.g., research with potential public health implications such as third-party
risks).
This pattern of prior approval of a challenge strain in a HIC prior to use in LMICs
may be due to a combination of multiple factors (see Box 4.8), including (i) lack
of laboratory capacity for the development of challenge strains in many LMICs, (ii)
lack of regulatory capacity for thorough review of challenge strains (meaning that
LMIC regulators may defer to HIC regulatory review) in part due to the low number
of HCS so far conducted in LMICs, and/or (iii) de facto or more formal requirements
from LMIC regulators and/or other institutions that HIC sponsors test investigational
agents (whether vaccines, drugs, or challenge strains) in HIC populations prior to
testing in LMICs (see Box 4.8).
Box 4.8 Regulatory norms and practices in LMICs
[S]ome regulators may not be comfortable taking a model into their country until it’s
been used in the US, and that can be for a number of reasons. [First, regulators might
not like] their people being experimented on as ‘guinea pigs’, and so they want data
from the US first. [Second,] some of it is just this idea … that if something goes
first to an endemic setting it’s ethically suspect and it’s something that wouldn’t have
been allowed in the US, and so it’s like an ethical double standard. [Third,] some of it
may be just the people want some preliminary data before they’re comfortable with
allowing a study to go forward. But whatever it is … I’ve noticed that sometimes
there is this resistance by regulators to having a study be conducted in their [LMIC]
setting if it hasn’t first been done in a [HIC] non-endemic setting. [Ethicist, North
America]
[O]n the GMP side of things, how this is produced and how [it] is ensured that no
contaminations are there, and release criteria, [and so on, are things] that we have
not discussed with the regulators in Gabon … [I]t is also because these assessors
there, they are not … trained like those at the FDA for example … but there are
now programs to improve this regulatory environment and capacities in Africa … I
know there’s one, for example, between these German regulators and these African
regulators, because they’ve seen that this is a problem and they have to rely really
on the judgment of others. [Benjamin Mordmüller, scientist, Germany]
[There is a] concern that developing countries don’t have the regulatory infrastructure
to really evaluate these studies and they don’t have the clinical trial [infrastructure]
or [other important] infrastructure to do these studies. So [LMIC regulators] want to
make sure that, before a challenge study goes to an endemic area, it’s been thoroughly
[tested] in the United States, because it gives regulatory authorities in the developing
countries confidence that they’re not the first to see this. I’m hoping that as we build
up the regulatory infrastructure in some of these developing countries, that they will
feel more confident in being first, but I don’t think they’re there yet and... I don’t
necessarily think challenge studies have to be done in developed countries first. [Anna
Durbin, scientist, USA]
Some of the regulators in Malawi [said] ‘What regulations do you have?’ and we
[said] ‘Oh in the UK we have this, and in the US they have that and in France they
have this’ and so, for setting it up, the regulatory considerations are really important
in an endemic setting but there’s nothing that you can copy and paste; there’s no
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gold standard that you can refer to, and that’s a potential problem, and you know,
will the government of Uganda decide to take a liberal view on challenge studies
whereas the government [of] Malawi decide to take a more conservative view on
that? [It would help to have] a bit more clarity and … consistency [internationally].
[Dr. Malick Gibani, scientist, UK]
Stakeholders interviewed in this project identified regulation of research (and
HCS in particular) in LMICs as an area that might benefit from capacity building.
Fortunately, there are a number of on-going LMIC regulatory capacity building
initiatives, particularly in Africa (Ndomondo-Sigonda et al. 2017), although these
are usually focused on regulation of vaccines and therapeutics, rather than challenge
strains. Likewise, there are opportunities for communication betweenHIC andLMIC
regulators, although these tend to be ad hoc rather than usual practice according to
formalised procedures (personal communication, expert stakeholder). This review
focused on the five LMICs in which HCS have been conducted and published since
1992; a wider review of the regulatory environment in other countries considering or
conducting HCS could help to inform future regulatory guidance and international
collaborations.
4.3.3 Challenge Studies and Licensure of New Interventions
A key unresolved question related to regulatory approval of new interventions (e.g.,
vaccines) is the role of HCS in the development pathway towards approval/licensure.
HCS can play a role at multiple steps in development pathways, for example in the
context of (i) basic science and very early phase research (e.g., exploring infectious
disease pathogenesis, immune correlates of protection, and developing models of
infection), (ii) phase IIB studies (i.e., providing preliminary estimates of efficacy to
enable the selection of candidate interventions for prioritised investigation in field
trials), and (iii) phase III studies (i.e., more definitive estimates of efficacy intended
to obviate the need for field trials) (Sauerwein et al. 2011; Chattopadhyay and Pratt
2017; Shah et al. 2017; Baay et al. 2018; Roestenberg et al. 2018a).
The degree to which phase 2B HCS can be used to predict (phase 3) field trial
efficacy (which is sometimes sufficient to support licensure of a vaccine) and,
similarly, the degree to which phase 3 HCS can support licensure decisions will
depend in part on whether the findings of the HCS are generalisable to the disease
epidemiology in the target population for the intervention (see Sect. 3.2.1.1). For
example, (i) results from HCS in US volunteers were used to support licensure of a
cholera vaccine for travellers (but not for those living in endemic settings because
the results were not considered generalisable to these populations—in whom
higher doses of the vaccine were required to generate a similar immune response
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(Sow et al. 2017))3 and (ii) results from HCS in UK volunteers were used to
support WHO prequalification (which endorses the product for licensure in WHO
member states) of the first typhoid vaccine (which is manufactured by an Indian
company) (Jin et al. 2017; World Health Organization 2018). The latter HCS used a
wild-type typhoid strain (making it more generalisable to natural infection than
attenuated strains) and HCS results with this strain were found to correlate with
immunogenicity in (non-HCS) field trials in children in endemic areas, thus
supporting using this vaccine in such settings/populations (Feasey and Levine
2017; Jin et al. 2017).
HCS designs have also been used to provide preliminary (Phase 2B) estimates of
vaccine efficacy for malaria vaccines that have subsequently entered clinical trials
(e.g., the PfSPZvaccine (Hoffman et al. 2002;Olotu et al. 2018)) and/or been licensed
for use (e.g., the RTS, S vaccine (Ballou 2009; RTS 2015)) and to ‘deselect’ vaccines
that showed no efficacy against malaria challenge (Spring et al. 2009; Roestenberg
et al. 2018b) including in a Gabonese HCS reviewed below (Dejon-Agobe et al.
2018). Safety and/or efficacy trials of at least twomalaria vaccines usingHCSdesigns
have taken place in Sub-Saharan African countries (Dejon-Agobe et al. 2018; Olotu
et al. 2018). The degree to which current falciparum malaria HCS designs can be
used to supplant field trials, however, remains controversial. This is in part because
few falciparum malaria strains are available for use in HCS, and some doubt that
efficacy measured against this limited number of strains would be generalisable to
diversemalaria infections “in thewild” (see Box 4.9 and also Box 3.3 in Sect. 3.2.1.1)
(Chattopadhyay and Pratt 2017).
Box 4.9 The role of HCS in licensure of new interventions
[A] couple of years ago [in 2016] we approved a cholera vaccine [for travellers to
endemic countries] where the efficacy data was based entirely on a human challenge
study. So that sort of creates a new paradigm or it establishes a precedent for a
new paradigm. [Although] this is not something FDA did in isolation. We had …
public advisory committee meetings to discuss this pathway toward approval … and
there was agreement from our [external] advisory committee [made up of infectious
disease experts with no declared conflicts of interest] that this would be a reasonable
way to proceed. [Regulatory representative, North America]
[T]he regulatory authorities as far as I can see … tend to be extremely wedded to
the way they’ve always done things, so I think somebody should, people should,
be making … the case for looking [at the role of HCS in licensure pathways] from
first principles and looking at what is the evidence that this is likely to predict future
benefit. [Scientist, UK/Europe]
[F]or malaria the problem is: Can you licence a product on the basis of a few human
challenges done with a few different strains and say that that provides coverage for
3For details of FDA licensure, see https://www.fda.gov/downloads/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/UCM509681.pdf. [Accessed 1 March 2019].
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the diversity of parasites out there in the world? That’s the biggest regulatory hurdle
… [North American Scientist]
I think a clearer, better lined regulatory pathway would be helpful. WHO does not
rule the regulators of… the EuropeanUnion, the U.K., Japan or the U.S. but certainly
does influence very heavily the regulators in low- and middle-income countries. It
would be nice to see more fromWHO [regarding] how such studies should be done.
[Gagandeep Kang, scientist, India]
4.3.4 Regulation of Over-Volunteering
Since HCS often attract high levels of payment, they may be one area of research
that could be particularly likely to be undermined, scientifically and ethically, by
over-volunteering. The underlying ethical concerns are that participation in too
many studies, too frequently, may (i) lead to excessive risk to volunteers and/or (ii)
distort research results (or interpretation thereof) when a participant is not
representative of the general/study population due to past interventions, possibly
including relevant vaccines and/or other challenge strains. Some interviewees
identified concerns related to over-volunteering, particularly in LMICs (see
Sect. 3.6.2); however, few empirical data are available to assess the extent and
effects of this phenomenon in particular countries.
In the UK, The Over-volunteering Prevention System (Allen et al. 2017),
governed by the MHRA, requires that participants enrolled in (predominantly
phase I) studies of healthy volunteers are registered to prevent overly-frequent
research participation. It is unclear whether HCS participants are always required
to be enrolled in this system. Similar systems exist in France, Germany, the
Netherlands, Belgium, and Switzerland, although to our knowledge these systems
are optional rather than required. In any case, it is widespread common practice to
exclude those known to have recently participated in other research involving
exposures that could interfere with the results of subsequent studies. In the absence
of a formal regulatory system, this relies on potential HCS participants to declare
such information—but they may be especially reluctant to do so in cases where
study participation is motivated by monetary payment. Thus, this may be an area in
which other national regulators and/or policymakers may be able develop systems
that reduce risks to participants and support safe, efficient, and transparent research
with healthy volunteers.
4.3.5 Laws Criminalising Intentional Infection
In the background of specific regulations governing research, some countries may
also have laws prohibiting the intentional infection of individualswith pathogens. For
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example, the UK only repealed a law of this kind in 2010 (Brazier and Gostin 2016).
Thus, researchers and regulators in each country must also be mindful of local laws
(beyond specific research regulations) that may be relevant to HCS, including those
that criminalise infecting others. Depending on how such laws are interpreted, they
may, in some cases, preclude conducting HCs in a particular country. There are on-
going debates regarding the ethics of criminalising infectious disease transmission
(Stanton and Quirk 2016) and relevant future work in this area could include a
review of international laws regarding infectious diseases, especially in countries
considering conducting (more) HCS.
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Chapter 5
Case Studies: Challenge Studies in Low-
and Middle-Income Countries
This review identified 13 case studies involving primary publications detailing HCS
in 5 LMICs published from 1992–2018:
(i) 4 enteric pathogen HCS in Thailand with cholera (Suntharasamai et al. 1992;
Pitisuttithum et al. 2002) and Shigella (Bodhidatta et al. 2012; Pitisuttithum
et al. 2016),
(ii) 5 falciparummalariaHCS in Sub-SaharanAfrica in Tanzania (Shekalaghe et al.
2014; Jongo et al. 2018), Kenya (Hodgson et al. 2014), and Gabon (Lell et al.
2017; Dejon-Agobe et al. 2018), and
(iii) 4 vivax malaria HCS in Colombia (Herrera et al. 2009; Herrera et al. 2011;
Arévalo-Herrera et al. 2014; Vallejo et al. 2016).
These endemic-region HCS together recruited approximately 400
participants—which, as mentioned earlier, amounts to less than 1% of the >40,000
human volunteers who have participated in HCS worldwide (i.e., >99% of HCS
participants have been in HICs) since World War II (Evers et al. 2015; Kalil et al.
2012). While other LMIC HCS may have taken place during this period of time
(e.g., unpublished studies and/or those not captured in the detailed case studies
below), the authors who estimated that 40,000 individuals have participated in HCS
overall suggested that this total would be an underestimate—meaning that LMIC
participants have in any case been grossly under-represented (Evers et al. 2015).
This suggests that endemic-region HCS has been a neglected area of research, even
though the vast majority of infectious disease morbidity and mortality occurs in
endemic LMICs. In addition to the above studies, HCS are currently being
considered and/or conducted in LMICs including Equatorial Guinea, Gabon, India,
Indonesia, Kenya, Malawi, Mali, Tanzania, Thailand, Uganda, and Vietnam
(Personal communications from study participants) (Baay et al. 2018).
Although these 13 published studies all took place within endemic countries that
have active transmission of the pathogen in question in at least part of the country,
they frequently took place in a city/location where there was no local transmission
(e.g., the studies in Kenya and Colombia were in non-endemic areas). We discuss
the ethical salience of decisions regarding the location of study sites below.
© The Author(s) 2021
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These 13 studies from 1992 to 2018 were increasingly pre-registered (in line
with general trends for clinical research (Ioannidis 2015)). Pre-registration is
arguably ethically important since it can help to (i) improve transparency (e.g., by
requiring analyses and methods to be specified in advance rather than altered once
the trial is in progress), (ii) reduce publication bias (e.g., by providing an incentive
for publication of all research findings, whether favourable or not), (iii) reduce
unnecessary duplication of research efforts (thus reducing the chance that
participants will be exposed to challenge infections unnecessarily) and (iv) increase
standardisation and/or comparability across similar research programs (if research
groups are able to co-ordinate) which may serve to increase the accuracy and
impact of results (Ioannidis 2015). As one interviewee argued:
[It’s important that] the results are disseminated very widely, whatever the results are, which
is a major issue that we have across all of research…you’re putting these individuals at more
risk than in some clinical research, it makes it get an even greater imperative to disseminate
the results, totally transparently. [Scientist, UK/Europe]
5.1 Cholera and Shigella Challenge Studies in Thailand
We identified 4 studies of diarrhoeal disease using HCS designs in Thailand, all
using models developed in previous (non-endemic) North American studies. These
comprised 2 HCS that aimed to replicate infection models of cholera (Vibrio
cholerae) developed in the US (Suntharasamai et al. 1992; Pitisuttithum et al.
2002); and 2 HCS using Shigella sonnei (a major cause of bacterial dysentery), first
to develop an infection model (Bodhidatta et al. 2012) and subsequently to test a
live attenuated vaccine using this model (Pitisuttithum et al. 2016) (See Table 5.1).
5.1.1 Rationale and Review Process
The cholera HCS conducted at Mahidol Univeristy, Bangkok, Thailand, published
by Suntharasamai et al. (1992) is, to our knowledge, the first endemic-region LMIC
HCS since 1956 (see history section above) (Suntharasamai et al. 1992) and was
followed by a similar HCS by the same group with a different cholera serotype in
2002 (Pitisuttithum et al. 2002). The stated rationale for the two cholera studies
was to replicate previous cholera HCS studies (in non-endemic populations)
because “ethnic factors, gut flora, and immunological background” could lead to
important differences in the response to cholera infection in the (endemic) Thai
population (Suntharasamai et al. 1992; Pitisuttithum et al. 2002). It was thus
intended to (i) investigate hypotheses regarding host-pathogen interactions in
semi-immune individuals (which would be infeasible in a non-endemic setting), (ii)
develop models of infection in an endemic population against which interventions
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Table 5.1 Cholera and Shigella HCS in Thailand
Pathogen Cholera (el Tor) Cholera (O139) Shigella sonnei Shigella sonnei
Year of publication 1992 2002 2012 2016
First author Suntharasamai Pitisuttithum Bodhidatta Pitisuttithum











N/S N/S N/S 2 months

































Clinical attack rate 90% 100% 75% 20% (controls)


















Yes Yes N/S Unclear; less
shedding of
vaccine strain















Long-term effects N/S N/S N/S N/S
Pathogen Cholera (el Tor) Cholera (O139) Shigella sonnei Shigella sonnei
Year of publication 1992 2001 2012 2016
First author
surname
Suntharasamai Pitisuttithum Bodhidatta Pitisuttithum













Nil USA, WHO USA USA
Prior HIC HCS Yes Yes Yes Yes
Pre-registration N/S N/S N/S Clinicaltrials.gov
(continued)
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Table 5.1 (continued)
Pathogen Cholera (el Tor) Cholera (O139) Shigella sonnei Shigella sonnei
Year of publication 1992 2001 2012 2016
First author
surname
Suntharasamai Pitisuttithum Bodhidatta Pitisuttithum
Country Thailand Thailand Thailand Thailand
Community
engagement
N/S N/S N/S N/S













n 26 35 36 20 (6 controls)







N /S not specified, IV Intravenous,WHO World Health Organisation, HLA-B27 a genetic marker
of the risk of post-infectious arthritis
‘International collaborators’ were derived from institutional affiliation of authors only
could be tested, and (iii) respond to local disease burden priorities. The models
developed were intended for use in future local cholera vaccine trials, although no
subsequent vaccine trials have cited these studies thus far.
The stated rationales for the Shigella studies were more detailed. In addition to
assessing different response to challenge in a Thai population, the authors noted (i)
the large global burden of Shigella (including among Thai children) related to acute
disease and its long-term complications (post-infectious bowel symptoms, arthritis),
(ii) increasing drug resistance of Shigella, and (iii) the lack of an animal model
(because humans are the only natural host of the pathogen). Themodelwas developed
in the 2012 ShigellaHCS and subsequently used in 2016 to test a vaccine. The studies
were reviewed and approved by the local institutional ethics committee, the Ministry
of Public Health (Thailand), and, in the case of the Shigella studies, the U.S. Army
Human Subjects Research Review Board. The vaccine used in the 2016 study was
produced according to US FDA cGMP and presumably approved for research use
by the Thai FDA. The challenge strains used were not governed by specific Thai
regulation. The 2016 trial was the first of the Thai studies to be pre-registered on
clinicaltrials.gov.
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5.1.2 Recruitment, Participant Selection, Consent,
and Payment
One of the four studies reported the background of participants: 43% students, 37%
labourers, and 20% unemployed (Pitisuttithum et al. 2002). Participants were
recruited from a population in which the diseases are endemic, although not all
participants had evidence of high levels of past exposure (for example, in the 2012
Shigella study 20% of those screened had antibodies to Shigella) (Bodhidatta et al.
2012). Exclusion criteria included (i) in all studies: general co-morbidities and
pregnancy (due to potential increased risks), (ii) in the Shigella studies: carrying
HLA-B27 (due to the associated risk of post-infectious arthritis) (iii) in the vaccine
trial: those with abnormal bowel habit (which might reduce the risk of
post-infectious irritable bowel syndrome and/or improve the clarity of vaccine
efficacy estimates). Cholera severity is known to vary with blood type, thus the
cholera studies recruited individuals with a variety of blood types in order to
increase generalisability of findings. Participants also underwent psychological
screening by investigators to select those who would tolerate inpatient isolation. All
Thai HCS involved a written test of comprehension as part of the informed consent
process. Payment is not recorded in the publications, but was apparently indexed to
local wages for unskilled labour and the period of isolation in the inpatient unit
(Personal communications from interview participants).
5.1.3 Burdens (Including Risks to Participants and Third
Parties)
If required, symptomatic participants (e.g., those with diarrhoea and/or dysentery)
received oral or intravenous rehydration. Among subjects who became symptomatic,
therewere few severe symptoms, although stool volumes in the cholera studies ranged
from around half a litre to up to 16 litres. On average, symptoms were milder than in
similar studies in non-endemic North American populations, suggesting that enteric
pathogen HCSmay at least sometimes be less burdensome in an endemic population.
Post-infectious complications, including irritable bowel syndrome, reactive
arthritis, and Guillain-Barre syndrome, have been observed after Shigella infection
(Thabane et al. 2007; Hannu 2011; Ajene et al. 2013) but they are rare and have not
been reported to occur among HCS participants. The probability of such
complications can be difficult to predict in the absence of known risk factors.
Reactive arthritis has the known risk factor of HLA-B27 (a genetic marker) (Hannu
2011); thus those with this marker were excluded to avoid excessive
risks—although even those who do not carry HLA-B27 have a small risk of
post-infectious arthritis and other complications. Scientists interviewed for this
study were not aware of any long-term complications related to study participation.
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The studies were conducted in fully inpatient settings with strict biosafety
procedures, decontamination of effluent, and treatment of participants (with proof
of cure) to reduce third-party risks. In the Shigella trial, among those vaccinated
56% were found to shed the vaccine strain in stool, which could potentially spread
to others, although no cases of transmission were reported in a previous Israeli
study of this vaccine (Orr et al. 2005).1
5.1.4 Summary and Outcomes
The Thai Cholera HCS were noteworthy in the sense that they demonstrated that
such studies could be successfully and safely conducted in an endemic LMIC. The
model was able to demonstrate differences in symptomatic disease in an endemic
population, but it has not yet been used to test novel interventions for cholera. The
Shigella model was relatively quickly advanced to a vaccine trial, however the
latter was not able to provide accurate estimates of vaccine efficacy because the
attack rate among controls (given placebo) was 20% (i.e., a failure to replicate the
attack rate of 75% in the HCS in which the model was developed (Bodhidatta et al.
2012))—since so few of those who were not vaccinated developed disease, the
estimate of vaccine efficacy (i.e., equal to any further reduction in risk of disease
post-challenge in vaccines) was not statistically significant. We have been informed
that Thai researchers are considering undertaking more HCS in the future (Personal
communications from study participants).
5.2 Falciparum Malaria Challenge Studies in Africa
We identified 5 Sub-Saharan African HCS involving falciparum malaria in
Tanzania, Kenya, and Gabon (Hodgson et al. 2014; Shekalaghe et al. 2014; Lell
et al. 2017; Dejon-Agobe et al. 2018; Jongo et al. 2018). These studies are part of
an international research program using cryopreserved P. falciparum (Pf)
sporozoites from a laboratory strain (NF54) known to be sensitive to chloroquine
and produced in increasingly controlled laboratory settings since the 1980s (Chulay
et al. 1986). The research program began at the US Walter Reed Army Institute of
Research (WRAIR) and is now led by a US private company, Sanaria Inc., in
collaboration with several research centres worldwide. This laboratory strain has
been tested in multiple studies (in both HICs and LMICs) where it has been used as
(i) a human challenge agent (non-attenuated) and (ii) a vaccine candidate (radiation
attenuated), administered either by injection (intradermal, intramuscular, or
1Oral live attenuated vaccines, such as the oral polio vaccine, can immunise others in the community
when spread via the stool of those vaccinated.
5.2 Falciparum Malaria Challenge Studies in Africa 109
intravenous) or by mosquito bite (Lyke et al. 2010; Hodgson et al. 2014;
Shekalaghe et al. 2014; Gómez-Pérez et al. 2015; Olotu et al. 2018).
The US FDA-approved NF54 challenge strain is produced according to cGMP
regulations designed to ensure purity (only the sporozoite form of malaria
parasites, only one strain) and asepsis (not containing bacterial or other pathogens).
After multiple models and trials in non-endemic-regions, this research group, with
international collaborators, has more recently been conducting endemic-region
falciparum malaria HCS, resulting in the sub-Saharan African publications
reviewed below (See also Table 5.2). One advantage of this model is that it does not
require mosquitoes to administer the infection challenge (which is instead injected
by needle) thus obviating the need for high biosafety level insectaries (which are
rare in LMICs and involve significant costs) and/or the need to import mosquitoes
(which might involve risks to the local population, as discussed in Sect. 3.4)
(Billingsley et al. 2014); whether malaria HCS by needle is generalisable to
wild-type infection by mosquito bite is unknown, but the model uses sporozoites
(i.e., the same form of malaria parasite involved in transmission from mosquitoes to
humans) in order to investigate the early stages of malaria infection (and, for
example, whether these can be prevented or reduced by novel interventions).
5.2.1 Rationale and Review Process
This program of sub-Saharan African HCS research, conducted in conjunction with
HIC collaborators, was designed to (i) test hypotheses regarding host-pathogen
interactions in malaria-endemic and/or semi-immune populations (that would have
been infeasible in HIC HCS) as well as those with genetic traits thought to affect
malaria infection (e.g. sickle cell and α-thalassaemia), (ii) develop models of
infection in an endemic population against which to test interventions (thus aiming
to improve the generalisability of malaria HCS to African populations), (iii) test
malaria interventions (e.g. vaccines) against these models, (iv) respond to local
disease burden priorities, and (v) further develop local capacity for infectious
disease research (at well-established African institutions in all three countries with
significant pre-existing research expertise). Four of the five studies were focused on
investigating host-pathogen interactions and/or developing Africa-specific infection
models as translations of models that had previously been conducted in
non-endemic HICs. The fifth study used the locally-tested model to trial a malaria
vaccine candidate (GMZ2) against challenge (Dejon-Agobe et al. 2018).
All five studies were pre-registered (with US clinicaltrials.gov and/or the
Pan-African Clinical Trials registry). Ethics committees at the African institutions
and collaborating HIC institutions reviewed the studies, which were also reviewed
by national committees in the African countries. The challenge strain had prior
regulatory approval by the US FDA, and was reviewed by Kenyan, Tanzanian, and
Gabonese regulators. The studies took place at three research institutes with
longstanding African-HIC collaborative international research programs.
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The Kenyan group published ethics committee and regulatory approval times
(local Kenyan committee: 6 months; collaborating UK university committee:
2 months; Kenyan Pharmacy and Poisons Board: 3 weeks) (Hodgson et al. 2015).
Since the timeliness (as well as thoroughness) of ethical review can itself be
ethically important (e.g., because undue delays of beneficial research arguably
delay benefits of new interventions for the eventual target population), more
standardised reporting of review times across multiple studies might be called for.
5.2.2 Recruitment, Participant Selection, Consent,
and Payment
The Kenyan study was conducted in Nairobi, a non-endemic part of the country
and the investigators found it difficult to recruit as many semi- and/or
highly-immune individuals as they had planned, largely because of a lack of
exposure to prior infection in the local population in Nairobi (the research group
have since begun conducting HCS in and/or recruiting from more endemic parts of
Kenya (Kapulu et al. 2018)). In contrast, the Tanzanian and Gabonese studies took
place in endemic areas and were able to recruit semi-immune individuals (and/or
those with innate resistance to malaria) more easily. All studies aimed to recruit
healthy, non-pregnant, African adults who would share at least some characteristics
(e.g., similarities in genetic factors, microbiome, etc.) with high priority target
populations for falciparum malaria interventions (e.g., African children). In
addition, the studies (to varying degrees) aimed to recruit individuals with acquired
immunity (from past malaria infection) in order to study relationships between
immunity and response to challenge; the study in Gabon by Lell et al. also recruited
a small group of local expatriate Europeans in order to make direct comparisons
between European and Gabonese HCS outcomes (Lell et al. 2017).
In order to reduce risks to participants, all five studies excluded those who were
pregnant or intending to become pregnant and those with various medically
significant comorbidities and/or particular co-infections (e.g., HIV, viral hepatitis).
In terms of comorbidities, exclusion criteria included having certain risk factors for
cardiac events (based on previous data of cardiac events during malaria HCS
(Nieman et al. 2009; van Meer et al. 2014), see Sect. 3.3.5) and psychiatric risk
factors (see Sect. 3.3.6.1) (Dejon-Agobe et al. 2018). Investigators in this program
had initially planned to exclude individuals with α-thalassaemia trait (because this
trait may provide some innate resistance to malaria infection leading to concerns
that this could affect HCS results); but they ultimately included these individuals
when the high frequency of the trait in the local population became apparent
because of the need to avoid (potentially unfair) exclusion of such individuals in
future vaccine trials.
Consent in all cases involved a test of understanding. Some studies aimed to
recruit relatively well-educated individuals, with a particular focus in the Kenyan
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study on recruiting medical students, because it was expected that such individuals
would be more able to understand the study and thus provide adequately informed
consent (Hodgson et al. 2014; Shekalaghe et al. 2014; Hodgson et al. 2015).
Although the Kenyan study only conducted information sessions for prospective
participants with medical students (from whom the majority of the study
population was expected to be recruited), the final study population was mixed
(54% students, 17% unemployed, 29% other); the authors concluded that “there
was no clear advantage to exclusively targeting medical students and future studies
would appeal to students of all disciplines.” (Hodgson et al. 2015). Given that
non-students and unemployed individuals were also able to pass a test of
understanding as part of the consent process, these findings might also support the
recruitment of (a larger proportion of) the general adult population in future
studies. In Tanzania, all participants were drawn from higher learning institutions,
and 100% were male (reflecting lower local rates of higher education among
females in general (Kilango et al. 2017)).
The Kenyan group published payment amounts in an article highlighting
“lessons learnt” from their first HCS. Participants were paid around $50 USD per
overnight stay, as well as smaller amounts for clinic visits and travel costs,
amounting to total payments of around $250-$500 USD (Hodgson et al. 2015;
Nordling 2018). Payment levels were carefully considered by both local and UK
ethics committees, which judged that decided amounts would “neither unduly
coerce potential participants nor set a difficult precedent for other research
conducted within the programme” (Hodgson et al. 2015; Njue et al. 2018).
Payment did, however, lead to short-lived controversy in the local media (Gathura
2018; Kenya Medical Research Institute (KEMRI) 2018). In response to media
coverage, the local research institution issued a Statement that included details of
the study (including the study rationale, the reasons for inpatient monitoring, the
minimisation of risks to participants, and the prior approval by relevant ethical
review bodies) and information regarding determinations of the level of payment.
The Statement notes that “[T]he participants were compensated for the time they
spent at the in-patient facility. The amount compensated was arrived at by
considering what they would earn on a daily basis were they engaged in their daily
earning activities.” (Kenya Medical Research Institute (KEMRI) 2018).
As a comparison, the HCS in Gabon paid participants similar amounts indexed
to local wages (personal communication, expert stakeholder), although the
Gabonese study was an outpatient design and payment figures have not been
published; in any case payment has not led to controversy in that setting. One
Kenyan researcher interviewed for this project indicated that, despite the media
controversy, local researchers felt that the level of payment was
appropriate—although the group did consider a series of smaller payments rather
than one large payment at the end of the study:
[Payment has] been controversial, I think, because of the amount that ended up being given.
And it’s not so much the daily amount than the lump sum amount – and because it ended up
being quite a substantial figure, if you add it up. But if this was being given on a daily basis
probably during the study [it wouldn’t have seemed] that high …What changed? Might we
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have reconsidered given the [controversy in the media]? I think we still feel that rate was
fair, in our context. And I don’t think there were any plans to lower it, because it wouldn’t
make sense if you consider the fact that [it was based on national] minimum wage … for
casual labour… probably what might ever been considered is…whether to give it as a lump
sum or give it periodically instead of building up into a nice packet at the end of the day. I
can see participants will want a lump sum, because then they can do something practical.
But, we fear that [this large amount] was again being seen … people focus on the lump sum
amount more than what the participants need. [Scientist involved in the Kenyan HCS]
5.2.3 Burdens (Including Risks to Participants and Third
Parties)
The rate of severe malaria symptoms was generally lower in African individuals
(with the exception of the Kenyan study, discussed below), especially those with
innate or acquired immunity, than in previous HIC falciparum malaria HCS. In this
sense these endemic LMIC malaria HCS presented relatively lower risks to
participants than HIC HCS. Arguably, the use of more sensitive diagnostic methods
(e.g., PCR) could have reduced risks in terms of symptoms still further, and
perhaps helped to support the case for outpatient studies. For example, in some
previous HIC malaria HCS, if a participant had symptoms without malaria
parasites on blood microscopy, investigators had access to quantitative polymerase
chain reaction (qPCR) testing for malaria (a more sensitive test than microscopy)
and initiated treatment if this was positive (Sheehy et al. 2013). Timely qPCR was
not locally available in these African studies (although samples were tested using
such methods at a later date for research purposes). In any case, treatment was
effective and no participant experienced treatment failure or recurrent
(study-related) malaria during the follow-up period.
A large proportion (61%) of Kenyan participants ultimately developed at least
one severe symptom of malaria—a rate similar to European participants, perhaps
in part due to the non-endemic setting in Nairobi—but none required hospital care.
In contrast, the rate of severe symptoms was much lower among Tanzanian and
Gabonese participants (see Table 5.2), potentially because they were drawn from
more endemic populations (and thus had greater immunity).
The Gabonese studies took place in an endemic area and predominantly involved
outpatient design. Likewise, the Tanzanian studies took place in an endemic area and
used a mixed out- and inpatient design. The Kenyan study conducted in Nairobi (a
non-endemic area) employed impatient design partly because traffic-related delays
could prevent timely access to medical care and partly because investigators were
being especially cautious as this was the first HCS performed in Kenya. One member
of the research team described decisions related to the design of the study as follows:
I would have been happy to do the Kenyan study as an outpatient setting [but] the traffic
was a massive issue … [And especially because this] was a pilot study, [the] first one in the
country. [People] said, ‘There will be a lot of anxiety about this’ … [T]he idea was that we
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would need to [have close inpatient monitoring] to provide reassurance [to]the ethical bodies
… but, you know, it was terrifying, actually, when you’re travelling to and from the setting,
because the traffic was such that if there was an ambulance coming through, the traffic was
so gridlocked, you couldn’t actually physically get an ambulance along any of the roads.
[Scientist involved in the Kenyan HCS]
In terms of risk to third parties, universal treatment upon diagnosis and/or at the
end of the study period and the short duration of challenge infection reduced risks
significantly. Duration of malaria infection affects third-party risk because
gametocytes, the transmissible form of malaria, take 7–15 days to develop (Roberts
et al. 2013)—meaning that risks to third parties increase with time since infection.
The Kenyan study posed the lowest risk of transmission (effectively zero risk), both
because it was an inpatient study and because of a lack of mosquito vectors in
Nairobi. In the 2014 Tanzania study, participants were kept as inpatients for
21 days and any who had not been diagnosed with malaria by this time were
discharged and continued to participate as outpatients until day 28, at which time
they were treated regardless of whether they met the diagnostic threshold. There
was a (perhaps very) low probability of transmission of malaria in such
circumstances (Karl et al. 2011; Roberts et al. 2013) (and this could, in future, be
quantified by qPCR measurement of gametocyte levels during study participation).
The Gabon study was conducted on a largely outpatient basis and likewise may
have involved a low probability of transmission from study participants to the
wider community, in the context of a high local background malaria transmission.
5.2.4 Summary and Outcomes
Among these studies were two significant milestones for LMIC HCS research: the
first HCS in Africa since the 1950s (Allison 1954; Bearcroft 1956; Shekalaghe
et al. 2014), and the first HCS involving vaccine efficacy testing in Africa
(Dejon-Agobe et al. 2018). In terms of scientific outcomes, the research program
has clarified the protective effects of acquired immunity (which led to a delay to
onset of parasitaemia), sickle cell trait (which was shown to be associated with
lower levels of symptomatic malaria), and α-thalassemia (which was less protective
than anticipated), which might support the recruitment of such groups to future
vaccine efficacy trials.
Authors of the Kenyan study noted that one participant had (qPCR positive,
microscopy negative) asymptomatic parasitaemia (which was successfully treated)
at the end of the study, and that future (endemic region) studies of longer duration
could investigate the transmissibility of such asymptomatic infections in partially
immune individuals (see also Vallejo et al. 2016). However, they also note that this
would entail ethical trade-offs involving difficult choices between (i) long periods
of inpatient isolation for participants or (ii) potential risks of transmission to third
parties where an outpatient model is used and there are local mosquito vectors.
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The Kenyan group published an extensive account of “lessons learnt” during
and after this HCS. Such lessons included (i) the importance of prospective multi-
stakeholder engagement and listening to the concerns of the local community, (ii) the
need for extensive information sessions for participants to ensure that they were able
to understand the study, (iii) the need to include local sub-populations (e.g. thosewith
haemoglobinopathies) so that they would not be unfairly excluded from the benefits
of HCS research, (iv) the need for longer duration studies of naturally-acquired
immunity (since semi-immune participants took longer to develop an infection after
challenge) and models of transmissibility, and (v) the importance of support from
other centres with prior experience conducting malaria HCS in helping to ensure
the safety and efficiency of the Kenyan study (Hodgson et al. 2015), Researchers at
the same institution have also subsequently published social science work related to
malaria HCS (Njue et al. 2018). The publication of such insights from experience
with HCS, as well as the integration of biological and social science work related to
HCS, could be considered a model of best practice in terms of engagement and the
sharing of ethically relevant practical details that might inform future HCS designs.
5.3 Vivax Malaria Challenge Studies in Colombia
The 4 published vivax malaria HCS in Colombia, beginning in 2009 (the earliest
malaria HCS in an endemic country that we identified apart from the historical
cases discussed above—See Sect. 2.5) were conducted by a well-established
research group in Cali (a non-endemic city with endemic areas of transmission
relatively nearby–within a few hours’ drive). The local institution has been involved
in malaria research for many decades, including, for example, maintaining a
longstanding malaria vector mosquito insectary, which provided the mosquitoes for
these studies. The HCS formed part of a local research program, one of the goals of
which is the development of vivax malaria interventions, especially vaccines.
Since there is no available laboratory strain of vivax malaria, the endemic country
setting of the institution enabled researchers to obtain wild-type malaria parasites
from consenting patient donors infected in nearby endemic parts of the country
(immediately prior to these patients receiving treatment), transport these parasites
to Cali, infect insectary-reared mosquitoes (after careful screening for other blood-
borne infections), and challenge HCS participants.
5.3.1 Rationale and Review Process
This research program, led by local researchers (in some cases in collaboration
with international scientists), was designed to (i) investigate hypotheses regarding
host-pathogen interactions, including in semi-immune individuals (i.e. study designs
that are only feasible in a study centre in/near an endemic setting), (ii) develop a
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model of infection against which to test interventions, (iii) test novel interventions
(e.g. a vivax malaria vaccine), (iv) respond to local disease burden and maximise
generalisability by using local wild-type parasites, and (v) ensure minimisation of
third-party risks by conducting HCS in a non-endemic area of Colombia with no
local vector mosquitoes (only laboratorymosquitoes were used under strict biosafety
precautions). The research program began by testing a new vivax HCS model in
malaria naïve individuals in 2009 (Herrera et al. 2009). This model was later refined
in 2011 (Herrera et al. 2011), tested in semi-immune individuals in 2014 (Arévalo-
Herrera et al. 2014), and ultimately used to test a vaccine in 2016 (Arévalo-Herrera
et al. 2016). From 2014, the studies were pre-registered on clinicaltrials.gov.
The studies were reviewed and approved by local institutional ethics committees
and,where therewas significantUS collaboration, byUS committees at collaborating
institutions. The first study was also reviewed byWHO. Challenge organisms are not
governed by specific Colombian regulations; interviewed scientists with knowledge
of the studies described significant efforts thatweremade to ensure that the laboratory
environment (including insectary-mosquitoes) and the challenge material were as
close to FDA-style GMP as possible (including extensive screening of donor blood),
noting that full compliance with stringent GMP requirements (such as those used
for the NF54 lab strain in the African studies above) would not be possible in the
absence of a laboratory strain of vivax.
One regulatory issue that affected the group was applying for insurance (e.g.,
for research-related harm to participants). Local Colombian insurers (backed by
international, usually North American, reinsurers) were initially reluctant to cover
the research, which created a delay of approximately two years, as described by a
member of the research team:
[Insurers didn’t] want to provide the insurance … they are thinking that maybe … we are
not designing the [study] protocol [well], or that the volunteers are at high risk of [problems
related to] safety. So, to convince them, it was very difficult for us … For the first clinical
trial, the phase one … it took us like two years [to get] that insurance … [Since we got it,
and they know us] we [have been able to] renew our insurance without problems. [Myriam
Arévalo-Herrera, scientist, Colombia]
The researchers have never had to make a claim against this insurance (since no
lasting harms have occurred among volunteers), however this experience highlighted
an additional practical issue that may sometimes be more difficult in LMICs than
HICs (Table 5.3).
5.3.2 Recruitment, Participant Selection, Consent,
and Payment
The studies recruited healthy adults from the general population with a focus on
malaria-naïve and/or semi-immune volunteers depending on the research question.
The authors note the ethically relevant point that, because new interventions for
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Table 5.3 Vivax malaria challenge studies in Colombia
Pathogen Malaria (vivax) Malaria (vivax) Malaria (vivax) Malaria (vivax)
Year of
publication
2009 2011 2014 2016
First author
surname
Herrera Herrera Arévalo-Herrera Arévalo-Herrera







Cali (no vectors) Cali (no vectors)
Pre-registration N/S N/S Clinicaltrials.gov Clinicaltrials.gov








Brazil, USA Brazil USA
Prior HIC HCS No No No No
Community
engagement







Local review Local review
Challenge strain
regulation








n 18 22 (5 controls) 16 28
% female 50% 52.9% 37.5% 64%




Pathogen Malaria (vivax) Malaria (vivax) Malaria (vivax) Malaria (vivax)
Year of
publication
2009 2011 2014 2016
First author
surname
Herrera Herrera Arévalo-Herrera Arévalo-Herrera

















18 months 1 year 3 months 2 months
(continued)
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Table 5.3 (continued)
Pathogen Malaria (vivax) Malaria (vivax) Malaria (vivax) Malaria (vivax)
Year of
publication
2009 2011 2014 2016
First author
surname
Herrera Herrera Arévalo-Herrera Arévalo-Herrera





























































N/A N/S Yes N/A







N/S N/S N/S N/S
N /S Not Specified, ICH International Conference on Harmonisation, FDA US Food and Drug
Administration
‘International collaborators’ were derived from institutional affiliation of authors only
malaria (e.g., vaccines) will potentially be used in semi-immune individuals, such
individuals should arguably be included in at least some HCS research (an argument
also made in support of the recruitment practices of African malaria HCS discussed
above). Exclusion criteria were predominantly designed to reduce risks (e.g., G6PD
deficiency—a risk factor for adverse effects with primaquine treatment of vivax, HIV
and other major co-infections, and pregnancy).
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The consent process allowed time for consideration across multiple sessions,
and prospective participants were encouraged to discuss their participation with
family members. A written test of understanding was used from 2011 onwards. The
authors emphasise that participants could withdraw from the studies at any time.
This did sometimes occur before challenge, but there were no withdrawals after
challenge. Basic literacy was required, because individuals who could not read the
study material and consent form were excluded. However, unlike some other
challenge studies (see African HCS above) where medical students were
considered ideal candidates, the research group tended to avoid preferential
recruitment from the healthcare sector after an unfortunate episode in an earlier
study where a participant, who was elsewhere employed as a paramedic, was
suspected to have self-treated with anti-malarial medication after challenge
(Herrera et al. 2009).
Participants in the Colombian HCS were reimbursed for their costs related to
participation but, as per Colombian norms, did not receive any further payment.
Though they did not financially incentivise participation, the research group reports
no difficulty recruiting volunteers. One member of the research team attributed
recruitment success to local experiences of clinical malaria and altruism among the
local population:
[T]he difference between here, and [the USA] is that [participants in the USA are] doing that
for money and here they are doing it because they are convinced, they are altruists. They have
seen people suffering from malaria and they want to contribute to solve the problem. It’s a
significant difference between a volunteer in the States and a volunteer in Colombia. They
know we cannot provide any payment, but do it because they are convinced, not because
they need money. [Sócrates Herrera, scientist, Colombia]
5.3.3 Burdens (Including Risks to Participants and Third
Parties)
Since the Colombian HCS used wild-type vivax parasites from infected human
donors, the authors document an extensive review of possible risks to participants
(and/or uncertainties) related to the challenge infection. In consultation with
independent experts, they reached a consensus that there are no known cases of
non-malaria pathogens being transmitted by Anopheles mosquitoes, but the consent
process included a discussion of uncertainty related to “exposure to potential
unknown pathogens” (Herrera et al. 2009). Blood/parasite donors were tested for
known pathogens (as per usual blood bank screening) and excluded if any were
detected. Mosquitoes that had fed on blood with co-infections (e.g., falciparum
malaria with vivax, or viral hepatitis) were discarded. It is likely that multiple vivax
strains were transmitted by challenge; although, to our knowledge, this was not
tested. One advantage of not testing/screening for this is better generalisability to
wild-type infection. The presence/transmission of multiple strains, furthermore,
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does not necessarily increase the risk of symptoms in participants challenged—and
local rates of antimalarial resistance are low (in particular, there is no known
resistance to cure of the dormant form of vivax). Physical severe adverse effects
were rare, but one patient was admitted to hospital overnight (which meets criteria
for a severe adverse effect) with an anxiety crisis (see Sect. 3.3.6.1).
With respect to third-party risk, the local city (Cali) is at relatively high altitude
and has no local vector mosquitoes, which minimises the risk of transmission. The
mosquitoes used for challenge were laboratory-reared, and any escaping the
insectary would face a climate inimical to their survival. The study was conducted
on an outpatient basis, and the authors requested that participants avoid travel to
areas with vectors while infected, in order to minimise transmission to others.
Parasitaemia cleared rapidly with treatment, suggesting that post-treatment
transmission risks would have been minimal (if participants later had contact with
vectors). Follow-up after the studies was of long duration (up to 18 months
reported). Three months after the 2014 study, one participant developed vivax
malaria and was treated appropriately. Rather than reactivation of the challenge
infection, this was presumed to be a new case of malaria resulting from recent
travel to an endemic area—but further testing (e.g., genotyping) to confirm this was
not undertaken (Arévalo-Herrera et al. 2014). Local researchers interviewed for this
project indicated that there has never been a case of vivax relapse judged to be
caused by challenge infection in Colombia.
5.3.4 Summary and Outcomes
The Colombian vivax studies represent a particularly longstanding locally-initiated
LMICHCS program (with support from international collaborators) that, in response
to local disease burden, has successfully moved from model development to vaccine
testing. The radiation-attenuated vaccine tested by HCS in 2016 showed protective
efficacy of 42%, although it required a long and relatively burdensome schedule of
immunisation by mosquito bite. At the end of 2018, no field trial had yet cited the
2016 HCS by this group, so it is not yet possible to compare field trial efficacy with
that observed in HCS.
Particularly from 2014 onwards, the group has performed a number of secondary
analyses on samples collected during HCS, thus maximising the scientific yield per
challenge. For example, the researchers used samples from their 2014 study in a
later analysis that aimed to quantify any differences of the risk of transmission (by
measuring gametocytes, the form ofmalaria transmitted from humans tomosquitoes)
from individuals infected by challenge as opposed to those diagnosed with naturally-
acquired infection in the community (Vallejo et al. 2016), which has implications
for potential third-party risks of their study design. In contrast to some older data
derived from malariotherapy, the study failed to transmit malaria to mosquitoes by
feeding them on subjects recently infected by challenge; however, participants from
the naturally infected groups were able to transmit malaria to mosquitoes. Since the
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authors failed to show infectivity of mosquitoes fed onHCS participants, there would
have been a very low risk (if any) of onward transmission of the challenge infections
during the study period, even if the participants were to leave the study location and
travel to an endemic area while infected. Such data may facilitate third-party risk
estimates of future vivax malaria HCS involving the infection model developed by
this research team.
5.4 Summary of Case Studies
5.4.1 Rationale and Review Process
We identified 13 publishedHCSconducted inLMICs from1992 to 2108. The number
and frequency of LMICHCS is increasing: 11 of the 13 studies were conducted in the
last ten years, andmore LMICHCS are currently being considered and/or conducted.
Yet these are still vastly outnumbered by HIC HCS, suggesting that LMIC HCS has
been a neglected area of research, especially relative to local disease burden. Each of
the 13 studies involved a pathogen endemic to the LMIC in which it was conducted,
although in 5 publications the HCS was conducted in a non-endemic area within
the country. Common reasons for conducting these LMIC HCS were (i) to improve
understanding of host-pathogen interactions in an endemic population, (ii) to develop
models of infection (for later HCS vaccine trials), (iii) to test vaccines (in 3 studies),
and/or (iv) to improve local capacity for infectious disease research.
All of the studies took place within well-established research institutions that
had existing collaborative arrangements with HIC institutions with HCS research
experience. With the exception of the Colombia vivax program, most LMIC HCS
programs to date (9 of 13 studies) have begun by replicating prior HIC HCS in the
local LMIC population. Although the LMIC institutions had experience conducting
other types of research, significant capacity building was required in order to conduct
HCS, including the capacity of local ethics committees to review such research.
Like most HICs, the LMICs in which HCS have been conducted do not have
specific regulations governing challenge strains. Regulatory bodies in Sub-Saharan
Africa did review the malaria challenge strain used, aided by previous FDA review
and approval. In Thailand and Colombia, the local institutions (and, for the Thai
studies, the collaborating US institution(s)) were responsible for the quality and
safety of the challenge strains used.
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5.4.2 Recruitment, Participant Selection, Consent,
and Payment
All LMICHCS recruited healthy adult volunteers from the local population (and, for
one study in Gabon, a sub-population of European expatriates for comparison (Lell
et al. 2017)). Depending on the research question, some studies preferentially aimed
to include those with acquired immunity from past infection and/or innate resistance
to the disease under study—and recruiting from such groups was a notable advantage
of conducting the studies in endemic LMICs. Exclusion criteria were designed to
reduce risks to participants, including reducing the probability of lasting harm.
In all studies, consent processes involved multiple sessions and/or a formal test of
understanding, suggesting a high standard of informed consent. Many studies aimed
to recruit students and/or relatively well-educated individuals in order to improve
the quality of understanding; however, recent social science work in Kenya has
challenged this assumption, suggesting that less educated individuals may be able to
provide adequate informed consent (Njue et al. 2018). This is particularly important
if/when there are scientific reasons to recruit from highly endemic rural areas in
which the average education level may be lower than in (less endemic, or non-
endemic) large cities. There are two further issues with recruiting tertiary-educated
individuals: firstly, this may lead to the relative exclusion of women, in countries in
which women are less likely to receive tertiary education—and this could lead to the
results of HCS being less generalisable to women; secondly, students might in some
cases feel pressured to agree to participate (e.g., where the HCS is being conducted
by researchers from the university/faculty in which the students are studying), which
warrants consideration in future HCS designs (whether in HIC or LMIC settings)
(Bonham and Moreno 2008).
These LMIC studies, like HIC HCS, involved significant burdens for participants
(see below). Payment was usually indexed to burden and to local wages for unskilled
labour—with the exception of Colombia, where no payment was offered apart from
reimbursement for financial costs incurred by participants.
5.4.3 Burdens (Including Risks to Participants and Third
Parties)
LMIC HCS participation involved a range of types and levels of burdens—including
being exposed to risk and experiencing symptoms of infection; monitoring, bodily
examinations, and blood draws by study staff; time away from normal activities
including, in some cases, long periods of inpatient isolation; and so on.
Though generally uncommon, severe physical symptoms did occur—and they
were more likely in participants from less endemic populations (e.g., Nairobi) and
those without innate resistance or acquired immunity to the pathogen used. One
participant required treatment for psychiatric symptoms. Based on published data
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and interviews with relevant stakeholders, no cases of lasting harm related to LMIC
HCS were identified. In some cases the burdens of symptomatic infection could
arguably have be further reduced by earlier diagnosis and treatment (e.g., through
the use of PCR as opposed to microscopy diagnosis of malaria), particularly where
this would not undermine the scientific value of the study.
In terms of risks to third parties, since 5 of the 13 studies were conducted with
vector-borne pathogens (falciparum and vivax malaria) in non-endemic areas of
LMICs where there are no local vectors, and a further 4 studies were conducted
under conditions of strict inpatient isolation (i.e., a total of 9 studies entailed zero or
near-zero risks of transmission), only 4 studies posed potential risks of transmission
to third parties. These 4 HCS involving malaria in endemic areas of Sub-Saharan
Africa, however, would have had low potential for third-party risk due to the short
duration of infection and the high local prevalence of, and immunity to,malaria. Some
stakeholders felt that such small risks were acceptable, whereas others suggested that
they should be reduced still further (see Sect. 3.4).
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6.1 Lessons Learned to Date
Perhaps the most significant lesson learned in LMIC HCS to date is that HCS can be
conducted safely and to a high scientific standard in LMICs where pathogens such as
malaria, cholera, and Shigella are primarily endemic. As one stakeholder in Africa
noted:
I think [an important] lesson people have learned is that [although] a number of the partners
from the [global] North were very skeptical that this could be done in Africa, now it has
been proven that it can be done in endemic countries and it can work well. It’s a good way to
see that possibly we can start having the whole development process start fairly early in the
region and possibly moving this forward. And I think, for me, the feeling is that, we need
to sustain doing this so the competency further develops and then we move to the next level
and also start getting involved in the entire process of vaccine and even drug development,
using the same platform. [Scientist, Africa]
Conducting such research in endemic settings enables HCS that address basic
science research questions that would be difficult or impossible to address in
non-endemic HICs (e.g., the pathogenesis of infection in partially immune
individuals) and the testing of new interventions in a study population from which
the results may be more generalisable to the eventual target population for an
intervention, with 3 vaccine trial HCS already conducted in LMICs. Furthermore,
preparing LMIC institutions to conduct HCS (often in collaboration with HIC
institutions) can help to build capacity for infectious disease research and the
ethical review of complex HCS designs. As more LMIC institutions are able to
conduct HCS for pathogens that are primarily endemic in LMICs, it may arguably
become appropriate to prioritise such HCS in LMICs over those in HICs—at least
where doing so would improve the generalisability of results and thus facilitate
realisation of the ultimate goal of reducing infectious disease burdens in endemic
settings.
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Many of the unresolved ethical and regulatory issues are common to both
LMICs and HICs (see Sect. 6.3), but the particular implications thereof may vary at
a local or national level. For example, the optimum models of ethical review of
HCS and regulatory review of challenge strains are yet to be determined and may
need to be adapted to different settings. However, there are generally much greater
funding and capacity constraints for scientific institutions, regulatory bodies and
ethics committees in LMICs as compared with HICs, and these should be
addressed to assure the quality of HCS conducted in such settings. The success of
the studies above has been partly attributed to significant capacity building efforts
(Hodgson et al. 2015).
In terms of the burdens of research, HCS in endemic populations with innate or
acquired immunity to the challenge pathogen often entail (on average) less risks for
participants than those in non-endemic populations with low prevalence (or absence)
of such protective factors. Some other burdens of participation were increased in
certain settings: for example, relatively long periods of inpatient isolation have been
used in endemic settings because of weak local infrastructure that might mean that
risks to participants and/or third parties would be unacceptably high with outpatient
designs.On the other hand, outpatientHCSwere successfully conducted inColombia
(in a non-endemic area) as well as in Tanzania and Gabon (in endemic areas). While
the latter involved a (perhaps very low) probability of transmission of malaria to third
parties, it is contentious whether such small increases in high (endemic) background
risk are of public health importance and/or ethically problematic.
Involving social scientists and community engagement workers in LMIC HCS
has been a successful strategy in terms of informing and learning from volunteers
and the local community. Such work has generated rich additional data regarding
controversial questions (such as whether to recruit by education level and how
individuals respond to payment for HCS participation) that will help to inform
future HCS design (Njue et al. 2014, 2018). Further (ethical and scientific)
improvement of LMIC HCS is particularly important given that such studies
constitute unique opportunities for improving scientific knowledge regarding, and
developing new interventions to reduce the burden of, neglected diseases primarily
endemic in LMICs. Researchers, ethics review committees, and regulators should
arguably continue to pay careful attention to HCS design in particular contexts
since the success of LMIC HCS partly depends on community acceptance of such
research designs, which in turn depends on an acceptable level of burdens for
participants (and third parties) and a thorough and transparent review process.
6.2 Points of Consensus
Based on a review of relevant literature and interviews with stakeholders with
expertise in LMIC HCS, there is widespread consensus that LMIC HCS can be
ethically acceptable if they have a sound scientific rationale and burdens to
participants (and third parties) are minimised (although the appropriate weightings
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of particular burdens and the optimum strategies for minimising them may be
contentious). While the majority of the stakeholders we interviewed were actively
involved in LMIC HCS, scientists and ethicists not involved in such studies also
agreed that they could be ethically acceptable—i.e., that infecting research
participants with pathogens is sometimes justifiable, including where such
participants are recruited from LMIC populations. Where a research question with
particularly important implications for public health can only be feasibly (and/or
efficiently) addressed by HCS that recruits from an LMIC population, there may be
particularly strong ethical grounds for LMIC HCS. In addition, capacity building
associated with HCS may lead to other benefits, including improvements in local
scientific research and ethical review.
Nevertheless, there was widespread agreement that HCS can be particularly
burdensome for participants, and that they sometimes involve risks to third parties.
Given the burdens to participants, the need for particularly stringent informed
consent processes (e.g., involving tests of understanding) is widely recognised, and
such processes are already established practice in LMIC HCS. Likewise, payment
of HCS participants is widely accepted; even stakeholders from Latin America,
where payment is not the norm, did not think that payment was unacceptable.
However, the appropriate model of payment remains contentious, and may vary in
different cultural and economic settings. Given the potential for the imposition of
excessive burdens (including third-party risk in particular) to undermine public
trust, the need to gauge and maintain public acceptance of HCS designs is widely
seen as an important reason for robust community engagement and/or social
science research to occur in parallel with LMIC HCS.
There was also consensus that HCS researchers must not only be scientifically
well informed, but also exceptionally careful in the conduct of HCS, particularly
regarding the safety of participants. As one interviewee noted:
Nomatter how careful we are in our regulations or ethical frameworks, ultimately conducting
a human challenge study in the right way will come down to a conscientious, compassionate,
careful investigator…perhaps evenmore fundamentally than other types of research because
there’s such an intensive component of involvement between the researcher and the subjects,
because there is this fact that the researcher is intentionally infecting people. [Ethicist, North
America]
6.3 Controversies and Unresolved Issues
Our review and qualitative interviews also identified a number of controversial and/or
unresolved issues in need of further empirical data and/or ethical analysis. Broadly,
these relate to (i) burdens and benefits, (ii) participant selection and payment, and
(iii) issues of governance.
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6.3.1 Burdens and Benefits
Regarding the burdens and benefits of (LMIC) HCS, further work will be needed to
(i) explore how requirements to share the benefits of research should apply to LMIC
HCS (e.g., those that explore the natural history of disease and thus lead to few
near-term benefits as compared with those testing a new intervention), (ii) clarify
what, if any, should be considered the upper limit of risk (and/or other burdens) to
whichHCSparticipants should be exposed, (ii) determinewhether a small probability
of irreversible or long-term harm is an acceptable risk of HCS participation and/or
how such risks should be weighed against benefits, (iii) determine how small third-
party risks should be weighted in the context of background risks of infection in the
community (e.g., in endemic settings), (iv) clarify the degree to which limits to risk
(including third-party risk) should depend on implications for community trust and/or
acceptance, (v) determine the conditions under which exposing HIC populations
to the burdens of HCS with pathogens endemic only in LMICs can be ethically
justified. In addition, the design and review of HCS (in LMICs and elsewhere) could
be improved by more systematic risk-benefit assessment, including comparisons
to alternative study designs (e.g., field trials). Such risk-benefit assessments would
ideally include methods for (i) assessing controversial issues (such as those listed
above), (ii) dealing with situations of uncertainty (e.g., first-in-human HCS), and
(iii) making ethically acceptable trade-offs between risks to participants and public
health benefits (e.g., using low risk strains in HCS might reduce risks to participants
but also compromise generalisability to wild-type infection).
6.3.2 Participant Selection and Payment
Current controversies regarding participant selection and payment surround
questions related to (i) the appropriate models of payment for highly burdensome
HCS in different settings, (ii) whether, or when, less educated individuals should be
excluded from HCS, (iii) the generalisability of adult HCS results to children (e.g.,
under what conditions, if any, would HCS in HIC adults be more generalisable to
at-risk children in LMICs than HCS in LMIC adults?), and (iv) the conditions
under which, if any, it would be acceptable to involve children in HCS. One area of
consensus related to (iv) was that significant community engagement should be
conducted and/or international consensus should be sought before the further
planning of HCS in children.
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6.3.3 Governance
The ideal model(s) of ethical and regulatory governance of HCS are yet to be
determined. In particular, further work is needed to clarify (i) the appropriate model
of regulatory governance of challenge strains (including in LMICs) and whether
this can be standardised (to a greater degree) at an international level, (ii) the role(s)
of HCS in regulatory pathways for the development of new interventions, (iii) the
conditions under which HCS protocols should be reviewed by standard ethics
committees and/or specialised committees, (iv) the (potential) need for a
specialised ethical framework and/or principles/guidelines for HCS in general
and/or HCS in LMICs—and the specific content thereof.
6.4 Future Directions
Challenge studies are a growing area of research that has the potential to advance
science and lead to improvements in public health, especially in LMICs. They
involve ethically sensitive research practices, however, and raise numerous
controversial issues. Further work is needed by biological scientists, social
scientists, community engagement experts, and bioethicists in order to establish
norms of best practice for HCS that ensure the safety of participants and promote
public trust and acceptance of this type of research so that its potential benefits can
be realised in the long term. Further research and/or related activities regarding
ethical and regulatory issues related to (LMIC) HCS could include (i) more
detailed analyses of the controversial and/or unresolved issues identified in this
report, (ii) broader surveys of other stakeholders (including HCS participants and
members of the general public as well as policymakers in different settings), (iii)
workshops with policymakers and regulatory representatives (including in endemic
regions), (iv) multidisciplinary collaborations regarding HCS study design, (v) the
development and refinement of risk-benefit assessment tools to compare HCS
designs with one another and compare HCS with alternative designs from both
ethical and scientific points of view, (vi) further research capacity building in
LMICs (including the strengthening of existing ethics review mechanisms for
HCS), (vii) a more extensive review of international regulatory requirements and
laws regarding intentional infection, (viii) education and awareness-raising
regarding HCS (including their scientific importance, ethical issues, and sharing of
insights from past HCS) with stakeholders at institutions where future HCS are
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